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Abstract 
Aberrant hepatic fat accumulation (“fatty liver”) represents a pathophysiological hallmark of 
obesity and is associated with extended glucocorticoid therapy, obesity, Type II diabetes, and 
starvation. Elevated glucocorticoid levels under these conditions are causative for the fatty liver 
phenotype, although the molecular mechanisms of their action remain largely unclear.  
This study demonstrates that glucocorticoids (GCs) promote fatty liver development through 
facilitated fat transport into the liver and not due to increased de novo fat synthesis. Transient 
knock-down of hepatic GR was associated with decreased hepatic gene expression of the fat 
transporters CD36 and caveolin 1 and with decreased expression of peroxisome proliferation-
activating receptor gamma (PPARγ) – a transcription factor promoting CD36 and caveolin 
expression.  
Moreover, glucocorticoids inhibited hepatic expression of transcriptional repressor Hairy and 
Enhancer of Split-1 (Hes-1) a previously identified anti-lipogenic factor. In fatty liver mouse 
models characterized by elevated GC levels diminished Hes-1 levels correlated with increased 
hepatic lipid stores. Genetic restoration of hepatic Hes-1 levels in obese mice normalized 
hepatic triglyceride levels and improved systemic insulin sensitivity. In mice injected with GCs 
for three weeks, genetically restored hepatic Hes-1 levels inhibited GC-induced liver fat 
accumulation. In both models, sustained Hes-1 was accompanied by increased oxidative 
consumption of triglycerides and decreased fat import into the liver. Hes-1 re-expression 
inhibited hepatic PPARγ, CD36 and caveolin expression resembling effects in mice with 
transient GR knockdown. Loss of function analysis in primary hepatocytes confirmed PPARγ 
and Cav1 as Hes-1 target genes. The data suggest that Hes-1 antagonizes GR-mediated 
transcriptional regulation of fat transport programs in the liver. 
Mechanistically, glucocorticoid exposure of hepatocytes lead to the disassembly of a cAMP-
dependent CREB transactivator complex on the proximal Hes-1 gene promoter. The 
glucocorticoid receptor was shown here to decrease intracellular P-CREB levels and to interact 
with CREB via the bZIP domain of CREB. Furthermore, GR associated to glucocorticoid 
response elements in the proximal Hes-1 promoter region. 
Inhibition of hepatic Hes-1 provides a rationale for glucocorticoid-induced fatty liver 
development. Restoration of Hes-1 activity might, therefore, represent a new approach in the 
treatment of Non-Alcoholic Fatty Liver Disease and its associated complications such as hepatic 
insulin resistance. 
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Zusammenfassung 
Die erhöhte Einlagerung von Neutralfetten in der Leber (“Fettleber”) stellt ein 
pathophysiologisches Kennzeichen von Fettleibigkeit dar und korreliert mit Langzeit-
Glucocorticoid-Therapie, Typ II Diabetes und Übergewicht aber auch mit Langzeithungern. 
Erhöhte Glucocorticoidwerte in den genannten Zuständen verursachen das Auftreten der 
Fettleber. Die zugrunde liegenden molekularen Mechanismen sind bisher jedoch nur wenig 
erforscht. 
In der vorliegenden Arbeit konnte gezeigt werden, dass Glucocorticoide (GCs) die Entstehung 
einer Fettleber begünstigen, indem sie die Aufnahme von Fetten in die Leber über 
Fetttransporter erleichtern. Andererseits konnte keine erhöhte Neusynthese von Fetten als 
Ursache der Glucocorticoid-bedingten Fettleber belegt werden. Transiente Verminderung des 
hepatischen Glucocorticoid-Rezeptors (GR) mittels shRNAs wird von einer erniedrigten 
Genexpression der Fetttransporter CD36, Caveolin1 und von einer Unterdrückung der 
Expression von Peroxisome Proliferation-Activating Receptor gamma (PPARγ) begleitet, der 
die Expression von CD36 und Cav1 anregt. 
Darüber hinaus inhibieren GCs die hepatische Expression des anti-lipogenen transkriptionellen 
Repressors Hairy and Enhancer of Split (Hes-1). In Fettlebermodellen, in denen erhöhte 
Glucocorticoid-Konzentrationen auftreten, korrelieren erniedrigte hepatische Hes-1 Mengen mit 
erhöhten Leberfettwerten. Genetische Wiederherstellung der Leber-Hes-1-Mengen in 
übergewichtigen Mäusen hat eine Normalisierung der Leberfette zur Folge und verbessert 
gleichzeitig die systemische Insulinsensitivität. In mit GCs behandelten Mäusen inhibieren 
aufrechterhaltene Hes-1 Spiegel den Transport von Fetten in die Leber und damit deren 
Ansammlung in Hepatozyten. Hes-1 vermindert die Expression von PPARγ, CD36 und Cav1, 
was dem Phänotyp in hepatischen GR Knock-down Mäusen gleicht. Hes-1 Erniedrigung durch 
shRNAs in primären Hepatozyten bestätigt Cav1 und PPARγ als Hes-1 Zielgene. 
In in vivo Hes-1-Promotorstudien destabilisieren GCs den cAMP-abhängigen CREB 
Transaktivatorkomplex. Der GR verringert intrazelluläre P-CREB Mengen und kann außerdem 
mit der bZIP-Domäne des CREB-Proteins interagieren. Schließlich bindet der GR direkt an 
Glucocorticoid Response Elemente in der proximalen Hes-1 Promotorregion. 
Zusammengefaßt stellt die Inhibierung der hepatischen Hes-1 Mengen eine Ursache der 
Glucococorticoid-induzierten Fettleber dar. Die Aufrechterhaltung der Leber-Hes-1-Aktivität 
kann daher als neuer Ansatz in der Behandlung der Nicht-Alkohol-abhängigen Fettleber und 
deren Folgeerkrankungen wie zum Beispiel hepatische Insulinresistenz angesehen werden. 
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1 Introduction 
 
During 2.5 million years of human development, the principal evolutionary pressure to survival 
has been famine. The development of adipocytes as energy stores provided means for coping 
with the occurrence of undernutrition (1). With the industrial revolution, an unprecedented 
change in the availability of food took place in western countries. For the first time famine was 
replaced by unending overnutrition, the effects of which were furthermore amplified by 
permanent underexertion imposed by sedentary occupations and immobilizing technologies of 
modern life (1). Since compensatory mechanisms that buffer the metabolic consequences of 
short-term overnutrition were incapable of compensating for such chronic changes in caloric 
balance, diseases of overnutrition became increasingly prevalent. Nowadays, poor diet and 
physical inactivity are the second leading cause of preventable death in the United Stated and 
are predicted to be number one within the next decade (2).  
 
Diseases associated with overnutrition and obesity include coronary artery disease and the so-
called Metabolic Syndrome – an umbrella term summarizing complications such as 
dyslipidemia, hypertension, insulin resistance, fatty liver, non insulin-dependent diabetes 
mellitus (NIDDM) and heart disease (3-5). With regard to the prevalence of obesity in western 
societies and the steadily growing number of patients suffering from obesity the Metabolic 
Syndrome, and its consequences will be a major cause of morbidity and mortality in the so-
called civilized countries. While it is no longer doubted that the excessive fat storage itself is not 
harmless, it remains unclear how much fat accumulation can be tolerated and whether an upper 
threshold for the absolute amount exists. 
1.1 Metabolic homeostasis and the liver 
Energy homeostasis is a prerequisite for a healthy organism and many tissues participate in the 
maintenance of it. Amongst them, the liver plays a unique role as it represents the largest gland 
of the organism. It is one of the main tissues involved in the regulation of protein-, lipid- and 
carbohydrate metabolism (6, 7), and secretes a number of essential proteins into the blood such 
as coagulation factors (fibrinogen), lipoproteins and albumins (8). The liver is also a major 
source of fatty acids, triglycerides, ketone bodies and cholesterol (9, 10). Additionally, it 
produces bile and secretes it through a duct system. Bile serves as an emulsifier of fats thereby 
increasing solubility of dietary fat and facilitating their subsequent enzymatic cleavage. 
Moreover, the liver detoxifies the organism by removing metabolic side products such as 
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bilirubin and excess hormones. It metabolises drugs and toxins to prepare them for secretion. 
Vitamin B12 and minerals are stored in the liver, vitamin A is synthesized. Specialized liver 
cells, so-called Kupffer cells clear particulate material from the blood stream by phagocytosis 
(11, 12). 
Glucose homeostasis is achieved by the liver through removal of glucose from the blood after 
ingestion of food and storing it as glycogen. During fasting periods, liver glycogen is converted 
back into glucose and released into the serum to maintain blood glucose levels and to 
supplement extrahepatic tissues such as brain, erythrocytes and renal medulla (13). If glycogen 
stores are empty, the liver generates glucose from carbohydrate and amino acid precursors. Fats 
cannot be converted into glucose. The process of de novo glucose synthesis is called 
gluconeogenesis and solely occurs in liver and to a small degree in the cortex of the kidneys.  
Lipids transported into the liver serve on one hand as energy source for the organ. Free fatty 
acids can be activated and oxidized to the C2-precursor acetyl-CoA and NADH via β-oxidation. 
Acetyl-CoA can subsequently be metabolized in the citrate cycle or used for cholesterol 
biosynthesis. Excess acetyl-CoA is used for the synthesis of ketone bodies, which are secreted 
into the blood and serve as energy source for peripheral tissues. Dietary fats, that are not 
consumed to generate energy are transformed into phospholipids and triacylglycerides and 
transported in lipoprotein particles to adipose tissue, where they are stored. Serum free fatty 
acids can bind to serum albumins secreted from the liver and are transported to skeletal muscle 
or heart, where they are directly metabolized.  
Overall, the liver represents an allocation center distributing metabolites as diverse as glucose, 
cholesterol, ketone bodies and triglycerides between different tissues to meet the energy 
demands of the organism. Impaired liver function severely deteriorates whole body energy 
balance. 
1.1.1 Regulation of Liver Metabolism 
The fast and direct response of the liver to nutritional signals is accomplished by an ingenious 
and complex system of endocrine signals generated in the pancreas and the adrenal glands. After 
ingestion, the pancreatic β-cell hormone insulin triggers fast glucose uptake into peripheral 
tissues such as adipose tissue and skeletal muscle by stimulating translocation of glucose 
transporter GLUT4 to the cell membrane (14). Glucose enters the liver via a different glucose 
transporter – GLUT2 – that is not translocated to the cell membrane in an insulin-dependent 
manner (15). However, insulin inhibits hepatic gluconeogenesis and glycogen breakdown, 
thereby decreasing hepatic glucose output. At the same time, glycogen synthesis and de novo 
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triglyceride synthesis (lipogenesis) are stimulated. Thus, insulin maintains blood glucose 
concentrations in a range between 4 and 7 mM (16). Taken together, insulin signals a state of 
enery abundance and activates storage of fat and glycogen. 
 
Under fasting conditions the peptide-hormone glucagon (secreted from pancreatic α-cells), 
katecholamines (e.g. epinephrin) and the steroid hormones glucocorticoids (derived from 
adrenal glands) are released into the serum. Glucagon mainly stimulates hepatic glycogen 
breakdown within the first 24h of fasting. Once the glycogen stores are exhausted hepatic 
gluconeogenesis synergistically triggered by glucagon and glucocorticoids becomes the major 
source of glucose. To conserve blood glucose levels, glucocorticoids suppress glucose uptake in 
muscle and adipose tissue.  
Glucagon, epinephrin and glucocorticoids furthermore enhance lipolysis in adipocytes and liver 
(17-21) to augment substrate availability for β-oxidation. 
1.2 Transcription factors in metabolic control 
1.2.1 Molecular mechanisms of metabolic control  
Metabolic regulation in complex organisms consists of three main types of control. The first 
relies on the allosteric control of the activity of a key metabolic enzyme achieved by binding of 
an activator or inhibitor, which often is the enzyme substrate itself (22). Secondly, equilibrium 
of an enzyme between its active and inactive state can be adjusted by posttranslational 
modifications (e.g. phosphorylation, glycosylation, sumoylation etc.) or by proteolytic cleavage. 
These chemical alterations may also affect protein stability. The third mechanism is 
transcriptional regulation through which the expression level of key enzymes is adjusted (22). 
Most metabolic regulations are clearly realized by a coordinated action of all three mechanisms. 
However, in the following sections the focus will be on the role of transcriptional regulation in 
metabolic control. 
Transcriptional control requires specific signals to be transduced to the nucleus of the cell where 
subsequently defined sets of genes are targeted. The process can be subdivided into three 
successive steps that are 1) the transduction of the signal through the cell until it reaches the 
nucleus (upstream of transcriptional activity), 2) the molecular mechanism by which 
transcription factors will act and 3) effects that follow downstream of transcriptional activity 
and that are determined by the target genes ultimately leading to homeostasis.  
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1.2.1.1 General mechanism of transcriptional regulation 
Eukaryotic DNA exists in the compacted form of chromatin, where the DNA is wound around 
histone proteins in a complex called nucleosom (23). The nucleosom is composed of ~146bp 
DNA associated with an octamer of two molecules each of core histone proteins (H2A, H2B, 
H3 and H4) (24). Through DNA histone interaction the DNA is not accessible for the enzyme 
RNA polymerase II, which catalyses the synthesis of mRNA. This conformation of chromatin is 
described as closed and is associated with suppression of gene expression (25). It may also be 
noted here, that further compaction is achieved by interactions between nucleosomes and 
histones such as H1. Histone H1 has been implicated in prevention of transcription factor 
binding and thus its removal is a prerequisite for making nucleosomal DNA accessible to 
transcription factor binding (26).  
Transcription factors are proteins that are characterized by an affinity to specific DNA 
sequences (response elements) to which they can directly bind via a DNA binding domain. They 
control gene transcription by recruiting co-factors to specific DNA regions that in turn 
covalently modify histone proteins (e.g. phosphorylation, acetylation, methylation). As a 
consequence the tightly wound DNA is released allowing the recruitment of large protein 
complexes which stabilise RNA polymerase II binding. The most frequent observed 
modification of histone proteins ist acetylation by histone acetylases (HATs). Several important 
co-factors such as p300/CBP have intrinsic HAT activitiy (27). Increased gene transcription is 
associated with a concomitant increase in histone acetylation followed by decompaction 
whereas hypoacetylation is correlated with reduced transcription or gene silencing (25, 28).  
Repression of genes is achieved via histone deacetylation a process controlled by histone 
deacetylases (HDACs) (29). Subsequently, the winding of DNA is increased resulting in a dense 
chromatin structure and reduced access of transcription factors to their binding sites.  
Importantly, transcription factors react on external stimuli and therefore represent proteins that 
transform signals into transcription or repression of genes that are controlled by them. The fact 
that aberrant transcriptional activity is frequently observed in metabolic diseases has drawn 
much attention on the identification of transcription factors involved in the onset of metabolic 
diseases (16). 
1.3 Transcriptional regulation of liver metabolism 
In hepatocytes, insulin, glucagon and glucocorticoids are the major signals controlling the 
transcriptional activity of enzymes involved in carbohydrate-, lipid and protein metabolism by a 
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wide variety of transcription factors. The major effects on transcriptional regulation of these 
hormones on liver metabolism are summarized below. 
1.3.1 Transcriptional control mediated by glucagon 
The peptide hormone glucagon helps maintaining the level of glucose in the blood by binding to 
glucagon receptors on hepatocytes, causing the liver to release glucose - stored in the form of 
glycogen - through glycogenolysis. Binding of the hormone to its G-protein coupled receptor 
leads to dissociation of the heterotrimeric G protein into its α and β,γ-subunits and subsequent 
translocation of the α-subunit to adenylyl cyclase. Activated adenylyl cyclase generates cyclic 
adenosine 3’,5’-monophosphate (cAMP) – a second messenger, thereby amplifying the 
incoming signal (Figure 1.1). Increased intracellular cAMP inhibits activity of the transcription 
factor sterol-regulatory binding protein 1c (SREBP-1c) (30), a factor that is stimulated in an 
insulin-dependent manner and that activates lipogenic programs (31, 32). Key enzymes 
controlled by SREBP-1c are e.g. acetyl CoA carboxylase 1 (ACC1), fatty acid synthase (FAS) 
and stearoyl CoA desaturase 1 (SCD-1) (33). The mechanism  however has not been determined 
yet.  
Three main targets of cAMP have been identified: protein kinase A (PKA), GTP-exchange 
protein EPAC and cyclic-nucleotide-gated ion channels. PKA is activated by the binding of 
cAMP to the two regulatory R subunits, upon which their dissociation from the catalytic C 
subunits is initiated. A large number of proteins have been identified as substrates for PKA. The 
enzyme activates phosphorylase B kinase which in turn phosphorylates phosphorylase B. 
Phosphorylase B is the enzyme responsible for the release of glucose-1-phosphate from 
glycogen. 
Regulation of transcription by PKA is mainly achieved by direct phosphorylation of the 
transcription factors CREB, CREM and ATF1 that belong to the bZIP family of transcription 
factors. Phosphorylation of CREB, CREM or ATF1 is a crucial event, because it facilitates 
interaction with the transcriptional co-activators CBP and p300. CBP/p300 possess HAT 
activity and change chromatin structure into an open form by modification of histones so that 
transcription can occur (see Section 1.2.1.1). Importantly, the phosphorylation sites of CREB, 
CREM and ATF1(Ser-133 in CREB, Ser-117 in CREM and Ser-63 in ATF1) are also targeted 
by a variety of other kinases, supporting the notion that members of the CREB family play an 
important role in the nuclear response to a variety of external stimuli. 
Glucagon signaling is terminated by rapid degradation of cAMP by cyclic nucleotide 
phosphodiesterase (PDE), by inhibiting PKA activity with the protein kinase inhibitors α, β and 
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γ (PKIs or dephosphorylation of CREB family members by protein phosphatase 1 and 2a (PP1 
and PP2A).  
 
Figure 1.1: Glucagon signaling and transcriptional activation of target genes. Binding of glucagon 
to its receptor (purple) and its autophosphorylation lead to dissociation of associated G protein (Gs). The 
α-subunit translocates to adenylyl cyclase (AC) which generates cAMP. cAMP binds to regulatory 
subunits of PKA (R, red) releasing the catalytic subunits (C, red). C translocates into nucleus, where it 
phosphorylates transcription factors of the CREB family (CREB, grey). Signal is terminated by 
phosphodiesterase (PDE), protein kinase inhibitors (PKI) and protein phosphatases (PP1, PP2A). 
 
Transcriptional activation of the key-gluconeogenic enzymes phosphoenolpyruvate 
dehydrogenase (PEPCK) and glucose-6-phosphatase (G6Pase) expression via glucagons/ cAMP 
increases hepatic glucose output and at the same time glucagon counteracts lipogenesis by 
inhibition of SREBP-1c (30). 
1.3.2 Glucocorticoids and the glucocorticoid receptor 
On the molecular level, glucocorticoids mainly exert their actions via binding to the 
glucocorticoid receptor and to a minor extend via binding to the mineralocorticoid receptor (34). 
The glucocorticoid receptor belongs to a specific class of transcription factors – the so-called 
nuclear hormone receptors. The nuclear hormone receptor superfamily includes receptors for 
thyroid and steroid hormones, retinoids and vitamin D as well as different “orphan” receptors of 
unknown ligand (35). Nuclear receptors act as ligand-inducible transcription factors and 
undergo conformational change upon ligand binding. As all transcription factors they bind to 
specific recognition sites on the DNA and control gene transcription through recruitment of co-
regulators. However, their ligand-binding domain (LBD) distinguishes them from other 
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transcription factors because their activity can be directly modulated by small molecules making 
them very attractive targets for pharmacological intervention in diseases (22). 
The glucocorticoid receptor is encoded by the gene NR3C1 and the murine protein has a size of 
86 kDa. Two isoforms have been identified termed GR-α and GR-β (36). While GR-α is 
expressed in almost all tissues, GR-β expression is characterized by limited tissue distribution, 
where it acts as a dominant-negative inhibitor of GR-α  (37, 38). 
In the absence of its ligand, the GR is localized in the cytosol complexed with a variety of 
proteins including heat shock proteins 70 and 90 and FKBP52 (FK506 binding protein 52) (39). 
The endogenous glucocorticoid hormone cortison diffuses through the cell membrane. In the 
cytoplasm it is converted into the active cortisol (40). It subsequently binds to its receptor 
releasing in turn heat shock proteins from the inactivation complex. The hormone-bound GR 
translocates into the nucleus (40) where it binds DNA sequences called Glucocorticoid 
Response Elements (GREs) (41) via homo- or heterodimerization. However, GR confers its 
action not only via direct DNA binding but also via protein protein interaction (42, 43). 
Targeted knockout experiments in mice demonstrated that ubiquitous deletion of GR is lethal 
shortly after birth emphasising the pivotal role of the GR for survival (44). In contrast, 
transgenic mice bearing a mutation in the the GR dimerization motif (GRdim mice), thus unable 
to bind to GREs, are viable as impressively demonstrated by Reichardt et al. (45). Therefore, 
many of GR’s functions are exerted via protein protein interactions and not through DNA-
mediated control of target gene expression. 
In the liver, the ligand-bound GR acts as a regulator of gluconeogenesis by enhancing the 
expression of PEPCK in cooperation with CREB (46-49) and as an inhibitor of glycolysis 
through increased expression of 6-phosphofructo-2-kinase (50). To provide glucose, the rate of 
proteolysis is increased in response to GC/GR and coincident with the conversion of carbon 
skeletons of the amino acids into glucose, the ammonia resulting from deamination of the α-
amino group of amino acids is detoxified by the urea cycle. In this respect, GR controls hepatic 
up-regulation of the pace maker enzyme carbamoylphosphate synthetase (51). 
1.3.3 Insulin signaling and transcriptional control 
Insulin action is initiated upon binding of the hormone to and activation of its cell-surface 
receptor. The receptor consists of two extracellular α-subunits and two intracellular β-subunits 
composing a α2β2 tetrameric complex. Via conformational change of the receptor α-subunits 
ligand binding leads to induction of tyrosine kinase activity located on the β-subunit and 
subsequent intramolecular transphosphorylation. Each β-subunit phosphorylates its adjacent 
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partner (52). Subsequently, numerous proximal substrates are tyrosine phosphorylated including 
the members of the insulin receptor substrate family (IRS 1 to 4), Shc adapter protein isoforms, 
Cbl and others (53-56).  
Tyrosine phosphorylation of IRS proteins in turn creates recognition sites for additional effector 
proteins containing Src homology 2 (SH2) domains, e.g type 1A phosphatidylinositol 3-kinase 
(PI 3-kinase) (57-59). Activated PI 3-kinase generates the lipid phosphatidylinositol 3,4,5 
trisphosphate (PIP3), which triggers a protein kinase cascade by first stimulating 
phosphoinositide-dependent kinase 1 (PDK1) (60). Finally, PDK phosphorylates two classes of 
serine/threonine kinases, namely Akt (also known as protein kinase B) and the atypical protein 
kinase Cζ and λ (PKCζ /λ). Both kinases have been reported to lead to translocation of glucose 
transporter GLUT4 (16) (see Figure 1.2) yet this action is independent of transcriptional 
regulation. 
The diversity of of mechanisms of insulin-mediated transcriptional regulation is extremely wide, 
as reflected by the various promoter sequence that harbour so-called insulin response elements 
(IRS/IRE) (61). Whereas not all factors are known that can bind to these sequences SREBP-1c 
has been shown to be a major mediator of insulin-dependent transcriptional regulation. The 
helix-loop-helix protein SREBP-1c stimulates the expression of glycolytic and lipogenic genes 
in the liver (e.g. liver acetyl CoA carboxylase, fatty acid synthase) (31).  
On the other hand, insulin also negatively regulated transcription, in particular of gluconeogenic 
genes (e.g. PEPCK) (62). Insulin-dependent activation of AKT leads to phosphorylation of  
FOXO (forkhead family) transcription factors. Phosphorylated FOXOs are transported out of 
the nucleus resulting in a decreased transcriptional activity of their respective target genes (63-
65). This mechanism represents the most common mechanism through which insulin can 
mediate repressive effects. Decreased gene expression of fructose-1,6-bisphosphatase and 
glucose-6-phosphatase (gluconeogenesis) have also been associated with forkhead family 
members (66). 
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Figure 1.2: Signal transduction in insulin action. Upon binding of insulin to its receptor, 
autophosphorylation of the insulin/IGF-1 receptor and tyrosine phosphorylation of IRS proteins activate 
a protein kinase cascade that finally leads to the translocation of glucose transporter to the cell 
membrane. SREBP-1c expression is activated in response to PI-3-K and FOXO-mediated transcription 
blocked in an Akt/PKB-dependent manner.
1.4 Obesity – a risk factor for metabolic disease 
The delicate control of energy balance within an organism strongly depends on the functional 
integrity of all signaling pathways controlled by hormones. Obesity is often accompanied by a 
desensitization of metabolic tissues against hormonal signals, especially insulin accompanied by 
a concomitant hyperactivation of counter-regulatory hormones. Attenuated insulin sensitivity in 
adipose tissue limits the capacity of the tissue to store excess nutrients as fat. As a result, 
dyslipidemia by means of increased serum free fatty acids (FFA) concentration promotes fat 
accumulation in non-adipose tissue. Function and viability of nonadipocytes are compromised 
when their triglyceride content rises above normal.  
 
Generally, fatty acid delivery to non-adipose tissues is tightly coupled to the tissue-specific need 
for fuel. Serum FFA levels rise during exercise and fasting to be metabolized in the process of 
β-oxidation thereby generating energy. In hyperlipidemic situations, however, FFAs that are not 
needed for oxidative consumption can enter nonoxidative pathways such as ceramide synthesis. 
Increased ceramide synthesis has been implicated in the induction of β-cell apoptosis in 
pancreatic islets from obese fa/fa ZDF rats (67). Furthermore, long-chain fatty acids increase 
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intracellular nitric oxide (NO) production (68) thereby stimulating mainly cytotoxic actions of 
NO probably via greater production of toxic hydroxyl ions from peroxonitrite (69). Altered fatty 
acid uptake/utilization in heart can stimulate species lipid-induced programmed cell death via 
accumulation of cardiotoxic lipids (70, 71). These effects together are discussed as lipotoxic 
effects of FFAs on tissues.  
 
Inflammation has been tightly linked to insulin resistance. Hotamisligil showed that 
proinflammatory TNF-α was able to deteriorate insulin resistance in adipocytes, macrophages 
and hepatocytes (72, 73) by activating IKKβ/NFkB and JNK pathways. As a consequence, IRS 
were Ser/Thr phosphorylated which inhibited tyrosine phosphorylation by the insulin receptor. 
Therefore, insulin mediated signaling was blunted. 
Recently, FFAs were also shown to be strong signaling molecules stimulating the very same 
inflammatory pathways that have been implicated in manifestations of the Metabolic Syndrome: 
the IKK/NFkB pathway (74), the c-Jun amino-terminal kinase (JNK) pathway (75, 76) and the 
Toll-like receptor 4 pathway (77). Thus, free fatty acids themselves are able to decrease insulin 
sensitivity.  
 
In summary, dyslipidemia by means of increased serum FFA concentration perturbes all major 
tissues involved in regulation of metabolic homeostasis and therefore facilitates the 
manifestation of insulin resistance, a hallmark of the Metabolic Syndrome. The fact that 
function and viability of nonadipocytes is compromised when their triglyceride content rises 
above normal implies that normal homeostasis of their intracellular fatty acids is critical for 
prevention of complications of obesity.  
1.4.1 Non-alcoholic fatty liver disease 
Fat accumulation in the liver impairs its function as key-switch in metabolic control. 
Importantly, the amount of triglycerides stored in the liver inversely correlates with the 
responsiveness of the organ to insulin. Under pathophysiological conditions signal transduction 
via the insulin signaling cascade is attenuated or blunted. This condition is referred to as hepatic 
insulin resistance. 
 
The term non-alcoholic fatty liver (NAFLD) describes the accumulation of mainly triglycerides 
in the hepatocytes so that fat mass exceeds 5% of the organ weight (78). It is a benign and 
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reversible condition per se, but it can progress to more severe liver diseases such as non-
alcoholic steatohepatosis (NASH), a form of hepatitis and eventually cirrhosis and liver failure. 
 
In NAFLD, mild to moderate elevations of serum aminotransferases are the most common 
detected serum abnormalities found in affected individuals (78). Imaging studies such as 
computer tomography (CT) and magnetic resonance (MR) are sensitive in detecting abnormal 
retention of lipids within liver cells called steatosis. The grade and stage of the disease can only 
be determined with a liver biopsy. Using proton MR spectroscopy, the Dallas Heart Study 
reported that one in three adult Americans has liver steatosis (79). This implies that 
approximately 70 million adult Americans suffer from NAFLD. Central obesity, Type II 
Diabetes, dyslipidemia and hypertension are risk factors for the disease. NAFLD can also 
precede the development of these comorbidities, so it is unclear whether fatty liver causes these 
complications or vice versa (80). Additionally, NAFLD can also be induced by numerous drugs 
such as estrogens and tamoxifen, by glucocorticoids or toxins (petrochemicals, such as 
tetrachlorcarbon, phosphorus poisoning, Amanita phalloides).  
 
By a pilot study in humans, Marchesini et al. (81) showed a strong correlation between NAFLD 
and insulin resistance. NAFLD patients had basal hyperinsulinemia under fasting conditions and 
insulin infusion did not suppress hepatic glucose production. This clearly demonstrated that the 
liver itself was resistant against the hormone treatment. Furthermore, hypertriglyceridemia 
together with increased FFA levels was observed in serum in the same patient cohort. FFAs are 
responsible for reduced insulin clearance – thus the observed hyperinsulinemia. A lower-than-
normal decrease of serum FFA levels after insulin infusion suggested a decreased insulin-
mediated suppression of lipolysis. The study clearly demonstrated that Non-Alcoholic Fatty 
Liver Disease represents the hepatic manifestation of the Metabolic Syndrome (81).  
The extremely high prevalence of NAFLD together with its implications in the Metabolic 
Syndrome underline the necessity to understand the molecular basis of the disease and factors 
causing its development. 
1.4.2 Metabolic disease and transcription factors 
As described in Section 1.2 and 1.3 transcriptional regulation in energy homeostasis relies on 
the activity of transcription factors that control expression of distinct gene sets. Metabolic 
diseases on the other hand are often associated with aberrant expression or activation of 
transcription factors leading to altered gene expression patterns. 
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Pharmacological targeting of transcription factors that are known to be differentially regulated 
in metabolic diseases therefore represents a major aim of biomedical research (22). Modulation 
of transcription factor activity is difficult to accomplish as they mostly do not possess a ligand 
binding domain. However, nuclear receptors – a subclass of transcription factors – are 
characterized by a ligand binding domain to which their endogenous ligands bind. Signaling 
molecules that can activate hormone receptors include lipophilic substances e.g. estradiol, 
testosterone, vitamin A or cortisol. The glucocorticoid receptor represents a member of the 
nuclear receptor family and plays a role in the emergence of NAFLD. 
1.4.3 The implication of glucocorticoids in fatty liver development 
Increased circulating GC levels have been detected in insulin-resistant patients promoting 
pathophysiological characteristics such as hyperglycemia, dyslipidemia and fatty liver. In 
various animal models of obesity, dyslipidemia and hepatic steatosis, circulating GC 
concentrations are drastically elevated (82, 83). Furthermore, the GR itself has been found to be 
over-expressed in hepatocytes of rodent diabetes models, in particular in its nuclear fraction (84, 
85). Long-term treatment of Wistar rats with low doses of a synthetic glucocorticoid analogon 
resulted in increased hepatic triglyceride synthesis and decreased fatty acid oxidation promoting 
hepatic fat accumulation (86). Although chronically elevated GC levels have not been observed 
in obese subjects, local action of these hormones can still be increased. The enzyme 11-β-
hydroxysteroid-dehydrogenase (11βHSD), that converts the inactive cortison form into the 
active cortisol, has been demonstrated to increase local tissue GC levels (87). 11βHSD-deficient 
mice are protected against diet-induced obesity and are characterized by lower circulating 
triglyceride levels and enhanced fatty acid oxidation (88). Liver-specific 11βHSD 
overexpression resembles many phenotypic features of the Metabolic Syndrome such as 
abdominal obesity, hypertriglyceridemia and diminished glucose uptake rate by peripheral 
tissues (89) (glucose intolerance) suggesting an active role of GCs in the emergence of these 
complications. 
 
Although glucocorticoids are widely considered as a major player causing fatty liver 
development, little is known about the molecular targets leading to this phenotype. 
Glucocorticoids have been demonstrated to inhibit the soluble mitochondrial matrix acyl-CoA 
dehydrogenases and thereby diminish β-oxidation (90). Some authors suggested that GCs 
decrease the mRNA levels of the enzymes (91), however these results could not be confirmed 
by others (90).  
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It has become increasingly clear that visceral fat deposition, which is common in severe obesity, 
is associated with triglyceride accumulation in the liver. Glucocorticoids are the driving force 
for visceral fat formation (92) and thus indirectly contribute to the fatty liver phenotype. 
Visceral adipose tissue has greater lipolytic potential than subcutaneous adipose tissue and the 
release of FFA from visceral fat directly into the portal circulation creates a “first pass” effect 
(78). The increased flux of fatty acids to the liver leads to hepatic lipid accumulation, increased 
hepatic glucose production (93, 94) and decreased hepatic insulin clearance, which in turn leads 
to insulin resistance and hyperinsulinemia. Furthermore, portal FFAs are known to drive hepatic 
production and secretion of lipoprotein particles (95) thereby altering the serum lipid profile.  
 
Whether the rather indirect effect of glucocorticoids by elevating circulating FFAs is the major 
cause of GC-dependent hepatic steatosis is debated, however direct molecular mechanisms of 
GC-induced steatosis have not been determined. 
 
2 Aim of the Study 
 
Non Alcoholic Fatty Liver Disease nowadays represents the most common form of chronic liver 
disease in western countries. Due to the often accompanied hepatic insulin resistance, the liver 
is no longer capable to maintain various functions crucial for whole body energy homeostasis. 
Hyperactivation of hepatic GC/GR axis clearly promotes the transformation process of the liver 
towards the pathophysiological NAFLD state, yet the molecular mechanisms underlying these 
phenotypical effects are largely unknown.  
The approach taken in this thesis aims for the characterization of the role of hepatic GR/GC 
function in the context of fatty liver development and progression. A special focus lays on the 
identification of transcriptionally regulated metabolic pathways that eventually promote hepatic 
fat accumulation and target genes that are differentially expressed in correspondence to GC/GR 
signaling. This work will have new implications for the development of treatment strategies 
against NAFLD, a research area which has been given rising attention during the past years. 
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3 Results 
 
It is widely accepted that glucocorticoids contribute to fatty liver development. However, while 
the correlation between high glucocorticoid levels and hepatic fat accumulation is undoubted 
molecular rationales for hepatic fat increase remain largely unknown (96). To examine the role 
of the glucocorticoid receptor (GR) in fatty liver development targeting the GR specifically in 
the liver would be advantageous. Genetic models of liver-specific targeted knockout for the GR 
exist (97, 98), but are available only on a mixed genetic background (C57 BL/6J, 129SvEv, 
FVB/N). To study hepatic GR function in the context of a fatty liver, generation of liver-specific 
GR knockout mice on fatty liver-prone mouse strains would be necessary. However, this 
method does not allow the investigation of acute effects during the different stages of fatty liver 
manifestation. One way to circumvent these drawbacks is to employ transient knock-down 
techniques by taking advantage of adenoviral gene delivery technology.  
3.1 Generation of adenoviruses encoding for shRNAs against murine GR 
To investigate the role of the GC/GR axis during fatty liver development adenoviruses encoding 
for shRNAs targeting the murine GR were generated. 
Thus, shRNA sequences targeting the murine glucocorticoid receptor were selected using 
sequence data derived from Danielsen et al. (99) (accession number: X04435, see Section 5.5.1). 
One shRNA sequence was kindly provided by Daniel Habermehl from the Department of 
“Molecular Biology of the Cell I” (Prof. G. Schütz, DKFZ).  
Sequences were first adapted to the BLOCK-iT™ U6 RNAi Entry Vector Kit by adding a 5’-
overhang of 4 nucleotides and a loop sequence (TTCAAGAGA) and then cloned into the 
pENTR/U6 vector to obtain a knockdown cassette composed of the U6 promoter driving 
shRNA expression followed by a Pol III termination signal flanked by two recombination sites. 
The U6 RNAi cassette was subsequently included into a vector encoding for the human 
adenovirus serotype 5 (pAd/BLOCK-IT™-DEST) by recombination. The virus is replication-
incompetent as the E1 and E3 gene are both deleted from the viral genome. A schematic view of 
the adenoviral vector construct including the knockdown cassette is shown in Figure 3.1 A. In 
vivo transcription of the oligonucleotide leads to the formation of a stem-loop structure of the 
shRNA as shown in Figure 3.1 B for one chosen oligonucleotide. This structure facilitates 
processing by the RNAi machinery leading to the removal of the loop structure by RNase III 
Dicer. One strand of the derived dsRNA molecule is incorporated into a large protein complex 
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(with RNase activity) named RNA-induced silencing complex (RISC), that guides the targeted 
RNA to degradation (100, 101). 
 
Adenoviruses were generated by transfecting the adenoviral vector into human embryonic 
kidney cells (HEK 293A) that complement for E1 and E3. After virus amplification and 
purification (see Section 5.5.3 to 5.5.5) the knockdown efficiency of the adenovirus was 
determined by infecting mouse hepatoma cells (Hepa 1C1 wt cells) with different multiplicities 
of infection (MOI). As control an adenovirus encoding for a nontargeting shRNA was generated, 
the sequence of which was tested in silico against the mouse genome. No significant sequence 
homologies were obtained with this sequence. Investigation of the GR levels in cell lysates from 
infected hepatoma cells via western blot 48h after infection revealed that the vector encoding for 
the GR shRNA1 proved to be efficient in a dose-dependent manner (Figure 3.1 C). Also GR 
shRNA2 and 3 were able to diminish GR, however less effectively. Thus for subsequent 
experiments GR shRNA1 was used. 
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Figure 3.1: Generation of an adenovirus constitutively expressing an shRNA sequence targeting 
the murine GR.  A) Vector map of the pAd/BLOCK-iT™-DEST GR shRNA consisting of 33566 bp 
with the viral genome starting at the 5’ L-ITR indicated in yellow up to the end of the 3’-ITR (not 
shown). The knockdown cassette composed of the U6 promoter (indicated with small brown arrow), an 
oligonucleotide encoding for the shRNA sequence (blue) and a Pol III termination signal adjacent to it. 
The adenoviral genome sequence shown in lightgreen contains deletions of the early genes E1 and E3. 
The vector carries the AmpR resistance gene (dark red). B) Schematic view of the shRNA sequence 
derived from the oligonucleotide sequence included in the vector. In vivo it forms a hairpin structure as 
shown. Highlighted in red are the 19 nt specifically targeting exon 8 of the murine GR. C) Evaluation of 
knock-down efficiency of the adenovirus. Cell lysates of mouse hepatoma cells were obtained after 
infection with different multiplicities of infection as indicated using either a virus encoding for a non-
targeting shRNA (Con) or targeting the mGR (GR). Specific antibody against GR was used, the lower 
band represents an unspecific band observed in hepatoma cells. CREB served as loading control.
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3.2 Transient knock-down of hepatic GR in two fatty liver mouse models 
Adenoviruses can be injected at any time during the induction of the fatty liver and into any 
mouse model making it a very flexible tool. The persistence of the virus varies with the 
transgene included in the viral genome, but typically within one week after injection viruses can 
still be detected. Administration of the virus via the tail vein leads to an exclusive infection of 
the liver while other tissues remain unaffected.  
To take advantage of these characteristics as a research tool in an initial screening experiment 
two different fatty liver mouse models were chosen – an acute and a chronic model.  
 
Prolonged fasting periods lead to lipolysis in peripheral tissues(102, 103) e.g. adipose tissue and 
a subsequent fat transport towards the liver promoting intra-hepatic triglyceride accumulation 
(104, 105). Increased fat content in the liver deteriorates hepatic insulin sensitivity(78, 81, 106) 
but fatty liver induction in wildtype mice is easily reversible by feeding the mice ad libitum 
after starvation periods. Therefore, this simple model represents an early step of fatty liver 
development. To induce a fatty liver, thus wildtype C57 BL/6J mice were starved for 24 hours 
to acutely induce hepatic fat accumulation.  
As a chronic model of fatty liver diabetic db/db mice were chosen. These mice possess a 
mutation in the leptin receptor gene (long form Ob-Rb) leading to a loss of central nervous food 
intake control (107, 108). They display a metabolic phenotype characterized by severe obesity, 
insulin resistance and fat accumulation in the liver (109). Since the fatty liver is not easily 
reversible they represent a more advanced stage of fatty liver manifestation. 
 
Initially, seven mice per group were injected with adenoviruses encoding for either a non-
targeting shRNA or the GR shRNA1. Wildtype C57 BL/6J mice were given a dose of 1 x 109 
ifu/mouse, while db/db mice received a dose of 3 x 109 ifu/mouse taking the higher average 
weight of db/db mice into account (wildtype mice average weight 22.3g±0.4g, db/db mice 
47.4±0.7g). Mice were maintained for 6 days on a chow diet and free access to water. 24h prior 
to sacrifice food was withdrawn from the wildtype mice. The following day, all experimental 
groups were sacrificed and biopsies from liver, epidydymal fat and muscle (Gastrocnemius) 
were taken together with serum samples for biochemical analysis. 
3.2.1 shRNA-induced knockdown of GR 
The shRNA-induced knockdown of the GR in the liver was investigated on the mRNA as well 
as on the protein level. RNA was isolated from livers of all mice. The obtained mRNA was 
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reversely transcribed into cDNA and subjected to quantitative RT-PCR using Taqman® probes 
against the murine GR. The obtained values were normalized against TATA box binding protein 
(TBP). As shown in Figure 3.2 A, knockdown of the GR in wildtype mice was 1.9-fold 
(p≤0,001) and 1.7-fold in db/db mice (p≤0,01) on mRNA level. Since the knockdown observed 
at the mRNA level was not very prominent, hepatic protein levels were investigated as well. 
Liver protein lysates from three animals per experimental group were prepared. Lysates were 
separated on 10% SDS polyacrylamide gels and investigated by immunoblotting using specific 
antibodies against GR (Santa Cruz) and Valosin containing protein VCP (Abcam). VCP served 
in this experiment as marker for unspecific effects observed after viral infection and remained 
unchanged in all experimental groups. Remarkably, knockdown of hepatic GR was more 
pronounced on the protein level than on the mRNA level (Figure 3.2 B, compare lanes 1-3 vs. 4-
6 in wildtype mice and 7-9 vs. 10-12 in db/db mice). In db/db mice GR was barely detectable 
despite the fact that on the mRNA level down-regulation of GR mRNA was less pronounced 
than in control mice. 
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Figure 3.2: Analysis of shRNA-induced GR depletion in the murine liver. Mice were injected with 
adenoviruses (AV) encoding for non-targeting shRNAs (Control shRNA) or encoding for GR-targeting 
shRNAs (GR shRNA) as indicated. Α  Quantitative RT-PCR of RNA isolated from livers of all virus-
treated mice using a specific Taqman® probe against murine GR. Results were normalized against TBP. 
Data shown are means and s.e.m. N=7, ** p≤0.01;*** p≤0.001 B) Western Blot analysis of liver lysates 
prepared from three representative animals per experimental group. 20µg protein were used for SDS-
PAGE. Immunoblotting was done using specific antibodies against GR (M-20, Santa Cruz) and VCP 
(Abcam). Individual lane represents one animal. 
  
Knockdown of hepatic GR to almost undetectable levels alleviated the fatty liver phenotype in 
db/db mice where hepatic triglyceride levels were reduced (control 492 ± 45 vs. GR shRNA 376 
± 81 µmol/g liver). In the acute model hepatic triglyceride content was not diminished by GR 
shRNA adenovirus administration probably due to lower viral dosage.  
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Overall, the data reveal that the adenovirus developed against murine GR is able to deplete the 
protein in vivo with high efficiencies. 
3.2.2 Target gene analysis after GR knockdown 
3.2.2.1 Examination of pathways regulating hepatic fat content 
Next, target genes involved in liver fat metabolism were investigated. Principally, liver fat 
content can increase due to de novo fat synthesis (lipogenesis) or due to decreased oxidative 
consumption of fatty acids (β-oxidation). Altered influx or efflux of triglycerides also represents 
a possible explanation. Rate-determining enzymes and/or transporters were chosen to 
investigate the respective pathways.  
 
Figure 3.3 represents the results obtained after target gene analysis in wt mice after starvation. 
To evaluate the effects of hepatic GR knockdown, expression of gluconeogenic genes was 
investigated as positive control. During extended fasting periods serum glucocorticoid levels 
rise, activating the GR(110). In the liver, activated GR stimulates gene expression of 
gluconeogenic genes – namely phosphoenolpyruvate carboxykinase (PEPCK) to maintain blood 
sugar levels within a narrow range(46, 47, 49). Depletion of hepatic GR, therefore should lead 
to attenuated activation of PEPCK expression compared to starved wildtype mice. As shown in 
Figure 3.3, GR depletion led to an only 25% reduction (relative mRNA levels control virus: 1 vs. 
GR shRNA: 0,76) of PEPCK expression under starvation conditions. These results suggest that 
hepatic activation of GR in control mice might have been only moderate under the experimental 
conditions. This might explain why the overall effects on target genes investigated were mild. 
However, GR knockdown led to a highly significant increase in β-oxidation as shown by the 
increase in the expression of carnitine palmitoyl transferase 1a (CPT1α), a transporter limiting 
fatty acid transport through the mitochondrial membrane, thereby representing the rate-
determining step in β-oxidation. Most interestingly, gene expression of a key-regulator of 
lipogenic and fat transport programs – peroxisome proliferation activation receptor gamma 
(PPARγ) – was diminished highly significant. Interestingly, lipogenic gene expression was not 
affected instead slight activation of acyl-CoA carboxylase 1 (ACC1) was observed. However, 
this activation was not significant. No major changes were observed in fat transport or serum fat 
regulation (Figure 3.3). 
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Figure 3.3: Target gene analysis in wildtype mice after GR depletion. Animals were starved for 24h 
prior sacrifice. RNA was isolated from livers of all animals, transcribed into cDNA and subjected to 
quantitative qPCR evaluation using specific Taqman® probes against the target genes as indicated. 
ACC1 - acyl-CoA carboxylase, Angptl3 – angiopoietin-like 3, Angptl4 – angiopoietin like 4, Cav1- 
caveolin1,  CPT1α – carnitine palmitoyl-transferase 1α, FABP-1- liver fatty acid binding protein, 
G6Pase- glucose-6-phosphatase, PEPCK – phosphoenolpyruvate carboxykinase, PPARα – peroxisome 
proliferation activating receptor α, PPARγ - peroxisome proliferation activating receptor γ (depicted 
twice to show involvement in different pathways). Data shown are means and s.e.m. N=7 per group *** 
p≤0.001.  
 
The same investigations were undertaken in db/db mice. Also in this experiment, the effect of 
GR depletion on PEPCK expression was investigated as a positive control. As shown in Figure 
3.4, transient knockdown of hepatic GR caused a 40% reduction of PEPCK expression, the 
effect of which was statistically significant.  
Again, a highly significant reduction of PPARγ expression was seen accompanied by 
downregulation of distinct target genes of PPARγ, namely fat transporters CD36 (46% ± 15%) 
and Cav1 (51% ± 15%, p≤0.05). Interestingly, classical lipogenic genes such as ACC1 were not 
affected suggesting a specific down-regulation of fat import into liver under these conditions. 
Furthermore, enhanced CPT1α indicated accelerated β-oxidation, consistent with observations 
made in wildtype mice after starvation. 
Finally, in db/db mice GR depletion affected regulation of serum fats as indicated by the 
changed expression of liver-specific angiopoietin-like 3 (Angptl3, 43% ± 7%, p≤0.05) and 
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Angptl4 (57 ± 8%). Angptl3 and 4 are proteins secreted into the serum. They act as inhibitors of 
lipoprotein lipase (LPL) (111), which is localized on the surface of adipocytes. Reduced 
expression of these factors might indicate an increased activity of LPL leading to faster fat 
clearance because of accelerated triglyceride uptake into fat cells. However, in the experiments 
undertaken serum triglyceride levels were increased in GR shRNA injected mice (control vs GR 
shRNA 3.0 ± 0.9 µmol/ ml vs. 8.6 ± 2 µmol/ ml). It is unclear whether decreased liver fat uptake 
contributes to the elevated serum levels and it remains to be determined whether LPL activity on 
adipocytes was increased as a consequence of decreased Angptl3 levels in these mice. 
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Figure 3.4: Target gene analysis in db/db mice after GR depletion. Animals were injected one week 
prior sacrifice and maintained on standard chow diet until sacrifice. RNA was isolated from livers of all 
animals, transcribed into cDNA and subjected to quantitative qPCR evaluation using specific Taqman 
probes against the target genes as indicated. ACC1 - acyl-CoA carboxylase, Angptl3 – angiopoietin-like 
3, Angptl4 – angiopoietin like 4, Cav1- caveolin1,  CPT1α – carnitine palmitoyl-transferase 1α FABP-1- 
liver fatty acid binding protein, G6Pase- glucose-6-phosphatase, PEPCK – phosphoenolpyruvate 
carboxykinase, PPARα – peroxisome proliferation activating receptor α, PPARγ -  peroxisome 
proliferation activating receptor γ. Data shown are means and s.e.m. N=7 per group *p≤0.05*** p≤0,001.  
 
In summary, effects of transient GR knockdown were more pronounced in db/db mice as 
suggested by suppression of PEPCK expression. These observations correlate with the initial 
viral doses used in the individual experiments (1 x 109 ifu/mouse in wildtype mice vs. 3 x109 
ifu/mouse in db/db mice).  
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Analysis of potential target genes of GR revealed that PPARγ and CPT1α were two genes 
consistently regulated in both mouse experiments. In contrast, no significant changes in 
lipogenesis were observed.  
In db/db mice GR knockdown furthermore led to suppression of fat transporters Cav1 and CD36 
as well as Angptl3 and 4, which represent secreted inhibitors of LPL.  
3.2.2.2 Hes-1 – a transcription factor differentially regulated after hepatic GR 
knockdown 
When investigating genes differentially regulated after hepatic GR knockdown , the 
transcriptional repressor Hairy and Enhancer of Split 1 (Hes-1) was found to be increased after 
GR depletion in wildtype mice (1.3 fold, p≤ 0.05) and more dramatically in db/db mice (2,6-fold, 
p≤0.001) on the mRNA level. These changes were also reflected in the protein levels of Hes-1 
as shown in Figure 3.5. While no dramatic effects were detectable in C57 BL/6J mice (Figure B 
compare lanes 1-3 vs. 4-6), a marked up-regulation of Hes-1 was present in db/db mice injected 
with GR (Figure C compare lines 1-3 vs. 4-6). 
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Figure 3.5: Hes-1 expression is up-regulated after GR knockdown. C57 BL/6J mice were injected 
with adenoviruses encoding for either non-targeting shRNA (control shRNA) or GR shRNA 
(109ifu/mouse) and starved 24h before sacrifice. Db/db mice were injected with 3 x 10  ifu/mouse of the 
same viruses as indicated. A) Quantitative RT-PCR from hepatic RNA isolated from these mice using 
specific Taqman® probes against Hes-1. TBP was used for normalization. Data shown are means and 
s.e.m. N=7 per group * p≤0.05 , **p≤0.01. B) Western Blots from hepatic protein extracts isolated from 
the same animals as under A) and probed with specific antibodies as indicated. Individual lane represents 
one mouse. VCP served as loading control. 
9
 
These findings were very interesting since recently, Hes-1 has been identified as a novel 
regulatory switch and key determinant in hepatic lipid homeostasis under fasting conditions 
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(one simple model of fatty liver). Remarkably, Hes-1 was shown by Herzig et al. to inhibit the 
expression of nuclear hormone receptor peroxisome-proliferator-activated receptor γ (PPARγ), a 
key regulator of insulin-dependent lipogenesis in hepatic tissue (112).  
Intriguingly, as shown in Figure 3.5 knockdown of the GR led to an up-regulation of Hes-1 in 
two models of fatty liver development and the increased Hes-1 levels correlated with inhibition 
of PPARγ consistent with literature data. However, the functional role of Hes-1 in fatty liver 
development was completely unclear. 
  
3.3  Investigation of Hes-1 levels in different fatty liver mouse models 
 
To investigate the hypothesis that differentially expressed Hes-1 represents a characteristic of 
fatty liver development and a downstream target of the GR pathway, Hes-1 expression patterns 
in several fatty liver mouse models were examined. 
3.3.1 Starvation-induced fatty liver 
In an initial test experiment Hes-1 levels in starved and refed mice were measured. Male 9 week 
old C57 BL/6J mice were starved for 6 hours, 24h and 48h with free access to water. Control 
mice were starved for the same time but subsequently refed for another 24h before sacrifice. 
Liver biopsies and serum samples were taken from all mice for biochemical analysis.  
 
To monitor the amount of fat stored in the liver during treatment liver lipids were isolated (see 
Section 5.3.8) and triglyceride content was measured (see Section 5.3.10.1). After 24h food 
deprivation hepatic triglycerides were elevated 7.6-fold compared to the control group (Figure 
3.6 A compare bar 1 vs. bar 3,). Two days of starvation led to a 13-fold accumulation of TGs in 
the liver.  
 
Hes-1 expression was determined using qPCR analysis. Thus, mRNA was isolated from liver 
samples of fasted and refed animals and trancribed into cDNA. Interestingly, Hes-1 expression 
was down-regulated on the mRNA level 3.4-fold after 24h of starvation, the level of which did 
not further decrease during longer starvation periods (Figure 3.6 B 2.8-fold after 48h starvation). 
Hes-1 protein level was also diminished compared to control mice (Figure 3.6 C, compare lane 
1-3 vs. 4-6). Control mice did not differ in their Hes-1 values irrespective of the duration of 
starvation before the 24h refed period (data not shown). 
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Figure 3.6: Starvation-induced fatty liver and hepatic Hes-1 expression. A) Triglyceride content in 
liver extracts from C57 BL/6J mice. Time of starvation as indicated. Data shown are mean values and 
s.e.m. N=3. B) Quantitative RT-PCR analysis from RNA isolated from the same animals as under A) 
using Hes-1 specific primers. mRNA expression normalized to TBP values. Data are shown as mean 
values and s.e.m. N=3. C) Western Blot analysis of hepatic Hes-1 expression of mice starved for 48h 
(lane 4 to 6) or starved for 48h and then refed for 24h (lane 1-3). VCP serves as loading control.  
 
Down-regulation of Hes-1 under fasting conditions inversely correlated with increased liver 
triglycerides. However, while triglyceride levels still increased after 48h of starvation, Hes-1 
levels did not further decline indicating that minimum expression is already reached after 24h 
food deprivation. 
 
3.3.2 Chronic fatty liver models 
Db/db mice: Next, db/db (C57 BLKS/J Lepr_/_) animals were examined as an example of a 
chronic fatty liver model. Since a marked Hes-1 down-regulation in C57 BL/6J mice was 
already observed after 24 h starvation, db/db mice and wildtype controls with the same genetic 
background (C57 BLKS) were starved for 24 h or starved and subsequently refed for 24h. 
Surprisingly, in hepatic protein extracts of starved animals, no differences in Hes-1 protein 
levels were detected. However, in the refed group Hes-1 protein levels were significantly 
inhibited in db/db animals (Figure 3.7). Since it was observed before (Figure 3.6), that 
starvation itself diminishes Hes-1 protein levels, the comparable low protein amounts of Hes-1 
seen in db/db and wildtype mice might be associated with a starvation-induced Hes-1 inhibitory 
factor/ signal. 
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Figure 3.7: Hes-1 expression in db/db mice – a standard model of fatty liver. A) Western Blot 
analysis of liver protein extracts from db/db mice or wt controls after 24 h starvation. B) Western Blot 
analysis of liver protein extracts from db/db mice or wildtype controls after 24h starvation and 24h 
refeeding period. VCP served as loading control. 
 
Polygenic NZO mice: Db/db mice are excellent models of monogenic obesity and useful for 
researching type 2 diabetes, however they do only partially reflect the more common human 
obesity-induced diabetes (diabesity) syndromes and their dramatic phenotype is less 
characteristic for the metabolic syndrome (113, 114). Common human diabesity syndromes are 
polygenic, not monogenic, and therefore a polygenic mouse model of severe obesity and 
impaired glucose tolerance was chosen in addition to db/db mice. New Zealand Obese 
(NZO/HlJ) mice are in this respect the most useful mouse strain for investigations. These mice 
exhibit high birth weights and develop severe obesity even when maintained on a standard diet 
containing 4,5% fat (113, 115). Both sexes are characterized by impaired glucose tolerance, but 
subsequent type II diabetes maturity onset is limited to males with a phenotype penetrance of 
less than 50%. Therefore, these mice allow observation of Hes-1 levels in a complex model of 
the so called metabolic syndrome that is mainly characterized by alterations in fat metabolism.  
 
To explore whether Hes-1 downregulation is a feature of fatty liver in New Zealand Obese mice, 
male 10 weeks old mice were starved for 24h and sacrificed or refed after the starvation period 
for 24h and then sacrificed. As wildtype control served New Zealand Black mice (NZB). As 
shown in Figure 3.3, there is a tendency towards attenuated hepatic Hes-1 protein levels in NZO 
mice after re-feeding compared to NZB litters (Figure 3.8 compare lane 1-3 vs. 4-6). . 
NZB mice display a number of autoimmune abnormalities and during the course of the 
experiment NZB mice from the starvation group had to be sacrificied because of wounds and 
impaired wound healing most likely caused by autoimmune reactions. Hence, the number of 
mice investigated after starvation was decreased drastically. 
Hepatic Hes-1 protein levels of an unaffected NZB mouse were compared to a starved NZO 
mouse and a marked reduction in the New Zealand Obese mouse was observed. However, this 
tendency needs to be confirmed under starvation conditions by a representative group of animals. 
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In summary, NZO mice exhibit a tendency towards lowered hepatic Hes-1 levels while at the 
same time have higher hepatic fat content (116). 
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Figure 3.8: Hepatic Hes-1 expression in New Zealand Obese mice – a polygenic model of obesity 
and diabetes. Western Blot analysis of wildtype new zealand black mice (NZB) or new zealand obese 
mice (NZO) after starvation for 24h (fasted) or after starvation for 24h and subsequent refeeding for 
another 24h (refed). 
3.3.3 Model of diet-induced obesity (DOI) 
Finally, the influence of dietary components on hepatic Hes-1 expression was probed. In 
cooperation with the group of Sander Kersten from the University of Wageningen C57BL/6J 
mice were maintained either on a chow diet containing 10% fat or on a high fat diet with 45% 
fat. This high fat diet has been demonstrated in the past to lead to hepatic fat accumulation and 
to promote the development of a fatty liver (117) (109). 
C57BL/6J mice were maintained on the either chow diet or high fat diet for 2 weeks or 16 
weeks and then sacrificed in the random fed state. Protein extracts from liver were made and 
Hes-1 levels were investigated by immunoblotting.  
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Figure 3.9: Hepatic Hes-1 levels diet-induced obesity. A) Western Blot analysis of hepatic Hes-1 
expression with Hes-1 specific antibody in mice maintained for 2 weeks on a diet as indicated. LFD – 
10% low fat diet; HFD – 45% high fat diet. VCP served as laoding control. B) Western Blot analysis of 
hepatic Hes-1 expression with Hes-1 specific antibody in mice maintained for 16 weeks on a diet as 
indicated. LFD – 10% low fat diet; HFD – 45% high fat diet. VCP served as laoding control. 
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Unexpectedly, high-fat feeding of C57BL/6J mice for two weeks led to a slight induction of 
Hes-1 expression (Figure 3.9). Elevated Hes-1 protein levels ,however, were not observed after 
16 weeks treatment. These data suggest, that excess fats causing a fatty liver are not responsible 
for diminished Hes-1 levels. Furthermore, they indicate that the inhibition of Hes-1 
distinguishes different models of fatty liver development induced by different signals. 
 
Taken together, Hes-1 expression is diminished in starvation-induced fatty liver and chronic 
monogenic and polygenic mouse models of fatty liver disease. Hence, Hes-1 expression in fact 
is down-regulated in a variety of models. In contrast, Hes-1 levels remained largely unaffected 
in fatty livers that develop upon diet-induced obesity.  
3.3.4 Determination of serum glucocorticoids in fatty liver mouse models 
In the GR knockdown experiment Hes-1 expression was initially found to be activated. Thus, it 
was tempting to speculate that decreased Hes-1 levels would likely be caused by activation of 
hepatic GR in the investigated models. Using a radioimmuno-assay serum glucocorticoid levels 
were determined after starvation, in db/db mice and in NZO mice. 
 
As shown in Figure 3.10, serum glucocorticoids are increased in db/db mice when compared to 
their respective controls (388 ± 69 ng/ml vs. 113 ± 5 ng/ml, p≤0.01). As explained earlier, 
fasting is accompanied by enhanced GC levels and therefore mice fasted for 24h have 
significantly higher serum GC levels (356 ± 95 vs. 52 ± 6ng/ml). Unexpectedly, 
hypercorticoism was not observed in refed NZO mice when compared to their control 
background (NZB mice). However, as shown in Figure 3.8, most dramatic effects on Hes-1 
levels in NZB were measured under fasting conditions. Limited sample numbers did not allow 
examination of serum GC levels, so more studies are necessary to determine whether GC levels 
differ between NZB and NZO mice after fasting. 
Serum samples for high fat diet fed mice were not available, but several reseachers already 
proved that 16 weeks of HFD have no influence on serum GC parameters (118-119). 
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Figure 3.10: Serum glucocorticoid levels in different mouse models. Radioimmunoassay was used for 
determination of GC levels. Probed were db/db mice vs. control mice (bar 1 vs. bar 2), C57BL/6J fasted 
for 24h (wt fasted) or fasted and then refed for 24h (wt refed, bar 3 vs. bar 4) and refed NZO vs. refed 
NZB mice as indicated. Data shown are means and s.e.m. N=4 per group, *p≤0.05  **p≤0.01.  
 
3.4 The physiological signal causing decreased Hes-1 expression 
Observing the strong correlation between serum glucocorticoid levels and decreased Hes-1 
levels, it was important to investigate the functional relevance of an activated GC/GR axis in the 
regulation of hepatic Hes-1 protein levels. 
 
3.4.1 Glucocorticoid treatment of C57BL/6J mice and the consequences on hepatic Hes-1 
expression 
To test the hypothesis that GCs can trigger Hes-1 down-regulation in vivo, 10 weeks old male 
C57 BL/6J mice were injected with 1.2 mg/kg dexamethasone (dex) or 0,9% sodium chloride 
(saline) daily intraperitoneally over a period of 3 weeks (120-121). Mice were housed 
individually and injections were performed at 8 am at the beginning of the 12h light phase. The 
weight development of each individual animal was assessed daily and is shown in Figure 3.11 A. 
In the experimental period, dex-treated animals lost 10% ± 3% body weight while the weight of 
the control group was constant (100 ± 0.9% of initial body weight). The dramatic body weight 
change measured at day 17 was caused by overnight starvation of the mice because on day 17 a 
glucose tolerance test was performed (indicated with an arrow, Figure 3.11 A). Food 
consumption of all animals was monitored and did not differ between the two experimental 
groups (data not shown), although GCs have been described to stimulate appetite (122, 123). 
Hence, the weight loss in the dex-treated group is not due to altered food intake but most likely 
because of the catabolic action of glucocorticoids (102). 
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13 days after start of dex injections, blood samples were withdrawn from the mice and serum 
lipid parameters were measured. Surprisingly, serum triglycerides were decreased significantly 
in the dex-treated animals (Table 1) compared to the control group, while non-esterified fatty 
acid (NEFA) levels were indistinguishable between the two groups. Interestingly, the amount of 
cholesterol was increased in the group receiving dexamethasone.  
 
Table 1: Serum lipid parameters 13 days after Dexamethasone injection 
 Saline Dexamethasone p-value 
Triglycerides 17.6 ± 2.7 µmol/ml 12.2 ± 0.5 µmol/ml 0.0077 
Cholesterol 97.4 ± 6.9 mg/dl 134.8 ± 9.0 mg/dl 0.006 
NEFA 14.4 ± 3.3 mg/dl 16.2 ± 6.2 mg/dl 0.583 
 
After 17 days, the influence of glucocorticoids on the systemic glucose sensitivity was assessed. 
For this purpose, a glucose tolerance test was performed on day 17 of dexamethasone injection. 
Overnight-fasted animals received an intraperitoneal injection of glucose (see Section 5.4.1) and 
declining blood glucose levels were monitored over 2h. As shown in Figure 3.11 B, both groups 
were equally glucose sensitive despite altered serum cholesterol levels. The area under the curve 
(AUCcontrol = 29880 min x mg/dl, AUCdex = 32089 min x mg/dl) did not differ significantly.  
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Figure 3.11 Glucocorticoid treatment leads to weight loss. A) Weight development of C57 BL/6J 
mice injected with 1.2 mg/ kg dex or saline (control) i.p. daily. Arrow indicates overnight starvation 
during course of experiment. N=4. B) Glucose tolerance test of C57 BL/6J mice after 17 days of daily 
injections. Mice were starved overnight and were injected with 10µl of a 20% w/v glucose solution per g 
body weight. N=4. 
 
Bernal-Mizrachi et al. described that a 3-week dex injection into C57 BL/6J mice impair 
glucose tolerance and systemic insulin sensitivity (120). They also observed changes in fat 
metabolism contributing to the reported phenotype. To reproduce these observations, animals 
 
3. Results 
 
40
were sacrificed 23 days after injection and important tissues of energy homeostasis were 
isolated and weighed. In Table 2 results of different organ weights after dissection are 
summarized.  
 
Table 2: Organ weight parameters and blood glucose in dexamethasone injected 
C57BL/6J mice 
 control Dex p-value 
Body weight [g] 24.9 ± 0.82 22.5 ± 0.4  0.0019 
Blood glucose [mg/dl] 160.5 ± 17.9  119 ± 14.1  0.011 
Liver weight [g] 1.29 ± 0.09  1.06 ± 0.03 0.004 
Epidydymal fat [mg] 149.5 ±28.2  132 ± 22.3  - 
Gastrocnemius + Soleus [mg] 151 ± 5.7  135.8 ± 7.5 0.0004 
Tibialis anterior [mg] 50.8 ±2.7 44.6 ± 3.4 0.001 
Heart [mg] 161.5 ± 12.4 159.5 ± 9.7  - 
 
Clearly, muscle mass of peripheral muscles (gastrocnemius + soleus 10% weight loss and 
tibialis anterior 12% weight loss) was reduced, while no influence of dexamethasone on heart 
muscle mass was observed. The amount of epidydymal fat, the main visceral fat depot of the 
mouse remained unaffected by chronic GC treatment arguing against the hypothesis that GC 
treatment generally increases visceral fat depots (124, 125).  
 
The absolute liver weight of the dex-treated animals was 18% less than in control mice but 
relatively to the body weight the liver weight was comparable (5.2% of body weight in control 
mice, 4.7% in dex-treated mice, Table 2).  
 
To investigate the effects of glucocorticoid treatment on hepatic lipid homeostasis, liver fats 
were isolated and measured. Hepatic triglycerides were 3-fold increased in dexamethasone-
treated mice and the TG accumulation was highly significant (p ≤ 0.01, Table 3). Furthermore, 
the rise in triglycerides was specific as hepatic NEFA and cholesterol content remained 
unchanged after dex injection. The experiment clearly demonstrated that chronically elevated 
glucocorticoid levels augment liver triglyceride content and therefore promote fatty liver 
development.  
Interestingly, accumulation of hepatic triglycerides did not coincide with elevated serum 
triglyceride levels. Compared to the levels after 13 days of injection serum triglycerides 
declined approximately 2-fold in both experimental groups on day 23, but there were no 
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differences between dex-treated and saline-treated animals at the day of sacrifice (Table 3). 
Again, serum cholesterol – a prognostic marker for the development of the Metabolic Syndrome 
– was increased highly significant. Free fatty acid levels in liver and serum were 
indistinguishable between the experimental groups.  
 
Table 3: Lipid parameters at day of sacrifice.  
 Control Dex p-value 
Liver    
Triglycerides [µmol/g liver] 60.9 ± 52.2 183.51 ± 40.1 0.0098 
Cholesterol [mg/g liver] 264.3 ± 78.9 192.2 ± 22.2 0.129 
NEFA [mg/g liver] 66.5 ± 31.1 49.7 ± 14.6 0.365 
Serum    
Triglycerides [µmol/ml] 8.29 ± 2.2 4.41 ± 2.1* 0.064 
Cholesterol [mg/ml] 96.4 ± 4.5 121.3 ± 9.6* 0.0056 
NEFA [mg/ml] 28.3 ± 10.5 35.3 ± 6.1* 0.359 
Data are shown as mean ± standard deviation. Per experimental group N=4,  *Mean values are from three 
animals only. Serum samples were not available for one animal. 
 
Finally, Hes-1 expression was investigated on the mRNA and on the protein level. The dex-
induced fatty liver correlated with diminished Hes-1 levels on the mRNA level (4.5-fold 
decrease, p< 0.001, see Figure 3.12 A) as well as on the protein level (Figure 3.12 B). At the 
same time, liver fat accumulation was observed. Other members of the Hes-1 family that are 
usually not expressed in hepatocytes namely Hes-3 and Hes-5 (126) were investigated for 
compensatory up-regulation. However, levels of Hes-3 and Hes-5 were not detectable in liver 
after GC stimulation.  
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Figure 3.12: Chronically elevated glucocorticoid levels inhibit hepatic Hes-1 expression. A) 
Quantitative RT-PCR analysis of RNA isolated from livers of C57 BL/6J mice treated for 3 weeks with 
1,2 mg/kg dexamethasone using Hes-1 specific primers. Normalisation against TBP. Shown are mean 
values and s.e.m. N=4. B) Western Blot Analysis of hepatic protein lysates from the same animals as 
under A). VCP serves as loading control.  
 
The experimental results underline the concept that in vivo glucocorticoids are the signal 
causing decreased Hes-1 expression. The data are consistent with the observation, that Hes-1 
expression is attenuated in fatty liver mouse models and that Hes-1 expression increased in GR 
loss-of-function models. 
3.4.2 Starvation experiment in mice with a hepatic glucocorticoid receptor knock-out 
Glucocorticoids exert their action via the glucocorticoid receptor and to a lesser extend through 
the mineralocorticoid receptor. The synthetic glucocorticoid analogue dexamethasone, however, 
almost exclusively binds to the GR. Therefore, effects seen after dex treatment are attributed to 
the GR. In earlier experiments a correlative relationship between elevated glucocorticoid levels 
and diminished hepatic Hes-1 expression has been established.  
To ultimately prove a causal link between the GC/GR axis and the regulation of Hes-1 
expression in vivo, mice bearing a targeted genetic disruption of the glucocorticoid receptor in 
the liver (L-GRKO) were used. The mice were kindly provided by M. Kirilov and G. Schütz 
(DKFZ). Generation of the L-GRKO mice has been described previously (97, 98).  
 
Three mice per experimental group were available, however control mice were 4 months old 
while L-GRKO mice were 6 months old. To test the regulation of hepatic Hes-1 expression 
depending on a functional GR, control mice and L-GRKO mice were starved for 48h to increase 
serum GC levels and to induce triglyceride accumulation in the liver. Control refed groups for 
both genotypes were starved for 48h and subsequently refed for 24h. At the day of sacrifice 
body weight and blood glucose was determined. As shown in Table 4, L-GRKO mice were in 
average heavier than controls. No apparent differences in blood glucose values were measured, 
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although in L-GRKO mice blood glucose values in response to fasting had been reported to be 
decreased because of limited activation of gluconeogenic programs (98).  
Table 4: Body weight and blood glucose parameters of L-GRKO mice 
 control starved L-GRKO starved control refed L-GRKO refed 
body weight [g] 28.3 ± 0.7 32.9 ± 7.8 32.6 ± 5 36.9 ±5.3 
blood glucose 
[mg/dl] 
79 ± 22 75 ± 13 148 ± 16 162 ± 11 
 
As shown in Figure 3.13, a 2.5-fold induction of hepatic TG content was measured in wildtype 
mice after 48h starvation. In contrast, starvation of L-GRKO mice for 48h led only to a mild rise 
in liver triglyceride levels (1.4-fold induction). Moreover, in starved L-GRKO mice Hes-1 
mRNA levels were maintained on refed niveau while in the wildtype mice a 2.3-fold decrease 
was observed following starvation. Despite the limited number of animals per group the data 
suggested, that a functional GR is necessary to conduct the glucocorticoid-mediated suppression 
of hepatic Hes-1.  
Most notably, L-GRKO mice are protected against the GC/GR-dependent fatty liver induction. 
Therefore, the results clearly established a direct causal link between the GR activation and Hes-
1 suppression.  
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Figure 3.13:The Glucocorticoid receptor is necessary for starvation induced Hes-1 down-
regulation. A) Induction of triglycerides in hepatic lipid extracts from wt or liver glucocorticoid receptor 
knock out (GRKO) mice after 48h starvation (fasted) or 48h starvation and 24h refed period. Shown are 
mean values and s.e.m. N=3 per group. B) Quantitative RT-PCR from RNA isolated from the same 
animals as under A) with Hes-1 specific probes. Normalization against TBP. Shown are mean values and 
s.e.m. N=3 per group.
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3.5 Rescue of Hes-1 levels during starvation and in a pathophysiological 
mouse model  
3.5.1 Hepatic Hes-1 overexpression in wt C57BL/6J mice 
 
The inhibition of Hes-1 expression in fatty liver mouse models (see Section 3.3) prompted us to 
restore the protein levels transiently. Adenoviruses containing either a rat Hes-1 transgene or the 
GFP protein were used. Transgene expression was under the control of the constitutively active 
CMV promoter (Figure 3.25). 1 x 109 ifu were injected via the tail vein into C57BL/6J mice.  
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Figure 3.14: Adenoviral vector encoding rat Hes-1. Expression of the transgene Hes-1 (orange) is 
driven by CMV promoter (light green). To monitor virus localization GFP as second transgene (light) 
green is included. Vector carries a KanR resistance gene and the adenoviral genome of serotype 5. E1 and 
E3 are deleted (not shown). 
 
First, the effect of transient Hes-1 expression in liver was investigated in male 8 weeks old C57 
BL/6J mice treated with either GFP expression virus or Hes-1 expression virus. Initially, each 
experimental group consisted of five mice. On the day of injection no statistically significant 
differences in weight or blood glucose levels between the four groups were determined (Table 
3.1). After injection, mice were maintained for six days on a chow diet. On day 6, the animals 
were starved for 48h (starvation group) to induce fat accumulation in the liver (see Section 
3.3.1). Control mice were refed after the starvation period for 24h before sacrifice. On the day 
of sacrifice again no differences in body weight or blood glucose levels were measured (Table 
5). 
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Table 5:  Body weight and blood glucose at start and end of experiment 
  GFP starved Hes-1 starved GFP refed Hes-1 refed 
body weight [g] 17.94 ± 1.6 18 ± 1.3 17.42 ± 1.9 19.2 ± 1 
day 0 blood glucose 
[mg/dl] 
145 ± 12 168 ± 18 150 ± 13 161 ± 16 
body weight [g] 15.43 ± 1.3 16.5 ± 1.2* 16.7 ±1.5 17.5 ± 0.6**
day of 
sacrifice 
blood glucose 
[mg/dl] 
39 ± 5 43 ± 9* 126 ± 34 125 ± 15**
*one mouse died in this experimental group during course of experiment, ** two mice died during 
experiment 
 
Notably, injection of Hes-1 expression virus led to an increased mortality of C57 BL/6J mice (3 
of 10 animals died within 8 days after injection). The molecular rationale, however, is unclear.  
Starvation of C57BL/6J mice led in the control virus group to a 4-fold induction of hepatic 
triglycerides (814 µmol/g liver fasted vs. 211 µmol/g liver refed). Animals injected with Hes-1 
virus responded with a mixed phenotype. In two animals a marked reduction in hepatic 
triglyceride levels after starvation was observed (197 and 231 µmol/g liver), while the two other 
animals had equally high triglycerides (1078 and 874 µmol/g liver) compared to mice injected 
with control virus. Within the refed groups, a tendency towards lower liver triglycerides in the 
Hes-1 group was observed (mean of 89 µmol/g liver vs. 211 µmol/g liver in the control group, 
Figure 3.15 A). However, this effect was not statistically significant. 
 
Hes-1 had been implicated in hepatic lipid metabolism, though it was unknown whether Hes-1 
would affect systemic insulin resistance when over-expressed in liver. To test this, an insulin 
tolerance test was performed 5 days after virus-injection. Animals received an insulin dose of 
1.5 U/ kg body weight and the blood glucose decline was monitored for 2h. The test was 
performed before a fatty liver was induced by starvation. Therefore, the impact of Hes-1 
overexpression under otherwise physiological conditions was investigated. Hepatic Hes-1 
expression in wildtype C57BL/6J mice did not have any beneficial or negative effects on 
systemic insulin sensitivity (Figure 3.15 B). It remains speculative, however, whether insulin 
sensitivity in healthy mice is maintained at an optimum, or whether it could be still increased by 
manipulations such as hepatic overexpression of Hes-1. 
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Figure 3.15: Transient Hes-1 expression in C57Bl/6J mice. A) Triglyceride content in liver extracts of 
starved or refed C57BL/6J mice injected with 1 x 10  ifu GFP control or Hes-1 adenovirus. Dots 
represent individual animal. B) Insulin tolerance test in C57BL/6J mice after adenoviral injection. 
Animals were injected at 0 min with insulin (1,5U/kg bodyweight) and the blood glucose levels were 
measured at the timepoints indicated. Shown are mean values and s.e.m. N=5.  
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3.5.2 Hepatic Hes-1 overexpression in db/db mice 
Db/db mice are characterized by dyslipidemia and develop a fatty liver when fed ad libitum. In 
refed db/db mice, a marked down-regulation of Hes-1 protein has been demonstrated in 
previous experiments (see Section 3.3.2). Therefore, hepatic Hes-1 levels were restored in a 
mouse model with chronically perturbed liver lipid metabolism to evaluate the protein’s 
function in this setting and to investigate the impact of hepatic Hes-1 expression on systemic 
insulin sensitivity. 
 
Male, 13 weeks old db/db mice were injected with 1 x 109 ifu of either Hes-1-expressing 
adenovirus or GFP control adenovirus. Animals were sacrificed 7 days (starvation groups) or 8 
days (refed groups) after adenoviral injection. On day 0 no significant differences in body 
weight or blood glucose were determined (Table 7). During the experiment, Hes-1 injected mice 
had a tendency towards lower total body weight as they lost more of their initial weight (Figure 
3.16 A). The trend was at no time point statistically significant, however, on day 5, weight 
differences were most considerable (p=0.058). The Hes-1 specific effects on body weight on the 
days of sacrifice for starved or refed animals, respectively, might be masked by the influence of 
starvation and refeeding on total body weight. As shown in Table 6 the absolute body weight 
values of starved GFP mice were higher than starved Hes-1 mice, although animals lost the 
same percentage of initial body weight after 7 days in both groups (Figure 3.16 A). Also in the 
refed group no differences in the percental body weight loss was observed after 8 days.  
Blood glucose decrease in starved mice was equal in both groups (70 mg/dl after starvation), 
after refeeding, however, a trend towards normalized blood glucose levels was detected in Hes-1 
expressing mice (Hes-1: 163 mg/dl vs. 352 in GFP mice, Table 6) strengthening the notion that 
these mice had improved glucose control.  
 
Table 6: Body weight and blood glucose parameters at day of sacrifice 
  GFP starved Hes-1 starved GFP refed Hes-1 refed 
body weight [g] 54.6 ± 1.5 51.3 ± 3.1 51.4 ± 2.6 48.6 ± 3.2 
day 0 blood glucose 
[mg/dl] 
442 ± 41 332 ± 65 360 ± 38 352 ± 96 
body weight [g] 50.4 ± 1.6 46.6 ± 2.2 49.6 ± 2.6 45.8 ± 1.6 
day of 
sacrifice 
blood glucose 
[mg/dl] 
70 ± 21 70 ± 19 237 ± 150 163 ± 38 
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On day 5, an insulin tolerance test in mice fed ad libitum was conducted. Intriguingly, systemic 
insulin sensitivity was markedly improved as shown in Figure 3.16 C. Blood glucose levels in 
Hes-1 mice declined faster, reaching statistical significance 60 min and 120 min after insulin 
injection. Hes-1-injected mice exhibited a stronger response to insulin characterized by the 53% 
decrease of blood glucose levels compared to a 32% decrease in GFP-treated mice. Integration 
of the curve revealed differences in the area under curve (AUC) value of 20% (AUCGFP=8395 
min x mg/dl vs. AUCHes-1= 6697 min x mg/dl).  
 
Hepatic triglycerides in db/db animals are moderately elevated (127). Therefore, liver fat 
content was stimulated additionally by starvation for 48h before sacrifice. To examine the 
impact of Hes-1 on hepatic lipids, liver fat was extracted and triglyceride and cholesterol levels 
were determined colorimetrically. 
Remarkably, restored hepatic Hes-1 expression prevented hepatic triglyceride accumulation 
during starvation (Figure 3.16 D, Hes-1 virus 215 ± 84 vs. GFP virus 631 ± 148 µmol/g liver, 
p=0,016). Consistently, total triglycerides in refed mice were also 3,4-fold lower in Hes-1 
expressing mice (Hes-1 virus 99 ± 28.6 vs. GFP virus 334 ± 98 µmol/g liver, p=0.04).  
Furthermore, the effect was highly specific for triglycerides since hepatic cholesterol levels 
remained unaffected (Figure 3.16 F). Liver cholesterol levels did not change in response to 
starvation and re-feeding in liver and injection of Hes-1 virus also did not influence the liver 
cholesterol levels. 
To investigate whether the effects of Hes-1 on hepatic TG levels have an impact on VLDL 
secretion or blood lipid parameters in general serum triglycerides were measured. Generally, the 
serum TGs ranged between 8 and 25 µmol/ ml (3.16 E). These values underline the severe 
hypertriglyceridemia, since mice fed a high fat diet have serum triglycerides around 2 µmol/ml 
(128). However, despite reduced liver TGs, serum TGs were indistinguishable between the 
experimental groups. Furthermore, within the experimental groups the variation between 
individual animals was very high, indicating that the extend of hypertriglyceridemia was diverse. 
 
In summary, Hes-1 re-expression in livers of db/db mice, a chronic fatty liver model, generally 
improves the diabetic phenotype by reducing hepatic triglyceride storage and improving 
systemic insulin sensitivity. Trends towards normalized blood glucose levels in refed animals 
remain to be confirmed by further experiments. 
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Figure 3.16: Transient Hes-1 expression in db/db mice improves the metabolic phenotype. A) Body 
weight development of C57 BL/6J mice injected with 10  ifu GFP control virus or rat-Hes-1 virus during 
the course of experiment. *** p≤0.001, * p≤0,05 N=8, at day 8 N=4 Β  Western Blot analysis of Hes-1 
overexpression in virus treated animals using Hes-1 specific antibody. CREB served as loading control. 
C) Insulin tolerance test in db/db mice after adenoviral injection. Animals were injected at 0 min with 
insulin (1,5U/kg bodyweight) and the blood glucose levels were measured at the timepoints indicated. 
Shown are mean values and s.e.m. N=5. D) Triglyceride content in liver extracts of starved or refed 
db/db mice injected with 1 x 10  ifu GFP control or Hes-1 adenovirus. Same mice as under A) N=4  Dots 
represent individual animal E) Serum triglyceride levels of the same animals. N=4. F) Cholesterol 
content in liver extracts of the same animals as under B) N=4
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3.5.3 Phenotype analysis of Hes-1 overexpression in db/db mice 
 
Hes-1 is a transcription factor regulating gene expression, therefore the phenotype in db/db mice 
observed after adenoviral injection of Hes-1 was investigated on the molecular level using RT-
PCR techniques.  
Biochemical pathways known to either regulate or have an impact on lipid metabolism were 
probed by investigating expression levels of rate-determining enzymes/ transporters within these 
pathways. The results of this analysis are listed in Table 7. 
 
Table 7: Gene expression data from db/db mice treated with Hes-1 virus or control 
Gene GFP refed GFP starved Hes-1 refed Hes-1 starved 
De-novo triglyceride synthesis    
PPARγ 1 0.74 0.78 0.75 
FAS 1 0.1 1.51 0.13 
ACC1 1 0.25 1.15 0.18 
SCD1 1 0.15 0.98 0.16 
β-oxidation    
PPARα 1 0.71 0.9 0.74 
CPT1α 1 1.37 1.05 1.92 
Fat transport     
FABP-1 1 0.71 0.59 0.79 
Caveolin 1 0.62 0.66 0.61 
CD36 1 1.14 0.77 1.21 
ApoB 1 1.08 1.31 1.6 
MTTP 1 1.05 1.11 0.97 
Gluconeogenesis     
GK 1 0.54 0.78 0.44 
PEPCK 1 0.67 1.39 1.18 
G6Pase 1 0.44 1.04 0.85 
Glycogen and Pentose Shunt    
PDK4 1 2.94 0.59 2.01 
PP1s3c 1 1.12 0.67 1.47 
PGDH 1 0.21 0.46 0.18 
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First, the influence of Hes-1 on de novo triglyceride synthesis was investigated. Synthesis of 
triglycerides is under control of the enzymes acyl-CoA carboxylase 1 (ACC1), fatty acid 
synthase (FAS) and stearoyl-CoA desaturease (SCD1), whose expression is mainly regulated on 
the transcriptional level (129, 130). Since PPARγ has been described as a Hes-1 target, its 
expression was determined in correspondence to Hes-1 overexpression. A mild effect of Hes-1 
overexpression on PPARg expression was observed (GFP refed 1 vs Hes-1 refed 0.78 and GFP 
starved 0.74 vs. Hes-1 starved 0.75 relative units). 
During starvation, lipogenic processes are dramatically downregulated reflected by decreased 
expression of FAS (10-fold less), ACC1 (4-fold less) and SCD1 (6.7-fold less) in starved GFP 
animals compared to the refed GFP group. As shown in Table 8, hepatic Hes-1 expression did 
not alter this regulation. Only in the Hes-1 refed group was a 50% increase in FAS expression 
observed, though this effect did not reach statistical significance.  
 
Interestingly, fat transport seems to be differentially regulated in Hes-1 expressing mice under 
refed conditions. Liver-specific fatty acid binding protein (FABP-1), CD36, and caveolin 1 are 
transporters for free fatty acids which are esterified upon incorporation into the cell as 
triglycerides. Therefore, fat transporters control substrate availability of FFAs and limit the rate 
of esterification. Interestingly, expression of FABP-1, caveolin and CD36 is decreased in refed 
animals injected with Hes-1 virus point towards an attenuated uptake rate of free fatty acids by 
the liver. This suggests that decreased influx of FFAs is responsible for the diminished 
triglyceride levels observed in mice treated with Hes-1 adenoviruses. Remarkably, these results 
resembled the observations obtained in mice after hepatic GR knockdown, underlining the 
importance of Hes-1 as downstream target of GR. 
 
To investigate whether triglyceride efflux is also influenced by viral Hes-1 expression, the key-
determinants of VLDL production were examined. However, hepatic VLDL production was not 
altered as demonstrated by the unchanged expression of microsomal triglyceride transport 
protein (MTTP). On the other hand, a 1,3-fold induction of low density lipoprotein ApoB-100 is 
produced. Hes-1 injected mice were not characterized by elevated serum triglyceride levels (see 
Figure 3.27 E), consistent with the result that MTTP expression remained unchanged.  
 
The data implies, that triglyceride and/or free fatty acid disposal in the liver is decreased. This 
effect was not, however, reflected in serum triglyceride parameters that remained unaffected by 
hepatic Hes-1 re-expression. 
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Hes-1 expression in the liver also affected genes implicated in the regulation of glucose 
homeostasis and glycogen storage. Glycogen storage and hepatic fat storage inversely correlate 
and a shift towards higher lipid accumulation has been demonstrated to promote hepatic insulin 
resistance (131, 132). Pyruvate dehydrogenase kinase 4, an inhibitory kinase of the pyruvate 
dehydrogenase complex (PDC), was 1.7-fold downregulated in Hes-1 expressing refed mice 
indicating an activated PDC. The oxidative consumption of pyruvate by PDC limits availability 
of pyruvate for gluconeogenesis thereby decreasing hepatic glucose output. Consistent with 
activated PDC, blood glucose levels in Hes-1 expressing mice were lower under refed 
conditions compared to control mice as shown in Table 7. 
 
Furthermore, phosphogluconat dehydrogenase activity was 2.2-fold reduced in Hes-1 expressing 
mice (refed). Phosphogluconat dehydrogenase is one of only three enzyme producing NADPH, 
which is used in a wide variety of anabolic cellular processes e.g. fatty acid synthesis from C2-
precursors. Reduced NADPH levels could therefore imply diminished fatty acid synthesis and 
subsequently, less fat accumulation in the liver. 
 
The expression data point out that Hes-1 indeed affects hepatic lipid homeostasis. In this respect, 
mainly limited FFA influx seems to contribute to the observed phenotype. 
3.5.4 Reconstitution of diminished Hes-1 in dexamethasone-treated mice 
Finally, effects of Hes-1 reconstitution in dexamethasone-induced fatty liver models were 
investigated. Mice were treated with dex as described in Section 3.4.1 to induce hepatic fat 
accumulation and deplete hepatic Hes-1 levels One week prior to sacrifice, mice were injected 
with adenoviruses encoding GFP or ratHes-1. Mice were sacrificed and liver biopsies were 
taken for biochemical analysis.  
Liver protein extracts of all mice were immunoblotted using Hes-1 specific antibody. 
Dexamethasone treatment diminished Hes-1 protein levels significantly as shown in Figure 3.17 
(compare 1.X vs 2.X where X indicates the individual animal number). Injection of ratHes-1 
expression virus (109 ifu/ mouse) yielded moderate overexpression of Hes-1 in the liver 
(compare 1.X vs 3.X and 4.X) 
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Figure 3.17: Evaluation of Hes-1 expression in C57BL/6J mice after three weeks dexamethasone 
treatment. Liver protein extracts of all animals were immunoblotted and probed with Hes-1 specific 
antibody. Individual lane represents one animal. VCP served as loading control.
 
Effects of dexamethasone injection on hepatic lipid content were evaluated. Three weeks 
injection caused 1.5-fold triglyceride accumulation in liver in mice injected with GFP 
expressing virus (Figure 3.18 A, compare bar 1 vs. bar 2). in mice receiving Hes-1 virus, 
triglyceride enrichment in liver was prevented (compare bar 2 vs. bar 4), ultimately proving that 
restored Hes-1 levels are protective against GC/GR induced fatty liver development. Hes-1 
target gene identification confirmed fat transport genes caveolin1 and CD36 (Figure 3.18 B) and 
key-regulators of β-oxidation (PPARα, and CPT1α) that had been identified in GR knockdown 
studies (Section 3.2) as potential Hes-1 targets in db/db mice (Section 3.5.3).  
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Figure 3.18: Rescue of hepatic Hes-1 after glucocorticoid treatment prevents fat accumulation in 
the liver. A) Triglyceride measurement in liver lipid extracts from C57BL/6J mice treated for three 
weeks with 1.2 mg/kg dex or saline and injected with adenoviruses expressing GFP (white bars) or rHes-
1 (black bars) Data shown are means and s.e.m. N=5, B) Quantitative RT-PCR of mRNA isolated from 
the same animals as under A using specific Taqman® probes for Cav1, CD36, CPT1α, PPARα and 
PPARγ N=7 *p≤0.05, **p≤0.01, ***p≤0.001. 
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3.5.5 Generation of Hes-1 RNAi Adenoviruses 
Overexpression of Hes-1 promoted changes in lipid homeostasis. To confirm direct target genes 
of Hes-1, a loss of function approach was chosen. For this purpose, Hes-1 shRNA constructs 
were designed and tested for knock-down efficiency in vitro and in vivo. Oligonucleotides 
comprising the shRNA sequence were selected employing the BLOCK-iT™ RNAi Designer 
from Invitrogen (https://rnaidesigner.invitrogen.com/rnaiexpress, for details see Section 5.5). 
The Hes-1 target sequence with accession number NM_008235 was used and 7 shRNA 
oligonucleotides recognizing sequences within the open reading frame, the 5’ UTR and the 3’ 
UTR were tested. Virus was generated as described (see Section 5.5). To test knock-down 
efficiencies, mouse hepatoma cells (Hepa 1C1 wt) were infected with multiplicities of infection 
ranging from 1 to 100. The cells were incubated for two days with virus and mRNA as well as 
protein lysates were analyzed for the respective target protein knock-down. An adenovirus 
containing an unspecific shRNA sequence was used as control.  
 
From all viruses tested, pAD BLOCK-iT/DEST mHes1 RNAi4 showed best knock-down 
efficiency in Hepa 1C1 wt cells. A 4-fold reduction of Hes-1 mRNA was observed at MOIs of 
10 and 100 (Figure 3.19 A), while the Hes-1 mRNA in the control groups remained unchanged. 
Western blot analysis confirmed a dose-dependent down-regulation of Hes-1 protein levels. 
However, treatment of Hepa 1C1 wt cells with control RNAi virus also decreased Hes-1 protein 
(Figure 3.19 B). At all virus doses tested, Hes-1 RNAi virus exceeded the knockdown effect 
observed with the control virus. The mechanism causing Hes-1 depletion after treatment with 
control virus remained unclear. 
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Figure 3.19: Transient Hes-1 knock down using adenoviruses. A) Quantitative RT-PCR from mRNA 
extracted from Hepa 1C1 wt cells treated for 48h with adenoviruses containing either a shRNA against 
murine Hes-1 or an unspecific shRNA. MOI as indicated. Data were normalized to TBP. Data are means 
and standard deviation. N=2 B) Western Blot analysis from protein extracts of Hepa 1C1 wt cells treated 
for 48h with the same viruses as under A). Immunoblot with specific antibodies. VCP serves as loading 
control. 
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To test whether the unspecific effects on Hes-1 expression seen after control virus treatment 
would affect starvation-induced down-regulation of Hes-1 in vivo control measurements were 
undertaken. mRNA samples from C57BL/6J mice injected with 109 ifu of a random shRNA 
expressing adenovirus and starved overnight (5 mice) and control mice refed for 6h (5 mice) 
were kindly provided by M. Berriel-Diaz. In a qPCR experiment no difference in the regulation 
of Hes-1 levels depending on food access was observed in these samples, strengthening the 
notion that viral injection interferes with Hes-1 regulation (Figure 3.20 A). These results were 
confirmed by examination of a second mouse experiment. Samples of two mice per group were 
obtained from E.Chichelnitskiy. Mice had been starved for 24h or starved and subsequently 
refed for 24h. As shown in Figure 3.20 B after starvation Hes-1 expression was not reduced 
approximately 2-fold (compare to Figure 3.6) but remained unchanged. Mechanistically, it is 
elusive, how adenoviruses compromise Hes-1 regulation under fasting conditions in vivo. 
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Figure 3.20: De-regulation of Hes-1 expression in response to adenoviral injection. A) C57BL/6J 
mice were injected with 10  ifu of an adenovirus expressing an unspecific shRNA construct. 7 days after 
injection mice were fasted overnight or fasted and then refed for 6h. mRNA from livers was isolated and 
the relative Hes-1 expression was examined in qPCR experiments. Normalization against TBP. Data 
shown are means and s.e.m. N=5 B) C57BL/6J mice were injected with 10  ifu of an adenovirus 
expressing an unspecific shRNA construct. 7 days after injection mice were fasted for 24h or fasted and 
then refed for 24h. mRNA from livers was isolated and the relative Hes-1 expression was examined in 
qPCR experiments. Normalization against TBP. Data shown are means and standard deviation. N=2 
9
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3.5.6 RNAi experiment in primary hepatocytes 
Since unspecific virus effects were observed in mice, effects of hepatic Hes-1 depletion were 
investigated in primary hepatocytes kindly provided by S. Bohl and P.Nickel from the 
Department of Systems Biology of Signal Transduction (Prof.Dr. U. Klingmüller, DKFZ).  
Cells were treated with a MOI of 100 for 48h. A virus encoding for a non-targeting shRNA was 
used as negative control as well as non-virus treated cells, to investigate non-specific viral 
effects. One hour prior harvest, cells Hes-1 expression was stimulated with 10µM forskolin. 
Hes-1 knockdown was evaluated in protein lysates and on the mRNA level. Figure 3.21 depicts 
the results obtained on the protein level. In uninfected cells and after treatment with non-
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targeting virus (sh Con) no significant changes in cellular Hes-1 protein levels are seen. 
Forskolin treatment induced Hes-1 expression in all controls (compare lane1 vs. 2 and lane 3 vs. 
4). Hes-1 levels were diminished after infection with Hes-1 targeting shRNA virus (compare 
lane 1 vs 5). Forskolin treatment failed under these conditions to increase cellular Hes-1 levels. 
α-Hes1
α-VCP
sh Hes-1: _ __ _ + +
sh Con: _ _ + + _ _
Fors: _ _ _+ + +
1 2 3 4 5 6  
Figure 3.21: Hes-1 is depleted in primary hepatocytes. Primary hepatocytes were treated with 
adenoviruses encoding for a non-targeting shRNA sequence (control shRNA) or Hes-1 targeting shRNA 
(Hes-1 shRNA) at a MOI of 100 or PBS only (no virus). Forskolin (10µM) was used to stimulate Hes-1 
expression 1h prior harvest. 48h after infection protein lysates were prepared and evaluated via Western 
Blot using specific antibodies. VCP served as loading control. 
 
Selected target genes identified in gain-of function experiments were investigated after Hes-1 
knockdown. Special emphasis was put onto genes regulating fat transport, such as caveolin 1 
and CD36. As shown in Figure 3.22, Hes-1 depletion resulted in increased PPARγ (3-fold 
compared to untreated cells, 1.8-fold compared to control-virus treated cells) levels as well as 
activation of caveolin1 expression (2-fold). Evaluation of effects caused by Hes-1 on CD36 and 
FABP-1 were not conclusive due to unspecific effects the adenovirus itself caused. In Figure 
3.22, dramatic induction of CD36 expression (22-fold) after infection with control virus was 
observed (compare bar 1 vs. bar 2 CD36), FABP-1 was induced 11-fold in control-virus treated 
cells. The remarkable unspecific effects of the adenovirus however, where not a general feature 
but limited to a few genes.  
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Figure 3.22: PPARγ and Cav1 are up-regulated after Hes-1 depletion in primary hepatocytes. 
Primary hepatocytes were treated with adenoviruses encoding for a non-targeting shRNA sequence 
(control shRNA) or Hes-1 targeting shRNA (Hes-1 shRNA) at a MOI of 100 or PBS only (no virus). 
After 48h RNA was isolated, transcribed into cDNA and analysed by qPCR using specicif Taqman® 
probes. Data shown are means and standard deviation. N=2 
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The loss of function analysis in primary hepatocytes, therefore, confirmed target genes of Hes-1 
namely PPARγ and caveolin1. 
 
3.5.7 Promoter analysis of new target genes for N-Box elements 
 
Hes-1 is a transcriptional repressor and associates to well-known response elements on the DNA 
– N-box elements (CACNAG) and C sites (CACGNG) (133). In studies with the human PPARg 
promoter N-Box elements to which Hes-1 associated were already identified (211). To test 
whether CD36 and Cav1 represent direct inhibitory targets of Hes-1 the 5’-UTR between -
1000bp and -1bp were searched for putative N-Box elements using Tessmaster in silico analysis. 
The sequences were derived from accession number NT_165760 in case of CD36 and from 
NT_039340.7 for Cav1, respectively. Two putative N-Box elements were identified in the 
investigated 5’-UTR of CD36, namely CACGAG (-5bp /-10bp) and CACAAG (-951bp/-956bp). 
No obvious binding sites were retrieved from analysis of the 5’-UTR of caveolin 1. Absence of 
classical binding sites on the caveolin promoter might indicate a different mechanism of 
inhibition. 
 
3.6 Mechanism of GC/GR mediated Hes-1 repression  
3.6.1 Glucocorticoids regulate Hes-1 expression on the transcriptional level 
Cellular Hes-1 levels are affected by a wide variety of signals including hormones regulating 
energy homeostasis. Previous studies demonstrated that the fasting hormone glucagon 
stimulated Hes-1 expression in a cAMP/CREB dependent manner (112). Glucagon activates an 
intracellular cascade of reactions finally leading to phosphorylation of the transcription factor 
cAMP responsive element binding protein CREB (see Section 1.3.1).  
The observation that other fasting hormones – namely glucocorticoids - diminished Hes-1 on 
mRNA and protein level thus was surprising. Therefore, the mechanism of GC-induced Hes-1 
depletion was investigated. 
To this end, rat hepatocytes (H4IIE cells) were stimulated with dexamethasone, forskolin (an 
activator of CREB (134)) or combinations of both to mimick the effects of fasting hormones in 
cell culture. Exposure of cultured hepatocytes to 10 nM dexamethasone for 3 hours significantly 
decreased Hes-1 expression (Figure 3.23 A, lane 2 compared to lane 1). In vitro activation of the 
GC/GR axis therefore reversed the effects seen in the loss of function model of hepatic GR (see 
Section 3.2.2.2).  
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In contrast to GCs, forskolin treatment (10µM for 1h) stimulated Hes-1 expression (Figure 3.23 
A lane 3 compared to lane 1). Co-treatment with both stimuli (lane 4) abolished forskolin-
stimulated Hes-1 expression indicating opposing effects of forskolin and dexamethasone.  
 
Glucagon-regulated stimulation of Hes-1 expression is controlled by a proximal promoter 
element containing a cAMP response element (CRE) between -217 and -211 bp, where CREB is 
constitutively bound. Phosphorylation of CREB on Ser-133 activates Hes-1 expression. The co-
treatment studies in H4IIE hepatocytes indicated that glucocorticoids surprisingly counter-acted 
glucagons action. Consequently, the effect of glucocorticoids on CREB phosphorylation was 
investigated. Notably, the amount of P-CREB in the cell was attenuated after stimulation with 
10 nM dexamethasone as shown in Figure 3.23 A (compare lane 1 vs. lane 2). Forskolin, in 
contrast, stimulated serine-phosphorylation of CREB.  
 
Glucocorticoids mainly mediate their actions through binding to the glucocorticoid receptor 
(GR), a nuclear receptor and transcriptional regulator. Altered CREB phosphorylation pointed 
towards interference with transcriptional activation of the Hes-1 promoter and not e.g. towards 
accelerated degradation of Hes-1 protein.  
In transient transfection assays, the transcriptional activity of the Hes-1 promoter in presence 
and absence of GCs was assessed. Transcriptional activation was studied in human hepatoma 
cells (HepG2) using the reporter gene vector pGVB Hes-1 prom (-467/+160). The reporter gene 
vector contained the murine proximal Hes-1 promoter region (-467/+160) controlling the 
expression of the luciferase reporter-gene. Promoter activity was stimulated by co-transfection 
of a vector encoding protein kinase A (PKA wt), a down-stream target of the cAMP signalling 
pathway, which phosphorylates CREB. As a negative control a kinase deficient PKA (PKA mut) 
construct was co-transfected. 
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Figure 3.23: Glucocorticoids inhibit Hes-1 expression in vitro by dephosphorylation of CREB. A) 
Western Blot analysis of H4IIE rat hepatocytes treated for 3 h with 10 nM dexamethasone and 1h prior 
to harvest with forskolin (10µM). B) Transient transfection of HepG2 hepatocytes with the proximal 
Hes-1 promoter (-467bp to 60bp) and co-transfection with expression vectors for PKA or kinase-
deficient PKA (PKA mut). 24h after transfection stimulation with 10µM dexamethasone for 24h. C) 
Transient transfection with proximal mHes-1 promoter (-194bp to 60bp) into HepG2. Stimulation as in 
B. Data shown are means and s.e.m. N=9 
 
Co-transfection of 50 ng PKA expressing vector to 100ng reporter gene vector caused 13, 4-fold 
increase in promoter activity as shown in Figure 3.23 B. Dexamethasone treatment attenuated 
basal promoter activity approximately 2,5-fold (compare bar 1 an 2). Furthermore, GCs also 
diminished PKA-dependent up-regulation of promoter activity 2,6-fold (compare bar 3 and 4). 
Hence, diminished Hes-1 levels after GC treatment are caused by transcriptional regulation of 
its expression.  
Glucocorticoid stimulation of a shorter Hes-1 promoter construct comprising the sequence 
between -194bp and +60 bp (pGL2 mHes1 -194bp) had no significant effects on transcriptional 
activity (Figure 3.14 C) narrowing down the GR responsive region to -467bp to -194bp. 
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3.6.2 Direct interference of GR on the Hes-1 promoter 
3.6.2.1 In silico analysis of the proximal Hes-1 promoter 
Glucocorticoids regulate Hes-1 expression on the transcriptional level (see Section 3.6.1). Thus, 
the proximal promoter region was searched for consensus glucocorticoid response elements 
(GREs) and other transcription factors that might mediate GC/GR effects. 
 
In silico analysis of the murine proximal Hes-1 promoter sequence (-440bp to -4bp) using the 
Transcription Element Search System from Pennstate University 
(http://www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=SEA-FR-Query) revealed several putative 
binding sites for transcription factors. Figure 3.24 shows a comprehensive overview of factors 
that were found via Tessmaster search and that likely bind to recognition elements on the Hes-1 
promoter together with transcription factors that have already been published. 
 
-440 ATCCTCTTTA CCTTGTTCCC TCCTTTTTTC AATCACTAAA TTTTGTCTTG
-390 GCCTATATCT GTTCAAAATA TTTTTCAAAT GAACTTATTA TACAAAGTAG
-340 TTATATTGCA TGCAGCAAGA ACAATAAAAA CCAAAGGCCT GGCCACAAAA
-290 GAAATAGACT AGACTAAAAC TAAGCAAAGC CCAGAGGAAA GAGTTAGCAA
-240 AGGGTTAAAA TCCTTTTGAT TGACGTTGTA GCCTCCGGTG CCCCGGGCTC
-190 AGGCGCGCGC CATTGGCCGC CAGACCTTGT GCCTAGCGGC CAATGGGGGG
-140 GCGCAGTC GGTGCCA CGAGC CGCGTGTCTC TTCCTCCCAT TGGCTGAAAG
-90  TTACTGTGGG AAAGAAAGTT TGGGAAGTTT CACACGAGCC GTTCGCGTGC
-40  AGTCCCAGAT ATATATAGAG GCCGCCAGGG CCTGCG  
Figure 3.24: Promoter Analysis of proximal Hes-1 promoter region (-440bp to -4bp). Binding sites 
were identified using bioinformatic search of known responsive elements (Tessmaster analysis) and 
literature data. Putative binding sites of transcription factors are indicated color coded. red: Hes-1 N-Box 
elements, grey: CREB, blue: C/EBP-α, green backgroud: GR, yellow background: RBP-Jκ, magenta 
background: c-FOS, underlined AP-1 site.  
 
The analysis revealed three N-Box elements in this region (-53 to -58bp, -127bp to -132bp and  
-160 bp to 165bp) , where Hes-1 itself associates in an autoregulatory manner to repress its own 
expression (135). The most proximal Hes-1 binding site (-53bp tp -58bp) overlaps with a 
binding site for RBP-Jκ (-56bp to -62bp). In total three binding sites are published for RBP-Jκ 
on the Hes-1 promoter (136), however they were not found by Tessmaster search. A putative 
NFkappaB site (5’-GGGAAGTTTC-3’) was identified between -60 bp and -69 bp, partially 
overlapping with RBP-Jκ sites. Additionally, the very same region also revealed a positive hit 
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for AP-1 from -59 to -65bp (5’-AGTTTCA-3’) as well as a putative binding site for C/EBPα (-
61bp to -71bp). 
 
Most interestingly, the in silico study recognized four putative binding sites for the GR between 
-427bp and -422bp, -350bp and -361bp, -318 bp and -323bp and between -158bp and -163bp. 
The consensus sequence of a glucocorticoid response element (GRE) is 5’-
AGAACCnnnTGTACC-3’ (137). But half site AGAACA as well as TGTGCC, which is related 
to the right half site of the 15 bp consensus, have both been shown to bind the glucocorticoid 
receptor (138) (139) (140). Exactly these two half sites have been identified on the Hes-1 
promoter. Also the half site TGTTCC has been reported to be contacted by the GR (141). The 
putative site 5’-TGAACTTATTAT-3’ is somewhat less characteristic as four mismatches 
indicate a decreased likelihood for GR binding when comparing to another consensus model 5’-
AGAACAnTGTTCT-3’. 
 
3.6.3 The GR binds to the proximal Hes-1 promoter region 
Since the in silico analysis clearly suggested association of the GR to the proximal Hes-1 
promoter, it was tested, whether the GR binds in vivo. To address this question chromatin 
immunoprecipitation (ChIP) experiments from liver extracts of mice starved for 48h or mice 
that were refed for 24h after the starvation period were performed. Samples from starved mice 
were investigated since upon ligand binding GR shuttles to the nucleus, where it exerts it action. 
ChIP experiments do not allow the mapping of distinct response elements, but of promoter 
regions around 1000 bp size (see Section 5.3.11). Thus, the individual elements identified in the 
Tessmaster analysis cannot be mapped with this assay. Rather an overall binding of the GR in 
the proximal promoter region can be assessed. 
 
As shown in Figure 3.25, using a GR-specific antibody the proximal Hes-1-promoter region was 
pulled-down confirming that GR is present in this DNA region. However, the amount of GR 
detected was variable between the mice (compare lanes 1-4, GR antibody). In one starved 
mouse (Figure 3.25, lane 1) no GR could be detected on the Hes-1 promoter despite three 
technical replicates of the experiment, although enhanced GR binding was predicted after 
fasting. In vivo, however, the results were less definite. Despite higher glucocorticoid levels, 
increased binding of GR to the proximal promoter in starved animals could not be demonstrated.  
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Figure 3.25: The glucocorticoid associates in vivo with the Hes-1 promoter. Chromatin 
immunoprecipitation from crosslinked liver protein/DNA extracts from C57BL/6J mice starved for 48h 
(starved) or refed after starvation for 24h (refed) using a GR-specific antibody or unspecific IgGs. After 
de-crosslinking, PCR of DNA with primers specific for the proximal Hes-1 promoter region was 
performed. Shown is a representative result of three experiments. 
 
3.6.4 The GR binds to two elements on the Hes-1 promoter 
To verify the in silico identified GREs Avidin-Biotin-Conjugated DNA binding Assays (ABCD-
Assay) were performed. Biotin-labeled oligonucleotides covering adjacent regions of the Hes-1-
promoter, a consensus GRE element as positive control and a random DNA sequence as 
negative control were probed against protein extracts from H4IIE rat hepatocytes (see Section 
5.3.10). Oligonucleotides were designed as such that predicted GREs were intact. Proteins 
bound to the respective oligonucleotides were eluted and identified in western blots. 
 
Figure 3.26 shows the result of the ABCD assay. A weak GR binding to the oligonucleotide 
comprising the region from -392 to -345bp was measured (compare lane 1 to lane 6). This 
sequence was also predicted to harbour a GRE (-361/-350bp). Association of GR to the -440bp 
to -393bp region, however, was even stronger, while no GRE was identified using 
bioinformatics tools (lane 2 vs. lane 6). Compared to a random oligonucleotide no increased 
binding of GR was observed between -296bp and -210bp (lane 3, 4 and 5 vs. 6).  
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Figure 3.26: The GR occupies to binding sites on the Hes-1 promoter. ABCD-Assay with 
oligonucleotides spanning the proximal promoter region of the Hes-1 promoter. Hes-392 (-392bp/-
345bp),  Hes-440 (-440bp/-393bp), Hes-296 (-296bp/-261bp), Hes-260 (-260bp/-225bp), Hes CRE (-
226/-196). Western Blot analysis of bound proteins using specific antibodies against GR (Santa Cruz, M-
20). Input represens 10% of the protein lysates used for the ABCD Assay. Shown on the right site is a 
schematic view of oligonucleotides comprising GREs (green). 
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To characterize the GREs as repressive or activating elements, further studies need to be done 
requiring transfection assays with Hes-1 promoter constructs comprising mutated versions of the 
identified GREs. These experiments are currently undertaken and are beyond the scope of this 
thesis. 
3.7 GR-mediated dephosphorylation of CREB 
In transient transfection experiments GCs interfered with Hes-1 gene expression directly on the 
transcriptional level (see Section 3.6.1). On the protein level glucocorticoids inhibited the 
activation of cAMP-responsive element binding protein (CREB), a key-regulator of Hes-1 gene 
expression, by decreasing its phosphorylation at Ser-133.  
Attenuated P-CREB levels provide a second rationale for decreased Hes-1 promoter activity, yet 
the mechanism of dephosphorylation induced by glucocorticoids was uncertain.  
 
3.7.1 Dexamethasone treatment of MKP-1 -/- mice 
GCs are generally capable of altering cellular phosphorylation status e.g. by activation of 
phosphatases. The activation of a CREB phosphatase by GCs was one possible explanation for 
the observed dephosphorylation. Depending on the cell type and physiological context, different 
CREB phosphatases such as PP1 (142), PP2A (143) and mitogen-activated protein kinase 
phosphatase-1 (MKP-1, also termed Dual-specific phosphatase 1, DUSP-1) (144) inactivate 
CREB. Among them, only MKP-1 has been described to be activated by glucocorticoids, 
therefore its function in a metabolic context was further investigated. 
 
MKP-1 has been implicated in GC-induced insulin resistance as a potent inhibitor of insulin-
triggered glucose uptake (145). Interestingly, MKP-1-/- mice display a metabolic phenotype. 
They are lean due to reduced body adiposity and have a decreased liver weight, apparently 
because of reduced hepatic triglyceride levels (146). Furthermore, in isolated MKP-1-deficient 
mouse embryonic fibroblasts (MEFs), cAMP-induced CREB phosphorylation is markedly 
increased and sustained compared to wildtype MEFs (144). Based on the available published 
data, we speculated that glucocorticoid-stimulated expression of MKP-1 leads to inactivation of 
CREB by dephosphorylation Subsequently, anti-lipogenic Hes-1 expression might be inhibited 
and fat storage programs could no longer be suppressed.  
 
To test this hypothesis, 3 and 4 months old male MKP-1-deficient C57 BL/6J mice (MKP-1 -/-) 
and controls (MKP-1 +/+) were treated with 1,2 mg/kg dexamethasone for three weeks 
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intraperitoneally to induce MKP-1 expression in wildtype animals and fat accumulation in the 
liver. Determination of body weight on day 0 revealed that MKP-1 -/- mice generally had lower 
initial body weights than wildtype control mice (26.6 ± 3.9 g vs. 30.24 ± 3.8 g, p = 0.041) 
confirming published data (146). 
After two weeks of injection, a glucose tolerance test was performed. Saline-injected MPK-1 +/+ 
mice were sensitive to glucose (Figure 3.27). MPK-1 +/+ mice treated with synthetic 
glucocorticoids showed a tendency towards glucose intolerance. The area under the curve 
(AUC)-value shows a 14% total increase (AUCwt=27584 min·mg/dl vs. AUCwt+Dex=31550 
min·mg/dl) for the dex-treated MKP-1 +/+ group. MKP-1 -/- mice injected with saline cleared 
glucose from the periphery with a slightly increased efficiency compared to wildtype mice 
(AUCMKP-1 -/-=24061 min mg/dl). In contrast to dexamethasone-treated MPK-1 +/+ mice, the 
MPK-1 -/- mice were protected against glucocorticoid-induced glucose intolerance (AUC MKP-1 -/- 
+ Dex=23021 min mg/dl, Figure 3.27) and this effect was found to be statistically significant. 
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Figure 3.27: MKP-1 mice are protected against GC-induced glucose in tolerance. Glucose tolerance 
test in wildtype and MKP-1 -/- mice after 16 days of treatment with saline or 1,2 mg/kg dexamethasone. 
N=4, except wildtype + Dex: N=3. Data shown are means, Student’s t-test compared wt mice vs. MKP-1 
-/- mice after dex treatment of both.* p ≤ 0.05, ** p ≤ 0.01. 
 
The observed differences in glucose sensitivity between wildtype and MKP-1 -/- mice implied a 
different body fat content. Therefore, body fat parameters were examined. Mice were sacrificed 
3 weeks after the start of injection and the total body weight and epidydymal fat pads were 
weighed. As shown in Table 8, a significant body weight reduction after GC-treatment was 
observed in the MKP-1 +/+ mice compared to saline-treated wildtype controls (20% less after 
dex-treatment, p=0.035). The weight loss is attributed to muscle atrophy (20% less 
gastrocnemius after dex-treatment) and the loss of visceral fat mass (32% less after dex), 
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respectively. In MKP-1 -/- mice the GC-induced weight loss was less pronounced (8,5%) and, in 
addition, also less visceral fat was degraded (17%). Notably the muscle mass remained almost 
unchanged (6% less gastrocnemius after dex-treatment) despite the high dose of a catabolic 
stimulus.  
 
Table 8: Weight parameters at day of sacrifice 
 wildtype wildtype + dex MKP-1 -/- MKP-1 -/- + dex 
body weight [g] 31.1 ± 4.3 25 ± 1.3 26.1 ± 3.2 23.9 ± 3.3 
blood glucose [mg/dl] 130 ± 14 139 ± 32 115 ± 24 103 ± 9 
liver weight [g] 1.64 ± 0.35 1.03 ± 0.14 1.16 ± 0.21 1.01 ± 0.13 
epidydymal fat [mg] 208 ± 61 141 ± 95 141 ± 58 117 ± 46 
gastrocnemius* [mg] 176 ± 20 141 ± 11 155 ± 19 146 ± 19 
tibialis anterior [mg] 58 ± 11 45 ± 8 52 ± 7 43 ± 6 
*gastrocnemius and soleus were dissected and weighed together 
 
Upon dexamethasone treatment hepatic MKP-1 increased dramatically (Figure 3.28 A, compare 
lane 1-2 vs. 3-4), while in control treated mice hepatic MKP-1 was barely undetectable. 
 
To correlate the observed glucose sensitivities of the GTT (Figure 3.27) with hepatic 
triglyceride content, liver lipid extracts were investigated. As shown in Figure 3.28 B in MPK-1 
+/+ mice dex treatment did not result in hepatic triglyceride accumulation (control: 96 ± 11 vs. 
MKP-1 -/- 125 ± 32 µmol/g liver). Total triglyceride levels did not differ between any of the 
groups. Therefore, the different glucose sensitivities might not be explained by an altered 
hepatic lipid profile, but might indicate different effects of GCs on muscle of MKP-1 -/- mice. 
The sustained muscle mass after dexamethasone treatment in MKP-1 -/- represents one possible 
explanation, since it indicates higher glucose disposal capacity in peripheral tissues compared to 
mice with muscle atrophy. 
Finally, protein levels of the GR, P-CREB and Hes-1 were assessed in western blots. In both 
genotypes investigated, GR was down-regulated on the protein level after chronic GC treatment 
for 3 weeks. However, downstream effects of the GC/GR axis were still functioning as 
represented by diminished CREB phosphorylation (Figure 3.28 C).  
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Figure 3.28: In MKP-1 -/- mice improved glucose tolerance does not depend on Hes-1. A) Western 
Blot analysis of hepatic protein extracts obtained from MKP-1 +/+ mice or MKP-1 -/- mice. Animals 
were injected for 3 weeks with 1.2mg/kg dexamethasone or saline. Lysates of 2 mice per group were 
analysed for MKP-1 expression. VCP served as loading control. B) Triglyceride content in hepatic lipid 
extracts of wildtype or MKP-1 -/- mice after 3 weeks treatment. N=4, except wildtype + Dex: N=3. Data 
shown are mean values and s.e.m. C) Western Blot analysis of hepatic protein extracts from the same 
mice as under A) with specific antibodies. Treatment as indicated. VCP served as loading control. 
 
Attenuated CREB phosphorylation in MKP-1 +/+ mice and MKP-1 -/- mice argues against the 
notion that MKP-1 might be the GC-dependent CREB phosphatase. Finally, inhibition of Hes-1 
expression was observed in all groups after dexamethasone treatment, irrespective of the 
absence of MKP-1 (Figure 3.28 C). Although MPK-1 -/- mice were protected against GC-
induced glucose intolerance this effect is not caused by sustained P-CREB and Hes-1 levels. It 
was therefore concluded under these experimental conditions MKP-1 was not the 
glucocorticoid-induced CREB phosphatase. 
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3.7.2 Protein-protein interactions 
Transcriptional activation of a CREB phosphatase by GC/GR would not necessitate GR to 
directly interact with CREB. In contrast, recruiting such a phosphatase specifically to CREB 
might implicate binding of GR to the transcription complex formed around CREB. 
 
To form a transcription initiation complex CREB is phosphorylated at Ser133 by PKA (see 
Section 1.3.1) the phosphorylation of which being a prerequisite of interaction with the histone 
acetyltransferase p300. CREB contacts via its kinase-inducible domain KID the KIX domain of 
p300 (147-149), thereby stabilising the interaction. Subsequently, p300 alters the local 
chromatin structure by acetylating histones. These processes facilitate effective transcription 
(150)(see Section 1.2.1). 
In Figure 3.29 the domain structures of p300 and CREB are summarized. 
 
A study of Imai et al. (151) demonstrated that GR can directly associate with CREB in vitro. No 
functional data, however, about the impact of such an interaction on CREB activation status was 
available. Moreover, GR can principally also associate with the histone acetylase p300 (152). 
Complex formation between CREB and p300, however, is inevitable for transcriptional 
activation. By affecting CREB/p300 interaction, GR therefore could diminish transcriptional 
activation. 
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Figure 3.29: Domain structure of CREB and CBP. A) Domain structure of CREB, Q1 and Q2/CAD 
represent contact elements of basal transcription, bZIP mediates CREB binding to CREs and KID 
(kinase inducible domain) represents the domain,w here CREB is phosphorylated (Ser133 and Ser142). 
Highlighted is the possible interaction of the KID domain with p300/CBP. B) Domain structure of p300: 
CH1/ CH2 and CH3 are cysteine/histidine rich domains, KIX – CREB binding domain, Bromo- 
bromodomain, HAT histone acetyltransferase domain and Gln-rich – Gln rich domain. Highlighted is the 
possible interaction between the KIX domain and GR (152). 
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3.7.2.1 The GR preferentially binds to the bZip domain of CREB 
To test this hypothesis, full-length CREB, CREB domains KID and bZip, as well as the p300 
domain KIX (see Figure 3.29) were mapped for a putative association of GR using a 
Mammalian-Two-Hybrid approach. A GAL4 GR fusion protein as well as VP16 fusion proteins 
of the putative interaction partners were employed. 
 
To exclude any unspecific binding effects between VP16 and GAL4 or VP16 and GR, in a 
control transfection the ability of the VP16 transactivation domain to interact with GAL4GR or 
GAL4DBD was examined. For this purpose, 600 ng of an artifical GAL4Luc promoter construct 
(comprising 5 GAL4 binding elements only) were co-transfected with 50ng of a vector encoding 
for aGAL4GR fusion protein or the GAL4 DNA binding domain (GAL4DBD) and 50 ng of a 
plasmid encoding for the transactivation domain of VP16 (pCMV VP16).  
 
As shown in Figure 3.30, the VP16 co-transfection with a GAL4GR construct did not result in 
increased luciferase activity under unstimulated conditions when compared to VP16–
GAL4DBD co-transfection (compare bar 1 and bar 3). Stimulation with 10nM dexamethasone 
did not alter luciferase activity in VP16-GAL4DBD co-treated cells (bar 1 vs. bar 2). After 
dexamethasone-treatment, however, a 12-fold induction of luciferase activity was observed 
when VP16-GAL4GR was co-transfected (bar 1 vs. bar 4). The effect, however, was not due to 
dex-stimulated interaction of VP16 with GAL4GR, but due to binding of glucocorticoids to the 
GR and its subsequent activation. The activation of GAL4GR after glucocorticoid stimulation 
could be observed in transfections without VP16 (data not shown). 
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Figure 3.30: The VP16 does not interact with either GAL4DBD or GAL4GR. 5xGAL4Luc promoter  
was co-transfected with expression vectors for GAL4DBD, GAL4GR and VP16 as indicated. 24h post-
transfection the cells were treated with 10nM Dex or control for another 24h. Luciferase activity is 
shown relative to GAL4DBD (1st bar). Data shown are means and s.e.m. of nine experiments. 
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Since no relevant background association of VP16 with GAL4GR occurred, a second 
experiment was conducted in which 600ng GAL4LUC and 50ng GAL4GR were transfected 
into HEK293 cells. Plasmids encoding for VP16 or fusion proteins between VP16, full length 
CREB, CREB domains (KID, bZip) or domains for p300 (KID) were co-transfected. The 
interference of GC/GR with CREB phosphorylation in cells had been observed after dex 
treatment (see above). The influence of dexamethasone treatment on protein interaction was 
investigated in the transfection assay to assess this observation. Increased luciferase activity in 
this assay indicated interaction of two proteins or protein domains, respectively. Figure 3.31 
summarizes the obtained results. 
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Figure 3.31: GR interacts via the bZIP domain with CREB. HEK293 cells were transiently 
transfected with 600ng GAL4Luc vector and 50ng GAL4GR vector. Vector constructs (100ng) encoding 
for VP16 or VP16 fusion proteins were co-transfected as indicated. Transfection was treated 24h after 
transfection with Dex for 16h. Cells were harvested and luciferase assay was performed to evaluate 
promoter activity. Data shown are means and s.e.m. N=9. ***p≤0.001. 
 
Co-transfection of VP16CREB with GAL4GR and GAL4Luc resulted in a 5.6-fold activation of 
promoter activity under basal conditions (Figure 3.31 compare bar 1 vs. bar 2), suggesting a 
protein protein interaction between GR and CREB. The same effect was seen after dex 
treatment (5,9-fold activation, compare bar 6 vs. 7). However, the absolute luciferase activity 
was enhanced in all samples treated with dex due to activation of GAL4GR as described above.  
Unexpectedly, VP16 KID co-transfection did not stimulate transcriptional activation (Figure 
3.31 compare bar 1 vs. 4 and bar 6 vs. 9). VP16bZip and GR instead interacted as shown by 2.3-
fold enhanced promoter activity (bar 1 vs 3 and bar 6 vs.8).  
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Interestingly, co-transfection of GAL4GR with VP16KIX led to a 3.3-fold activation of 
transcriptional activity (compare bar 1 vs bar 5) suggesting that GR and p300 associate 
transiently under untreated conditions. The interaction was also detectable after dex-treatment 
(bar 6 vs 10). 
 
The data confirmed that GR associates with CREB and p300. Moreover, the bZip domain of 
CREB was identified to mediate GR/CREB interaction. Whether the protein-protein interactions 
are inhibitory or activating cannot be concluded from this explicit Mammalian Two Hybrid 
experiment.  
 
3.7.2.2 GC/GR can decrease CREB activity in a cell-autonomous system 
Given the fact that GR interacts with CREB, it was tested, whether it is a common feature of 
GC/GR to attenuate CREB activity.  
A plasmid containing an artificial promoter sequence comprising 5 GAL4 binding elements that 
control luciferase reporter gene expression (pGAL4-Luc) was chosen to assure no binding of the 
ligand-bound GR to DNA. 600ng GAL4-Luc reporter gene vector was co-transfected together 
with either 20 ng of an expression plasmid encoding for GAL4DBD or GAL4CREB fusion 
protein into human embryonic kidney (HEK) 293 cells. The GAL4 transactivation domain in the 
fusion proteins mediates their binding to the artificial promoter sequence comprising only 
GAL4 response elements. To activate CREB phosphorylation 100 ng of an expression vector 
encoding wt PKA (control: kinase-deficient PKA) was co-transfected. Endogenous GR was 
activated by treatment of the cells with 10 nM dex for 16h.  
 
GAL4CREB co-transfection led to a 5.8-fold induction of basal GAL4-Luc promoter activity 
compared to GAL4DBD/GAL4-Luc (Figure 3.32). This observation might be explained by a 
basal phosphorylation of GAL4CREB by endogenous protein kinases. Intriguingly, the 
activating effect of GAL4CREB could be decreased 2.1-fold by dexamethasone and the effect 
was highly significant (p<0.001).  
 
Phosphorylation of GAL4CREB by co-transfection with wt PKA increased the luciferase 
activity 59-fold compared to GAL4DBD/GAL4-Luc basal activity. Dexamethasone treatment 
inhibited PKA-stimulated CREB activation 1,8-fold (p<0,05). Effects of dexamethasone and 
PKA on GAL4DBD were also tested, but did not yield activation or repression of GAL4-Luc 
promoter activity (data not shown).  
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Since the artificial promoter sequence is solely composed of GAL4 response elements, direct 
GR DNA-binding to the promoter sequence is extremely unlikely. The results sustain the 
hypothesis that for GC-mediated repression of CREB activity the GR does not need to bind to 
glucocorticoid response units on the DNA. Consequently, protein-protein interactions are 
necessary for GC/GR mediated CREB inactivation. Moreover, decrease of CREB activity is 
likely to be a general mechanism of GR function as observed on the Hes-1 promoter.  
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Figure 3.32: Glucocorticoids inhibit CREB activity under basal and activated conditions. A) 
5xGAL4Luc promoter  was co-transfected with GAL4DBD or GAL4CREB and wildtype or kinase-
deficient PKA as indicated. 24h post-transfection the cells were treated with 10nM Dex or control for 
another 24h. Luciferase activity shown are relative to GAL4DBD (1st bar). Data shown are means and 
s.e.m. of nine experiments. 
 
3.7.3 p300 can reverse GR/GC-mediated inhibition of CREB  
Mechanistically, it remained unclear how GR confered CREB inhibition. Association of GR to 
the KIX domain of p300 may limit the amount of available p300 for CREB. In this case, CREB 
and GR would compete for the same domain - KIX.  
 
In a variation of the Mammalian Two Hybrid assay (see Section 3.7.2), increasing amounts of 
p300 (10 to 50 ng) were co-transfected with 600 ng GAL4-Luc, 20 ng GAL4CREB and 100 ng 
PKA into HEK293 cells. To maintain the same transfected DNA amounts cells not receiving 
p300 were co-transfected with an empty vector (pcDNA3).  
Transfected cells were subsequently stimulated for 16h with 10 nM dex. As in earlier tests, dex-
treatment decreased PKA-dependend activation of CREB 2.1-fold. With increasing amounts of 
p300 dex-dependent CREB inhibition could be completely abolished therefore restoring CREB 
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activity (Figure 3.33). Therefore, p300 can counter-act the effects of activated GR on CREB. 
The results supported the mechanistic model that GR via binding to the KIX domain of p300 is 
able to disrupt the transcriptional activation complex formed between CREB and p300. It 
predicts furthermore that GR possesses a higher affinity for KIX than KID. The observed de-
phosphorylation of CREB in this model would chronologically follow disruption of KIX-KID 
interaction.  
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Figure 3.33: p300 abolishes GC-dependent inhibition of CREB activity. 5xGAL4Luc promoter was 
co-transfected with GAL4DBD or GAL4CREB and wildtype or kinase-deficient PKA as indicated. 
Increasing amounts of p300 or empty vector were co-transfected. 24h post-transfection the cells were 
treated with 10nM Dex or control for another 24h. Luciferase activities shown are relative to GAL4DBD 
(1st bar). Data shown are means and standard deviations of three experiments. 
 
3.7.4 Consequences of CREB dephosphorylation for Hes-1 promoter activation 
Finally, the impact of GC treatment on the transactivation machinery (comprised of CREB, 
p300 and other proteins) on the Hes-1 promoter was assessed, using chromatin 
immunoprecipitation experiments in H4IIE rat hepatocytes. 
 
H4IIE cells were stimulated for 3h with 10 nM dex or solvent only, and chromatin 
immunoprecipitation was accomplished as described in Section 5.3.11 using antibodies against 
CREB, P-CREB, p300, acetyl-Histon H3 or irrelevant IgGs. As shown in Figure 3.34, dex 
treatment had no influence on the amount of CREB bound to the proximal Hes-1 promoter 
region. However, the amount of P-CREB (Ser-133) was minimized after glucocorticoid 
stimulation (compare lane 1 and 2). Moreover, p300 was released from the transactivation 
complex after GC-treatment, resulting in diminished levels of acetylated histone H3. These data 
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clearly indicated that glucocorticoids lead to the disruption of a transactivation complex and 
subsequently to a condensation of chromatin, thereby shutting down transcription at the Hes-1 
promoter. 
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Figure 3.34: Glucocorticoid treatment leads to disruption of P-CREB/p300 transactivation 
complex on the Hes-1 promoter. H4IIE rat hepatocytes were stimulated for 3h with 10 nM 
dexamethasone or remained untreated. Endogenous proteins were cross-linked with DNA using 
formaldehyde. After sonification of cells immuoprecipitation with 5µg of antibodies specific for CREB, 
P-CREB (Ser-133), p300 and acetyl-Histon H3, respectively was completed. As control for unspecific 
binding irrelevant IgGs were used. After proteinase K digest, DNA was isolated and probed against PCR 
primers specific for the proximal Hes-1 promoter region. For the assay 10% of the chromatin samples 
were used as input.  
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4 Discussion 
 
Recent evidence suggests that glucocorticoids promote Non-alcoholic Fatty Liver Disease – a 
disease strongly associated with other co-morbid conditions such as insulin resistance 
dyslipidemia and hypertension.  
Paterson et al. showed, that liver specific activation of GC/GR axis is sufficient to resemble 
main characteristics of the Metabolic Syndrome (fatty liver, insulin resistance, hypertension), 
even in the absence of elevated circulating glucocorticoid levels (87, 89). We investigated the 
molecular mechanisms underlying this phenotype by taking advantage of adenovirus-based gene 
delivery of sequences encoding shRNAs against murine GR. Targeting hepatic GR in the 
context of fatty liver shed new light on the development and progression of the disease. 
 
4.1 Acute hepatic GR knockdown in fatty liver ameliorates steatosis by 
decreased fat import and increased fat utilization 
In the current work, transient knock-down of hepatic glucocorticoid receptor alleviated the fatty 
liver phenotype in chronically obese db/db mice by decreasing hepatic triglyceride levels. It 
indicates the pivotal role the activated hepatic GC/GR-axis plays in the development of Non-
Alcoholic Fatty Liver Disease. The effects are mainly attributed to reduced expression of 
proteins essential for fat import (CD36, Cav1, PPARγ) and increased oxidative utilization of 
triglycerides (CPT1α). Surprisingly, in none of the investigated fatty liver models did ablation 
of GR and concomitant PPARγ depletion cause reduced de novo triglyceride synthesis as 
measured by rate-limiting factors such as acyl CoA carboxylase and fatty acid synthase. The 
results indicate that it is unlikely that glucocorticoids promote fatty liver development by 
stimulation of lipogenesis.  
 
The work describes that facilitated fat import into the liver causes fatty liver development in 
response to glucocorticoids. Until now, hepatic fat accumulation in hypercortisolism was mainly 
attributed to lipolytic abdominal fat depots (153) that secrete FFA into serum, and because of 
close proximity the FFAs accumulate in the liver (“first pass” effect). Interestingly, the central 
obesity phenotype (characterized by abdominal fat) is especially highly associated with NAFLD 
and insulin resistance (153). In contrast, FFA serum concentration and flux in individuals with 
predominantly lower body obesity tend to be normal regardless of BMI. The mechanism, 
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referred to as the “first pass” effect, still may profoundly contribute to the observed net fat 
influx. Increased expression of fat transporters, however, dramatically accelerate this process.  
 
Several murine models of obesity, including ob/ob, A-ZIP, aP2/DTA and KKAy develop fatty 
livers that express enhanced levels of adipogenic transcription factors (e.g. PPARγ, sterol-
regulatory element binding protein 1 SREBP-1 and FABP4 and 5), while the normal liver lacks 
such expression (154-155). The unique role of PPARγ in development and maintenance of 
steatotic liver is highlighted by numerous studies (156-158), clearly demonstrating lipid 
accumulation in hepatocytes upon PPARγ activation (159). In th current work we demonstrate 
that glucocorticoids seem to promote hepato-specific activation of PPARγ expression. The 
results indicate a strong correlation between GR knockdown and PPARγ depletion in liver, 
thereby suggesting an activating function of GR on hepatic PPARγ expression. Since the obese 
state is often accompanied by hyperactivation of GC/GR either by increased circulating 
glucocorticoids (160, 161) or by enhanced tissue-specific transformation of precursors (87) the 
observations provide additional insights into hepatic PPARγ activation. The obtained data are in 
agreement with experiments showing that glucocorticoids increase PPARγ mRNA levels (162, 
163). However, PPARγ regulation by the hormone seems to depend on the celltype. In 3T3 L1 
adipocytes GC-treatment was overall reported to decrease PPARγ levels (164), but when 
examining individual isoforms PPARγ1 and 2, Vidal-Puig et al. showed dex-dependent increase 
of PPARγ1 after exposure to GCs (165).  
  
In contrast to surprisingly unaltered lipogenic programs, fat transport in db/db mice after GR 
RNAi was decreased as indicated by diminished Cav1 and CD36 expression. Both genes are 
characterized by similar expression patterns with highest abundance in adipose tissue (166). 
Cav1 deficiency is accompanied by kinetically delayed serum triglyceride clearance (166), thus 
implying a role as fat transporter. As a consequence, Cav -/- mice display a lean phenotype with 
decreased white adipose tissue (167). Liver specific functions of Cav1 have not been studied 
systematically, but our results suggest that down-regulation of hepatic Cav1 protects against 
steatotic liver formation. 
Transmembrane glycoprotein CD36 represents a transporter of long chain fatty acids with 
highest expression in macrophages, myocardial and skeletal muscle, and adipose tissue (168-
170). Ablation was associated with a large decrease in fatty acid incorporation into triglycerides, 
which could be accounted for by an accumulation of diacylglycerides (171, 172).  
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In the employed hepatic GR loss-of-function model, CD36 depletion correlates with attenuated 
fat accumulation. Cav1 and CD36 transporters are target genes of PPARγ (173-176) which 
argue for an indirect effect of GR on their expression via increased activity of PPARγ. However, 
direct transcriptional activation of CD36 and Cav1 cannot be excluded from these data. 
 
Results from this work lead to the current working model that hepatic GR activation by means 
of increased PPARγ expression promotes fatty liver development by increased net fat influx 
through fat transporters CD36 and caveolin1. 
4.2 Effects of transient hepatic GR knockdown on glucose metabolism 
In contrast to its effects on hepatic fat accumulation, the consequences of hepatic GR ablation 
on hepatic glucose metabolism have been investigated in several studies including genetic (97, 
98, 177) and pharmacological approaches (83, 178). Specifically targeting hepatic GR function 
is favourable due to the fact, that de novo glucose synthesis that contributes e.g. to high blood 
glucose levels in diabetic states is mainly dictated by the liver. Furthermore, systemic inhibition 
of the GR with pharmacological antagonists of glucocorticoids (RU-486) had, despite 
remarkable inhibitory effects on gluconeogenesis (178), unfavourable extra-hepatic effects, 
including activation of the HPA axis (177). Opherk et al.demonstrated that mice bearing a 
targeted disruption of hepatic GR have very low blood glucose levels after prolonged fasting. In 
contrast, in the experiments presented here transient knock-down of hepatic GR was not 
accompanied by lower fasting glucose levels in comparison to controls. However, Opherk 
observed the effects after 28h of starvation while in our studies wildtype mice were starved for 
24h suggesting that GR/GC activation was not completely realized at this time point. Into this 
direction point also data about the marginal differences of PEPCK activity in GR knockdown 
mice, which were not prominent. The absent induction of PEPCK in control mice might indicate 
that hepatic GR was not completely activated after 24h starvation thus explaining the observed 
phenotype.  
4.3 Transcriptional repressor Hes-1 represents an inhibitory GR target in 
steatotic liver 
It is commonly accepted that perturbations in liver metabolism as seen in insulin resistant states 
largely depend on the aberrant transcriptional activity of genes encoding metabolic key enzymes 
(16). Therefore, transcription factors putatively regulating the expression of such enzymes were 
identified. In gene profiling, studies in wt and db/db mice injected with GR shRNA adenovirus 
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induction of transcriptional repressor Hes-1 was noticed on mRNA and protein level, while 
expression of family members Hes-3 and Hes-5 remained unchanged upon hepatic GR depletion.  
 
Hes-1 is a well-established down-stream target of the Notch signaling pathway and its 
expression can be activated by ligands of the Notch receptor, namely Jagged 1 and Delta-like. 
Hes-1 expression, however, can also be triggered independently of Notch. A wide variety of 
other stimuli as different as β-estradiol (in epithelial cells), TGF-β(179), VEGF and TNF-α (180) 
regulate Hes-1 expression, and obviously always the cellular context plays a major role in these 
processes. The only evidence that Hes-1 is regulated by stimuli that control energy homeostasis 
comes from Shinozuka et al. who demonstrated that glucocorticoids induce Hes-1 expression in 
pancreatic HIT-T15 cells (181) and additionally from Herzig who showed glucagon-dependent 
Hes-1 activation (112).  
 
In the current work, Hes-1 expression in hepatocytes was differentially regulated after GC 
treatment. Following dexamethasone stimulation, Hes-1 levels were inhibited on the mRNA 
level and on the protein level in vitro and in vivo (in several models including long-term 
dexamethasone treatment of mice) and increased upon hepatic GR depletion. From this we 
conclude hepatic Hes-1 expression is negatively regulated by glucocorticoids and their 
respective receptor. 
Glucocorticoids have implications in the regulation of biologically diverse processes such as 
inflammation and energy homeostasis. Hes-1, on the other hand, responds to pro-inflammatory 
signals such as TNFα (180). In this regard, it does not seem surprising that the Hes-1 gene 
promoter activity is attenuated by GCs. Whether Hes-1 regulation plays a role in inflammatory 
processes is presently unknown. 
 
If Hes-1 is also directly regulated by hormones of energy metabolism such as insulin is currently 
investigated, however, in hepatocellular carcinoma cells increased expression and activation of 
IRS-1, IRS-2 and IRS-4 correlated with higher Hes-1 levels in these samples (182). It was 
shown that Hes-1 gene expression is stimulated via the MAPK pathway (183). TGFα-stimulated 
Erk1/Erk2 phosphorylation led to stimulation of RBP-J (CSL) that in turn caused enhanced 
transcriptional activity of the Hes-1 gene. Insulin is well known to affect the MAPK pathway, 
but insulin-controlled Hes-1 regulation remains speculative. Hes-1 levels further depend on 
nutritional signals such as glucose levels. In neuronal stem cells, Hes-1 is down-regulated when 
cells are cultured in high glucose medium (184).  
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4.4 Role of Hes-1 in hepatic lipid metabolism 
Hes-1 is expressed in a wide variety of tissues with the highest abundance in lung and the 
gastrointestinal tract of both adults and embryos (185). Heart, muscle and kidney also produce 
high levels of Hes-1 in the embryo but at low levels in the adult (185). Hes-1 expression is 
controlled in a tissue-specific manner.  
Targeted disruption of the Hes-1 gene in mice leads to severe neurulation defects and death 
during gestation or directly after birth (186). By inhibiting neural bHLH activators Mash-1 and 
MATH-1, suppression of neural differentiation is induced by forced expression of Hes-1 
suggesting a critical role of Hes-1 in embryogenesis (187). 
 
Despite its ubiquitous expression, the function of Hes-1 in the adult organism is only recently 
emerging. The few studies undertaken in this regard point towards an involvement of Hes-1 in 
the regulation of hematopoiesis (188-190), osteoblastogenesis (191, 192) and energy 
metabolism (112, 193). Soukas et al. identified Hes-1 in a global expression profiling screen as 
a critical factor of pre-adipocyte differentiation (194). Overexpression of Hes-1 in 3T3 L1 cells 
inhibited differentiation into adipocytes accompanied by a remarkable down-regulation of 
C/EBP-α and PPARγ (193), both markers of adipogenesis. Furthermore, in transient transfection 
assays Hes-1 was able to block promoter activity of fatty acid synthase (195). In hepatocytes, 
Hes-1 overexpression was demonstrated to directly repress PPARγ expression in a glucagon/ 
cAMP-dependent manner (112). Taken together, Hes-1 was identified as a negative regulator of 
mainly lipogenic programs in liver and adipose tissue.  
 
It is shown in the work presented here that reconstitution of hepatic Hes-1 levels in mouse 
models with elevated GC/GR action (db/db mice and dexamethasone treated mice) ameliorated 
a concomitant fatty liver phenotype present in these mice. Moreover, this effect is highly 
specific as no effects on cholesterol metabolism are evident. Most intriguingly, liver-specific 
restoration of Hes-1 significantly improved systemic insulin sensitivity in db/db mice thereby 
alleviating the overall diabetic phenotype. Hes-1 exerted a protective action mainly by limiting 
triglyceride influx into the liver, while no apparent effects on triglyceride synthesis were 
observed.  
After one week of liver-specific Hes-1 expression in a db/db mouse model, animals showed a 
tendency towards normalized serum blood glucose levels. Further studies need to be carried out 
to confirm this effect of Hes-1 on glucose metabolism. 
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The presented data establish Hes-1 as a new target for the treatment of Non-Alcoholic Fatty 
Liver Disease. Maintenance of hepatic Hes-1 levels critically influences the amount of 
disposable triglycerides in the liver, and therefore represents a new key regulator in hepatic lipid 
homeostasis. 
4.5 Genes regulated in Hes-1 loss-of function and gain-of-function models 
The current research was able to confirm PPARγ depletion in Hes-1 gain-of-function models in 
vivo (112) and PPARγ activation after acute Hes-1 knockdown in primary hepatocytes. Effects 
of Hes-1 on fatty acid synthase expression were not observed in either gain-of function or loss-
of function models, despite reports by Ross et al., that Hes-1 inhibits FAS expression (195). 
However, they claimed that inhibition of FAS expression depends on the ability of Hes-1 to 
interfere with SREBP-1 (12) by inhibiting association of SREBP-1 to its response unit. In the 
investigated models absent SREBP-1 activation might provide one rationale that no Hes-1 
effects on FAS expression were detectable.  
 
In addition to its recently emerging role in the lipid metabolism, Hes-1 might also affect glucose 
homeostasis. Hes-1 potentiates JAK/STAT signaling through protein-protein-interaction with 
STAT3 (196) where it does not exert its action as a transcription factor. The reported interaction 
is particularly interesting regarding the recently described role of STAT3 in the suppression in 
hepatic glucose production (197, 198). In the present study, hepatic over-expression of Hes-1 in 
db/db mice that are characterized by abnormally high hepatic glucose output led to normalized 
blood glucose parameters. No significant repressive effect on rate-limiting enzymes such as 
G6Pase and glucokinase were observed in refed animals. Moreover, slight activation of PEPCK 
and G6Pase was observed under fasting conditions. These data do not support the notion that 
Hes-1 mediated potentiation of hepatic STAT3 signaling contributes to normalized hepatic 
glucose production. How Hes-1 overexpression caused decreased serum glucose concentration 
needs to be further investigated. 
 
Reconstitution of diminished Hes-1 levels in db/db mice and dexamethasone-treated mice by 
means of adenoviral gene delivery caused repressed expression of PPARγ, Cav1 and CD36 – 
intriguingly exactly the genes that had been identified in mice with acute knockdown of hepatic 
GR. Vice versa depletion of Hes-1 results in a marked increase in PPARγ levels accompanied by 
a rise in caveolin 1.  
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Methodological limitations due to unspecific virus effects did not allow conclusions for CD36.  
Hes-1 overexpression data, however, indicate that indeed Hes-1 targets the CD36 gene. Due to 
the fact that PPARγ activates caveolin1 and CD36 expression, it is tempting to speculate that 
PPARγ depletion is the sole mechanism of Hes-1 mediating Cav1 and CD36 promoter 
repression. While consistent, the observed down-regulation of PPARγ after Hes-1 
overexpression was only moderate in magnitude. Therefore, PPARγ down-regulation may not 
fully account for decreased Cav1 and CD36 expression. 
 
Hairy-related proteins repress transcription by binding to specific hexameric sites and are 
characterized by a WRPW motif through which interaction with the transcriptional co-repressor 
groucho (or the mammalian homolog of grouho TLE) is mediated. This protein complex is 
sufficient to inhibit target gene expression (199-201). Hes-1 belongs to the so-called C-class 
proteins of transcriptional repressors and exerts its action by binding to class C sites (CACGNG) 
as well as N-box sequences (CACNAG) on the promoter of its target genes. To some degree, 
Hes-1 also associates to class B sites (CANGTG) (133). In this work, N-Box elements were 
identified in the 5’-UTR of CD36 suggesting physical presence of Hes-1 in this region. Cav1 
was not characterized by N-box motifs or C class binding sites. Hes-1 can inhibit target gene 
expression, however, via a dominant-negative mechanism by forming non-functional 
heterodimers with bHLH-type transcriptional activators that bind E box sequences (133). One 
example for this mechanism is the antagonizing effect of Hes-1 on transcriptional activity of 
muscle determination factor MyoD thereby inhibiting MyoD-induced myogenesis (185). In 
future studies on the Cav1 promoter, it might be interesting to search for E box motifs and to 
search for bHLH-type transcriptional activators. 
 
4.6 GR-mediated regulation of the Hes-1 promoter 
GR mediated fatty liver formation via repression of anti-lipogenic Hes-1 includes several 
mechanisms on the Hes-1 gene promoter that probably act in concert. Glucocorticoids 
negatively regulated cAMP-stimulated transcriptional activation. Antagonism between 
glucocorticoids and cAMP signaling has already been observed on the corticotropin-releasing 
hormone (CRH) gene promoter (202) and on the surfactant protein A (SP-A) promoter (203). In 
case of CRH, heterologous promoter approaches allowed identification of the DNA sequence 
mediating glucocorticoid repression of forskolin activated CRH expression –the cAMP response 
element (CRE) (202).  
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In the present work, dephosphorylation of CREB at Ser-133 is observed after glucocorticoid 
treatment in hepatocytes, an effect known from hippocampal neurons (204). This effect may 
contribute to the decreased levels of P-CREB found on the proximal Hes-1 promoter after GC 
stimulation. Attempts to identify a GR/GC-dependent phosphatase were not successful. Despite 
observations that P-CREB levels are sustained in mice bearing a targeted disruption of Mitogen 
activated protein kinase phosphatase 1 (MKP-1), we could not see protection against GC-
mediated CREB dephosphorylation in MKP-1 -/- mice. Inhibition of protein synthesis using 
cycloheximide promotes accumulation of P-CREB within the cells suggesting that continuously 
a CREB phosphatase is expressed (data not shown). In contrast to these observation, Rosen et al. 
demonstrated that glucocorticoid repression of endogenous CRH gene expression did not 
require ongoing protein synthesis (205).  
 
Imai et al. showed in in vitro experiments that CREB and GR can associate (151) and we could 
identify the bZIP domain of CREB as responsible for the interaction. bZIP has been reported 
before to interact with transcription factor TORC. Secondly, we could also confirm association 
of GR with the KIX domain of p300. Given the fact that the transcriptional activation complex 
composed of CREB and p300 is stabilized via interaction between CREB’s kinase inducible 
domain KID and p300’s domain KIX, one possibility of GR mediated interruption might be 
competetive binding of GR and CREB for the same p300 binding domain KIX. In this context, 
the ability of overexpressed p300 to revert the inhibitory effects of GR on CREB mediated 
transcriptional activation support this notion. Alternatively, association of GR with the bZIP 
domain of CREB could lead to structural changes of CREB thereby disrupting the privileged 
p300/P-CREB interaction complex. In both scenarios released phosphorylated CREB might then 
in turn be more easily accessible for CREB phosphatases.  
While at present the exact mechanistic details remain unclear, the negative effect of the GC/GR 
axis might represent a more common feature of gene regulation and could reveal new 
mechanistic insights into how glucocorticoids can negatively regulate target genes. Although 
beyond the scope of this work, implications of these mechanism for long-term memory 
adaptation are plausible. Glucocorticoids are for long known to interfere with long-term 
memory and learning capacity, while activated CREB plays a key-role in these processes.  
 
4. Discussion 
 
82
 
Figure 4.1: Glucocorticoid mediated repression of Hes-1 transcription. Α) Transcriptional activation 
of Hes-1 promoter in response to cAMP signaling. cAMP response element binding protein CREB 
(yellow) is phosphorylated and interacts with histone acetylase p300. By acetylating local histones 
chromatin structure is altered and transcription activated (not shown). B) Glucocorticoids cross the cell 
membrane bind to the glucocorticoid receptor (GR, blue) releasing it from an inactivation complex with 
heat shock proteins. GR translocates to the nucleus where it binds to GR response elements (GRE, grey) 
on the Hes-1 promoter and where it associates with the p300/P-CREB complex facilitating its disruption. 
Release of p300 indicates decreased promoter activity. 
 
In silico studies on the Hes-1 promoter revealed putative binding motifs for GR which were 
confirmed in vitro. In ABCD assays, GR binding was positively matched with the localization 
GRE half site TGTTCC (141, 206) (207). The GRE 5’-TGAACTTATTAT-3’ comprised a 
lower GR affinity and resembles more closely the consensus hormone response element 5’-
AGAACAnnnTGTTCT-3’ (208) than a canonical GRE (5’-GGTACAnnnTGTTCT-3’) (40). 
The region might therefore also be targeted by nuclear receptors such as the mineralocorticoid 
receptor or the androgen receptor. 
While GR binding to two predicted regions was confirmed, no conclusions about the nature of 
the response elements – whether activating or repressing – can be drawn. Molecular 
mechanisms of GR-dependent cis-repression of target genes are largely unsolved. To further 
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characterize the identified GREs mutation analysis in transfections using proximal Hes-1 
promoter constructs is necessary.  
4.7 Outlook 
 
Non-Alcoholic Fatty Liver Disease is the most common chronic liver disease and is tightly 
associated with resistance of the liver against insulin action. The high prevalence of NAFDL 
necessitates the development of new intervention strategies based on the underlying molecular 
mechanisms. Glucocorticoids promote the development and progression of the diseases and the 
study presented here aimed for the identification of metabolic pathways involved in this process. 
The current study identified the transcriptional repressor Hes-1 as a GC/GR-controlled target 
gene in liver. Maintenance of hepatic Hes-1 levels have been demonstrated to be critical to limit 
fat influx into the organ and to preserve hepatic insulin sensitivity. Hes-1 antagonizes GC-
triggered transcriptional activation of target genes of fat import and prevents accumulation of fat 
in the liver. Restoration of hepatic Hes-1 levels represents an attractive target for therapeutical 
intervention against GC/GR-dependent fatty liver. These findings will have implications for the 
development of treatment strategies against NAFDL and its associated co-morbidities. 
The work presented here furthermore demonstrated an antagonistic action of the fasting 
hormones glucagon and glucocorticoids on hepatic lipid metabolism as shown by the regulation 
of anti-lipogenic Hes-1 contrasting their syngergistic action on glucose metabolism. The data 
evidence that the transcription factors activated by the hormones – namely the glucocorticoid 
receptor and CREB interact with each other. The functional consequences of this interaction 
will increase the understanding of the synergistic and antagonistic effects mediated by GR and 
CREB. Further studies that describe the nature of this interaction in detail, however, are needed 
to unravel its metabolic meaning. 
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5 Methods and Materials 
 
5.1 Molecular Biology 
 
5.1.1 DNA gel electrophoresis 
For routine applications (fragments from 200 bp) normal agarose (Roth, Cat No. 12656) was 
dissolved in standard 1x Tris-borate-EDTA (TBE) buffer. Agarose was melted, cooled down, 
and 1 μl of ethidium bromide (10 mg/ml) were added per 100 ml of agarose solution. Depending 
on the gel size and concentration, gels were run at a voltage between 60 and 120 V with 
constant current. 
 
5.1.2 Extraction of DNA fragments from agarose gels 
DNA fragments were excised from agarose gels of the appropriate percentage using a UV lamp 
and purified using QIAquick Gel Extraction Kit (QIAgen #28704) according to the 
manufacturer’s instructions. After purification, DNA was ethanol-precipitated (1/10 volume 5 
M Na-acetate pH 5.2, 1µl glycogen (2mg/ml); 2.5 volumes 100% ethanol), washed in 70% 
ethanol and dissolved in the appropriate amount of sterile H2O. All isolated fragments were 
stored at –20°C until needed. 
 
5.1.3 Transformation of bacteria for plasmid amplification 
5.1.3.1 Transformation of chemically competent cells 
Chemically competent E.coli XL-1/blue cells were used for routine plasmid amplification. For 
special applications e.g. after ligation of three fragments XL-10 GOLD cells were chosen.  
50 µl of chemically competent cells were thawed on ice and then transferred to a chilled 14 ml 
Falcon round bottom tube. They were gently mixed with either 100ng plasmid-DNA (0,5 to 1µl) 
or 1 to 3µl ligation reaction mixture and chilled on ice for approximately 30 minutes followed 
by a 30 second heat shock in a water bath at 42°C. The reaction was chilled again for 2 minutes 
on ice and 450 µl 37°C warm LB-medium was added. The reaction mixture was incubated 45 to 
60 minutes at 37°C and 200 rpm.  
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Selection of positive clones was carried out by plating various amounts of the transformed 
bacterial culture onto LB-Agar dishes containing the appropriate selection antibiotic and 
incubation overnight at 37°C in an incubator. Positive clones were selected using wooden sticks 
and they were transferred into 15 ml Falcon tubes containing 4 ml LB-medium plus appropriate 
antibiotic.  
5.1.3.2 Transformation of electrocompetent cells 
Electrocompetent E.coli XL-1/blue cells were used for special applications e.g. after ligation 
reactions of blunt end fragments.  
Approximately 100 µl cell suspension were used for the transformation. They were thawed on 
ice and 1 to 3µl ligation mixture were added. Mixture was gently stirred and then transferred to 
a chilled electroporation cuvette. Electroporation was done with 2,5 kV and 400 Ω. Immediately, 
800 µl 37°C warm LB-medium were added to the cell suspension and the reaction was 
incubated for 1h at 37°C. Selection of positive clones was done as described in Section 5.1.4.1. 
5.1.4 Plasmid purification 
All plasmids were isolated by using plasmid purification Kits (QIAprep® Spin Miniprep Kit 
#27106, Invitrogen Pure-Link ™ High Pure Plasmid Cat No K2100-26) according to the 
manufacturer’s instructions. Purified plasmids were eluted with sterile H2O and stored at -20°C. 
DNA concentration was determined by spectrophotometric measurement using a Nanodrop ND-
1000 spectrophotometer (peqlab Biotechnology). Spectral absorbance at 260 nm was used for 
calculation and ratio between of OD260nm/OD280nm served as purity control. Ratios obtained were 
in the range between 1,8 and 2,1. 
 
5.1.5 Isolation of genomic DNA from murine tissue 
Approximately 5 to 10 mg tissue were incubated in 500µl tissue lysis buffer (10 mM Tris pH 
8.0, 100mM NaCl, 15 mM EDTA, 0,5% SDS, 0,5 mg/ml Proteinase K) at 56°C on a shaker 
(Thermomixer, Eppendorf) overnight at 400 rpm.  
Next day, sample is thoroughly mixed until no cell clumps are visible anymore and 500 µl PCI 
buffer (phenol pH 8.0 : chloroform : isoamylalcohol 25:24:1 (v/v)) are added. The reaction 
mixture is gently mixed for 20 seconds and then spinned at maximum speed (13 000 rpm, 
Eppendorf centrifuge) for 5 minutes at ambient temperature. The upper aqueous phase is 
transferred to a fresh tube and 500 µl PCI buffer are added again. The procedure is repeated and 
the aqueous phase is transferred to a fresh tube. 500 µl CI buffer (chloroform: isoamylalcohol 
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24:1 (v/v)) are added, the extraction is done again by mixing for 20 seconds and subsequent  
centrifugation for 5 minutes at 13000 rpm. Finally, the upper phase is transferred to a fresh tube 
and the DNA is precipitated by addition of 500 µl 2-propanol. After mixing the solution, it is 
centrifuged for 15 min at 13000 rpm and 4°C. The supernatant is discarded and 500µl 75% 
ethanol are added to wash the DNA pellet. After removal of ethanol by centrifugation for 5 
minutes at 4°C and 13000 rpm, the pellet is shortly air-dried and then re-solubilized in 30 to 100 
µl Tris-EDTA buffer pH 8.0. For complete solubilization the samples are kept overnight at 4°C. 
Next day, they are ready to use or can be stored for longer periods at 4°C. 
Generally, all pipetting steps should be carried out with care to avoid shearing forces. Buffers 
and materials used should be free of DNases. 
 
5.1.6 RNA isolation with Qiazol™ Lysis Reagent 
For most experiments the purity of the RNA obtained after Qiazol™ isolation is sufficient. If 
not, it is possible to further purify the RNA by DNase treatment and purification via the Qiazol 
RNeasy Mini purification kit (see section 5.1.7). 
 
5.1.6.1 RNA isolation from tissue samples 
Tissue samples, that were instantaneously frozen in liquid nitrogen after dissection, are suitable 
for the isolation of RNA from liver. Briefly, 10 mg of frozen tissue is are transferred into a 2mL 
RNase/DNase-free reaction tube containing 1 ml Qiazol™ Lysis reagent (Cat No: 79306) and a 
stainless steel bead (Qiagen, 5mm, Cat No. 69989). The samples are lysed by vigorous shaking 
in the TissueLyser™ (Qiagen) for 90 sec at a frequency of 30 Hz. The lysate is incubated for 
three minutes at room temperature to release nucleoprotein complexes and then transferred into 
a fresh RNAse/ DNase-free safety lock-reaction tube containing 200 µl chloroform. The mixture 
is vortexed for 15 sec and then centrifuged for 15 min at 12000 x g. The upper aqueous solution, 
containing mainly RNA, is carefully removed and transferred into a fresh reaction tube. For 
precipitation of the RNA 500 µl 2-propanol are added and the sample is mixed by inverting the 
tube. After 10 min incubation at room temperature the RNA can be pelleted by centrifugation 
for 10 min at 12000 x g. The supernatant is aspirated and the pellet is washed once with 1 ml 
75% ethanol. The solvent is discarded and the pellet is carefully air-dryed and resolubilized in a 
suitable amount of water (30 µl are fine in most cases). The solubilisation is facilitated by 
incubation at 55°C for 10 min on a Thermomixer (Ependorf). The samples should be stored 
until further use at -80°C.  
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5.1.6.2 RNA isolation from cell samples 
Adherent cells are stimulated according to experimental needs. The medium is removed and the 
cell monolayer is washed once with sterile PBS. The buffer is aspirated and 1mL Qiazol™ Lysis 
reagent is added/ 10cm plate (or 250 µl per well on a 6-well plate). The cells are scraped with a 
sterile cell scraper and transferred into DNase/RNase-free reaction tubes. The cells are 
incubated for 5 min at room temperature and are vortexed vigorously until no cell clumps are 
visible. The obtained cell lysate can either be stored until further use at -80°C or the RNA can 
be isolated as described in Section 5.1.6.1 startinf with steps that follow  tissue lysate 
preparation. 
 
5.1.7 RNA isolation with RNeasy Mini purification kit 
This protocol is suitable for applications, where genomic DNA impurities in RNA preparations 
are critical to be removed. Tissue samples are transferred into a 2 mL reaction tube equipped 
with 600 µl RLT buffer and 6µl β-mercaptoethanol and is lysed for 2 min at 30 Hz using the 
TissueLyser. The obtained lysate is transferred to a Qiashredder column and via centrifugation 
at 13000 rpm for 2 min the membranes of cell organells are sheared, DNA is released and also 
sheared.  
To the eluate 600µl 70% ethanol are added and the solution is gently mixed by turning the 
reaction tube. The reaction mixture is transferred to a RNeasy column (maximum 700 µl at once) 
and spinned for 1 min at 13000rpm. (RNA isolated using Qiazol™ Lysis reagent can be used for 
this procedure. In this case the RNA sample is diluted with 350µl RW1 buffer and applied onto 
the RNeasy column.) The flow-through is discarded and the column is washed with 350 µl RW1 
buffer for 5 min. The buffer is removed by centrifugation.  
To the dry column 80 µl DNase buffer (10µl DNase and 70µl RDD buffer) are added directly 
and the digest is incubated for 30 min at ambient temperature. Subsequently, 350 µl RW1 buffer 
are added and co-incubated for another 2 min. The column is washed twice with 500µl RPE 
buffer. Finally, the RNA is eluted in 30 µl RNase free water  
 
5.1.8 Evaluation of RNA quality and quantification 
To examine the degree of degradation after RNA isolation a 1% Agarose gel is poured with 
RNase-free reagents. RNA samples are denatured using formaldehyde/ formamide. To 10 µl 
RNA denaturation buffer 500 ng RNA sample are added and the samples are incubated for 10 
min at 65°C.  
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RNA denaturation buffer (per sample): 
 
 0,5 µl ethidium bromide (0,1%, Roth, Cat No. 2218.2) 
 0,5 µl 10 x MOPS buffer 
 5µl formamide  
 1,75 µl formaldehyde 
 1,7µl loading dye (Fermentas, #R0611) 
 0,55 µl RNase free water 
 
After denaturation samples are loaded onto the agarose gel and separated for at least 40 min. 
The quality of the RNA can be determined visually by examination of the ration between 28S to 
18S ribosomal RNA, which should be 2:1. Since the mRNA represents only 1% of total cellular 
RNA it is not possible to directly examine its degradation status. 
The amount of RNA was determined spectophotometrically at 260 nm using the Nanodrop 
device. Furthermore, the ratio 260nm/280nm was determined to measure protein impurities. The 
value should be between 1,8 and 2,1. 
 
5.1.9 cDNA synthesis 
For the synthesis of cDNA 500ng purified RNA are used, routinely. The RNA is adjusted to a 
volume of 9µl/sample with RNase/DNase-free water and 1µl oligo(dT)18 primers (Fermentas 
#K1612) is added per sample. The reaction mixture is vortexed and incubated for 5 min at 70°C 
for primer annealing at the polyA tails. Samples are chilled for at least 2 min at 4°C and then a 
reaction mixture is prepared according to the manufacturer’s instruction (Fermentas).  
 
Reverse Transcriptase Reaction Mixture (per sample): 
4 µl 5 x reaction buffer 
2µl 10 mM dNTP mix  
1 µl Ribolock ™ Ribonuclease Inhibitor  
 
The samples are mixed with the buffer and incubated for 5 min at 37°C, followed by addition of 
2µl M-MuLV reverse transcriptase (20u/µl). One control reaction without reverse transcriptase 
is performed. In the following quantitative PCR reaction, this sample will be important to 
estimate the amount of genomic DNA that was still present in the RNA isolation. 
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After 1 hour incubation at 37°C the cDNA synthesis is determined by heat inactivation of the 
reverse transcriptase for 10 min at 70°C. The cDNA can be stored at -20°. 
5.1.10 Quantitative Real-Time PCR 
The cDNA samples obtained under 2.1.9 were diluted ten-fold with DNase/RNase free water 
and per reaction 5µl of this solution were used. A master mix was prepared containing 10µl 
Platinum® Quantitative PCR Supermix, (Invitrogen Cat. No. 11730-025) 3,6 µl DNase/RNase 
free water, 0,4µl ROX dye (Invitrogen, Cat. No. 12223-012) and 1µl Taqman® probe per 
individual reaction. Technical duplicates of all samples were performed. The Taqman probes 
used were obtained from Applied Biosystems and are listed in Table XXX: 
 
Table 9: Taqman® probes used for qPCR experiments 
Probe Number 
ApoB Mm01545159_m1 
ACC1 Mm01304279_m1 
caveolin1 Mm00483057_m1 
CPT1α Mm00550438_m1 
CD36 Mm00432403_m1 
FABP-1 Mm00444340_m1 
FAS Mm00662319_m1 
Glucokinase Mm00439129_m1 
G6Pase Mm00839363_m1 
Hes-1 Mm00468601_m1 
Hes-2  Mm00456108_g1 
Hes-3 Mm00468603_m1 
Hes-5 Mm00439311_g1 
Hes-6 Mm00517097_g1 
Hes-7  Mm00473576_m1 
IkBa Mm00477798_m1 
MTTP Mm00435015_m1 
GR Mm00433832_m1 
PDK4 Mm00484152_m1 
PP1 regulatory inhibitor su3c Mm01204084_m1 
PGDH Mm00503037_m1 
PEPCK Mm00440636_m1 
PPARα Mm00440939_m1 
PPARγ Mm00440945_m1 
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As negative control water only was used and to determine the contamination with genomic 
DNA a cDNA sample that was not treated with reverse transcriptase was also routinely 
examined. 
20µl PCR reaction were transferred per well onto a MicroAmp™ Optical 96-well reaction plate 
(Applied Biosystems, Cat. No. 4316813) and quantitative PCR was done on a 7300 Real Time 
PCR System (Applied Biosystems). 
5.2 Cell Biology 
 
Cell cultivation of all cells lines was carried out in incubators at 37°C, 95% humidity and 5% 
CO2. Aseptic techniques were always used to maintain cells or for cell culture experiments.  
5.2.1 Cell line treatment and transfection 
5.2.1.1 Human Embryonic Kidney cells 
Human embryonic kidney cells (HEK 293 cells) were maintained and extended in Dulbecco’s 
Modified Eagle Medium with high glucose (DMEM) (Gibco Cat. No. 41966-052), 10% fetal 
calf serum (FCS) and 1 x penicillin/ streptomycin.  
Transient transfections were done with the Ca3(PO4)2-method according to Sambrook and 
Russle using a modified protocol: the cells were plated at a concentration of 1,16 x 105 cells/ ml 
the day before the experiment on a 12-well plate. Prior to transfection medium was exchanged 
and 500µl fresh medium/plate were applied again. Per well between 800ng and 2,5 µg total 
DNA were used for transfections and each condition was done in triplicates. For this purpose, 
the appropriate amount of DNA was diluted in sterile water and 12,6 µl 2,5 M CaCl2 were 
added to reach a final volume of the solution of 126µl. To facilitate ion exchange on the DNA 
from Mg2+ to Ca2+ the reaction mixture was incubated for at least 5 min at 37°C.  
Subsequently, 126µl HBSS buffer (pH 7.05) were added dropwise to the reaction while mixing 
the reaction. After incubation for exactly one minute 504 µl DMEM medium (37°C) were 
transferred to the solution, the transfection solution was mixed well and 190µl of it were 
transferred per 12-well immediately. After 3 to 4 hours very fine Ca3(PO4)2 crystals were visible 
microscopically. 
Transfection was done overnight and the following day, medium exchange to normal growth 
medium or stimulation was carried out. 
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5.2.1.2 HepG2 hepatocytes 
Human HepG2 hepatocytes were maintained and extended in a mixture of DMEM and F-12 
medium (1:1 (v/v)) including 10% FCS and 1 x penicillin/ streptomycin. Medium composition 
decreased the accelerated cell growth of HepG2 cells in pure DMEM and preserved the 
hepatocyte characteristics of the cells.  
For transfections HepG2 cells were plated at a concentration of 3 x 106 cells/ml on 6-well plates. 
After 6 to 8 hours cells were attached and transfection was done using a Ca3(PO4)2 method with 
triplicates of each experimental condition per transfection. Total DNA amounts between 1,5µg 
and 3µg were routinely used. DNA was transferred to a reaction tube and 400µl 0,25M CaCl2 
was added. The solution was mixed and 400µl 2xBBS buffer were added in drops to it while 
mixing the reaction. After 20 min incubation at room temperature 200µl of the reaction mixture 
were used per well. Transfection was allowed to complete overnight and the next day medium 
exchange to DMEM/ F-12 or stimulation was done, respectively. 
 
5.2.1.2.1 H4IIE rat hepatocytes, Hepa1C1 wt cells and 293A cells 
H4IIE cells were maintained in MEM medium (Gibco Cat No. 31095-052) with 10% FCS, 1% 
NAA and 1% penicillin/ streptomycin. 293A cells and Hepa1C1 wt cells were cultivated in D-
MEM medium supplemented with 10% FCS, 1% NAA and 1% penicillin/streptomycin. 
 
5.2.2 Harvest of transfected cells  
Cells were harvested 48 to 72h after transfection. The medium was discarded and the cells were 
washed once with PBS. Subsequently, harvest buffer (25 mM Gly-Gly pH 7,8, 15 mM MgSO4, 
4 mM EGTA, 0,1 mM DTT, 0,01% Triton X-100) was added to the wells. Typically, for one 
well on a 12-well plate 150µl harvest buffer were used. Cells were incubated for 5 min on a 
shaker to facilitate detachment from the dish and the lysate was transferred to a 1,5ml reaction 
tube. Lysis of the cell was facilitated by pipetting the suspension several times. Unsoluble debris 
was removed by centrifugation for 3 min at 13000 rpm and the supernatant was transferred to a 
fresh tube. The lysate can be used directly for reporter gene assays or stored at -20°C. 
5.2.3 Measurement of luciferase activity  
Luciferase assays are used to investigate a specific promoter activity driving the expression of 
the firefly luciferase gene. Luciferase is an enzyme catalysing a reaction in which beetle 
luciferin is transformed into oxyluciferin by oxidative decarboxylation thereby emitting photons. 
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Under the assay conditions the substrate luciferin is available in excess, consequently the 
amount of light emitted is proportional to the amount of firefly luciferase in the lysate.  
For the determination of luciferase activity in lysates of transfected cells, 30µl of this lysate are 
transferred into a well on a black 96-well-plate. The lysate is diluted with 100µl assay buffer (25 
mM Gly-Gly pH 7.8, 20mM K3PO4, 15 mM MgSO4, 4mM EGTA, 2 mM ATP, 1,6 mM DTT) 
and the plate is placed into a luminometer (Mithras 940 Luminescence) equipped with a 
dispenser. Automatic injection of 100µl luciferin buffer (0,32 mg/mL luciferin, 25 mM Gly-Gly 
pH7,8, 15 mM MgSO4, 4 mM EGTA) starts the reaction. 
Light emission is measured at a wavelength of 560 nm and as blank value harvest buffer (5.2.2) 
is used. Biological triplicates of all samples are done and each value is normalized against β-
galactosidase values (5.2.4.). 
5.2.4 Measurement of β-galactosidase activity 
Transfection efficiency is monitored by co-transfection of a plasmid constitutively expressing β-
galactosidase. For this purpose the vector pCMV β-galactosidase is used at various amounts. 
The β-galactosidase activity directly correlates with the amount of DNA incorporated during 
transfection, therefore it is a good measure to control transfection efficiency. It is important to 
test whether any experimental condition e.g. stimulation has an influence on the expression of 
β-galactoside to exclude variations.  
For the assay a buffer including the substrate ortho-nitrophenyl-β-galactopyranosid (ONPG) is 
prepared (1M Na2HPO4, 1mM MgCl2,10 mM KCl, 1mg/ ml ortho-nitrophenyl-galactopyranosid) 
and to 5 ml of this buffer 13,5 µl beta-mercaptoethanol are added prior to use. Into a clear 96-
well plate (Costar Cat No. 13631) 50µl cell lysate/ well is transferred and 50µl/ well ONPG 
buffer is added. As a blank value only harvest buffer is transferred into three wells. The plate is 
incubated until a clear yellow color is visible in the samples and the signal to noise ratio is 
higher than 5:1. The absorption is measured at 405 nm, the maximum absorption of the ortho-
nitrophenylat ion. 
5.3 Biochemistry 
5.3.1 Preparation of Protein Extracts from liver samples using PGC buffer 
Protein extracts are prepared with PGC lysis buffer. A 1,5 ml reaction tube is equipped with 1 
ml PGC lysis buffer, protease inhibitors and a stainless steel bead and incubated on ice. Into the 
ice-cold buffer approximately 30 mg frozen liver tissue are transferred and the sample is 
immediately homogenized in the TissueLyser ® (Qiagen) for 2 min at 30 Hz. The extracts are 
 
5. Methods and Materials 
 
93
incubated for 20 min on ice and the lysate is transferred to a fresh tube. The lysate is spinned for 
15 min at 13000 rpm. If a fat layer appears at the surface after centrifugation, it is discarded 
without perturbing the lysate. The lysate is transferred to a fresh reaction tube and a 
determination of the protein concentration is carried out as described in Section 5.3.3. All 
samples are adjusted to a concentration of 1 mg/ml protein with 2 x SDS buffer. These samples 
are incubated for 5 minutes at 95°C for denaturation and can be directly used for SDS-PAGE 
and immunoblotting. If not used immediately, the denaturated samples are stored at -20°C. The 
original lysates before denaturation should be kept at -80°C. 
5.3.2 Preparation of Protein Extracts from liver samples using SDS lysis buffer 
Approximately 20 mg snap-frozen liver tissue samples are tranferred to a 2 ml SafeLock ® tube 
equipped with 1 ml SDS lysis buffer (at room temperature so the SDS cannot precipitate) and a 
stainless steel bead. Protease inhibitors are not necessary when using this buffer. Immediately, 
homogenize the  samples for 2 minutes or until no tissue clumps are visible at 30 Hz  employing 
the Qiagen Tissue Lyser.  After homogenisation, samples are incubated for 5 minutes at room 
temperature and the lysate is transferred to a fresh tube. Subsequently, the debris is removed by 
centrifugation for 10 minutes at 13000 rpm and room temperature.  The supernatant is tranferred 
to a fresh tube and incubated for 5 to 10 minutes at 95°C.  The protein concentration is 
determined using the 2D-Quant Kit (see Section 5.3.4), since the high amount of SDS interferes 
with the protein determination of the BCA™ Protein Assay Kit.  
A part of the original lysates is adjusted with SDS lysis buffer to 1 mg/ml. Original lysates and 
adjusted samples can be stored at -20°C. 
 
5.3.3 Protein determination with the BCA™ method  
The assay is done in a 96-well format to allow the simultaneous measurements of up to 42 
samples. First a standard curve from 2µg to 10 µg protein in duplicates is transferred to the plate 
using BSA (2mg/ml, Pierce Cat. No. 23209). Then between 2µl and 8µl of protein lysates with 
unknown protein concentration are added to seperat wells. The protein concentration, however 
should lay within the range of the standard curve. If necessary, dilutions of the original protein 
lysate can be prepared using 0,9% saline for dilution. Next working reagent is prepared by 
mixing BCA™ reagent A with BCA™ reagent B in a ration of 50:1 (v/v). Per sample 200 µl 
working reagent are transferred with a multistep pipet onto the plates and the reaction mixture is 
incubated for 5 min at 37°C.  
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5.3.4 Protein determination with the 2D-Quant Kit 
The 2D Quant Kit (Amersham Biosciences Europe, 80-6483-56) is used for determination of 
protein samples containing high SDS concentrations (1% SDS and more). The procedure works 
by quantitatively precipitating proteins while leaving while leaving interfering substances in 
solution. The assay is based on the specific binding of copper ions to protein. Precipitated 
proteins are resuspended in a copper-containing solution and unbound copper is measured with 
a colorimetric agent. The color density is inversely related to the protein concentration. Accurate 
estimation of protein concentration is achieved by comparing to a standard curve. For the 
standard curve BSA (2mg/ml) is used.  
For the assay between 3 and 10µl protein lysates are used and proteins are precipitated 
following manufacturer’s instructions. Samples are done in duplicates.  
The absorbance of samples and standards is read at 480 nm in a spectrometer (Ultrospec, 
Pharmacia) using water as reference. Subsequently the standard curve is generated by plotting 
the known protein concentration against the absorbance. Absorbance values of unknown 
samples should lie in the same range, extrapolation is not advisable. 
 
5.3.5 SDS-PAGE 
For SDS-page, proteins are diluted in 2xSDS sample buffer (120 mM Tris pH 6.8, 200 mM 
DTT, 4% SDS, 20% glycerol, 0,01% bromophenol blue) and denatured by boiling for 5 min. 
Protein lysates are examined using SDS polyacrylamide gel-electrophoresis (SDS-PAGE) as 
introduced by Laemmli using discontinuous gels. Proteins are first focused in the low-percent 
collection gel and subsequently separated in the separation gel. For the separation gel different 
concentrations of acrylamide were used. Routinely, 10cm gels were poured as shown in Table 
12. During polymerisation the gel is overlayed with 2-propanol. 
On top of the separation gel, 3 ml collection gel are added (2,1 ml water, 0,38 ml Tris-HCl pH 
6,8, 0,5 ml 30% acrylamide mix, 30µl 10% SDS, 30µl 10% ammonium persulfate, 3 µl 
TEMED). Protein amounts between 10 and 50µg were subjected to separation on 10 ml gels in 
SDS electrophoresis buffer (1,92 M Glycin; 0,25 M Tris , 0,45% HCl; 30 mM SDS). 
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Table 10: Composition of polyacrylamide gels with different concentration of acrylamide 
 8% gel 10% gel 12% gel 
Water 4,6 ml 4 ml 3,3 ml 
30% acrylamide mix 2,7 ml 3,3 ml 4 ml 
1,5 M Tris (pH 8,8) 2,5 ml 2,5 ml 2,5 ml 
10% ammonium persulfate 100µl 100µl 100µl 
10% SDS 100µl 100µl 100µl 
TEMED 6 µl 4µl 4µl 
 
After electrophoretic separation gels were either stained with Coomassie or subjected to 
immunoblotting (Section 5.3.6). For Coomassie staining gels were briefly washed with water 
and then fixed in fixation buffer (25% 2-propanol, 10% acetic acid) for 1h and gentle shaking. 
The gels were washed twice with water and stained using PageBlue™ protein staining solution 
(Fermentas Cat. No. R0571) overnight. Excess staining was removed by washing the gel several 
times with water. 
5.3.6 Immunoblotting 
Proteins are electrophroretically transferred to nitrocellulose membranes, which has been 
equilibrated with transfer buffer (1,92 M Glycin; 0,25 M Tris, 20% methanol) overnight at 30V 
and 4°C. The slow transfer facilitates especially efficient blotting of larger proteins. After 
transfer membranes are washed briefly in water and the transfer was examined by Ponceau S 
staining (Sigma, Cat. No. P7170) for 5 min. Ponceau S is removed and membrane is washed 
twice with water followed by 1h incubation in blocking buffer (5% non-fat powder milk (Roth 
#T145.2)) dissolved in TBST buffer (20mM Tris pH 7.5,140 mM NaCl, 0.1% Tween-20®) for 
1 hour. Primary antibodies were used as indicated in Table 11. Subsequently, membranes were 
washed three times with TBST buffer for 15 min each. Secondary antibodies (conjugated to 
horse radish peroxidase (HRP)) were used at a dilution of 1:2000 to 1:5000 and were applied in 
blocking buffer for 45 min to 1h. Membranes were rinsed again three times for 15 min. To 
detect specific bands the enhanced chemiluminescence system (ECL™) Western Blotting 
Detection Reagent (Amersham Cat. No. RPN2106) was used, followed by the exposure to 
HyperfilmTM ECL films (Amersham Cat. No. RPN3103K). Exposure times varied between the 
different antibodies used.  
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Table 11: Primary and secondary antibodies for immunoblot 
antibody Source species Dilution 
CREB clone NL 904 Upstate 05-767 rabbit monoclonal 1:2000 
P-CREB (Ser-133) 05-807 (Upstate)  mouse monoclonal 1:2000 
FLAG M2 HRP A 8592 Sigma mouse monoclonal 1:1000 
GR M-20 sc-1004 Santa Cruz rabbit polyclonal 1:2000 
Hes-1 Tetsuo Sudo, Japan rabbit polyclonal 1:1000 
IκBα H-4 sc-1643 Santa Cruz mouse monoclonal 1:500 
MKP-1 sc-1102 Santa Cruz rabbit polyclonal 1:500 
p300 sc-584 Santa Cruz rabbit polyclonal 1:1000 
PPARγ H-100 sc-7196 Santa Cruz rabbit polyclonal 1:1000 
VCP ab11433 Abcam mouse monoclonal 1:10000 
anti-mouse IgG, HRP 170-6516 BioRad  goat variable 
anti-rabitt IgG, HRP 170-6515 BioRad  goat variable 
 
5.3.7 Isolation of hepatic lipids 
The lipids are extracted with chloroform/methanol (2:1 v/v) from frozen liver tissue. Frozen 
liver samples are cut on dry ice with a scalpel and weighed. The weight should be 
approximately 100 mg and it is annotated since the amount of triglycerides will be normalized 
with the initial organ mass. The liver tissue is transferred into a 2 ml polypropylene tube 
equipped with 2 ml chloroform/methanol. The tissue is homogenized with an Ultraturrax until 
no big tissue clumps are visible. To extract the lipids, samples are incubated for 20 min at room 
temperature on a rotating wheel. The tissue suspension is pelleted at 4000 rpm for 10 min and 
the supernatant is transferred to a fresh tube. The organic layer is extracted twice against 0,9% 
sodium chloride and the aqueous solution is aspirated carefully. Finally, 50 µl of the organic 
layer are transferred to a fresh tube and 10 µl of Triton-X 100/ chloroform (1:1 v/v) are added. 
The reagents are mixed and the solvent is evaporated. The residue containing the hydrophobic 
contents of the liver is resuspended in 50 µl water and stored at -20°C until further use.  
 
5.3.8 Isolation of hepatic glycogen 
Frozen liver samples are cut into 100 to 200 mg big pieces and the exact weight is determined. 
The liver is transferred into a reaction tube equipped with 1 ml 30% (w/v) KOH and a stainless 
steel bead. Homogenization of the samples is facilitated in the TissueLyser® (Qiagen) for 2 
minutes at 30 Hz. For complete tissue disruption the lysate is incubated for 30 minutes at 95°C 
with shaking in a Thermomixer (Eppendorf). The debris is removed by centrifugation for 5 
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minutes at 13000 rpm and the supernatant is transferred into a 15 ml reaction tube. The 
glycogen is precipitated by addition of 1,5 ml 95% ethanol and subsequent centrifugation at 
3000 x g for 20 minutes. The pellet is washed once with 1 ml ethanol and after air-drying the 
pellet for 5 minutes the it is resolubilized in 0,5 ml water and incubated for 30 minutes at 37°C. 
After vigorous mixing, the unsoluble material is removed by centrifugation for 5 minutes at 
3000 x g. The supernatant is transferred to a fresh tube and can be stored at -20°C until further 
use. 
5.3.9 Colorimetric Assays 
5.3.9.1 Determination of triglyceride levels 
The triglyceride measurement is a colorimetric assay in which the amount of glycerol 
deliberated from triglycerides is determined enzymatically. Since the stochiometric ratio 
between glycerol and triglycerides is one, the test allows the quantification of the amount of 
substance n. For the measurement, the serum triglyceride determination kit from Sigma (Cat No: 
TR0100) was used.  
Practically, 4µl of isolated hepatic triglycerides per sample (see Section 5.3.7) are transferred to 
a 96-well plate. As a positive control glycerol (2,5 mg/ ml, Sigma, Cat No G7793) is used and 
as negative control water. All samples are transferred in duplicates. 100 µl Free Glycerol 
Reagent is added per well and the plate is incubated for 5 minutes at 37°C and measured at 540 
nm. This measurement reveals the glycerol that has not been released from triglycerides.  
A second plate containing the same samples in duplicate is prepared and 100 µl Triglyceride 
Reagent are added. After incubation for 5 minutes at 37°C the optical density at 540 nm is 
determined. In this measurement the total amount of glycerol (free or as triglyceride) is 
determined. 
By susbtraction of the two obtained values per sample the amount of glycerol stored as 
triglycerides can be calculated. 
5.3.9.2 Digestion of glycogen with Amyloglucosidase and Determination of Glucose 
deliberated from Glycogen 
A stock solution of Amyloglucosidase (Sigma, A7420) is prepared by dissolving 0,33 mg 
enzyme in 0,2 M sodium acetate pH 4.8. Samples with isolated glycogen are thawed and 50 µl 
of glycogen sample is mixed with 450 µl Amyloglucosidase stock solution. The mixture is 
incubated for 2 h at 37°C on a Thermomixer (Eppendorf) while shaking the samples. The 
reaction is stopped by neutralisation with 10 µl 30% (w/v) KOH.  
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The glucose determination is done with the Glucose (HK) Assay Kit (Sigma, GAHK-20). The 
kit uses the following reactions: 
 
Glucose + ATP  Glucose-6-phosphate + ADP (catalysed by Hexokinase) 
Glucose-6-phosphate + NAD+              6-Phosphogluconate + NADH (catalysed by G6PDH) 
 
The release of NADH is directly proportional to the amount of glucose in the reaction. NADH is 
measured sprectrometrically at 340 nm. A standard curve with known concentrations of D-
glucose is prepared and the glucose content is determined according to the standard curve. The 
amount of sample used for the reaction varies, the obtained OD-values should lay within the 
range covered by the standard curve. The test is carried out according to manufacturer’s 
instructions. 
 
5.3.9.3 Determination of Free Fatty Acids 
Free Fatty Acids can be determined in serum samples or in lipid extracts (isolation of hepatic 
lipids, Section 5.3.7). A colorimetric assay from Wako (NEFA C, Cat No: 999-75406) is used 
for the measurement. 
The assay principle is the following (R-COOH any free carbonic acid) catalysed by (1) Acyl 
CoA synthetase, (2) acyl CoA oxidase and (3) peroxidase. 
 
1) RCOOH + ATP + CoA-SH                    Acyl-CoA + AMP + PPi
2) Acyl-CoA + O2               2,3-Enoyl-CoA + H2O2
3) H2O2 + 4-Aminophenazon + 3-methy-N-ethyl-N(β-hydroxyethyl)-aniline                      
Quinoneimine-color + 4 H2O 
 
A standard curve using oleic acid ( 1mM, Cat No: 270-76499) is used and 4 µl sample (in 
duplicates) are used for the measurement. The procedure is carried out according to 
manufacturer’s instructions. OD-values are determined at 550 nm and the amount of free fatty 
acid is calculated according to standard curve. 
5.3.9.4 Cholesterol measurement 
For cholesterol measurements serum samples or hepatic lipid extracts (see Section 5.3.7) have 
been used. The total cholesterol determination kit (Randox Laboratories, Cat No: CH5715) has 
been employed.  
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Cholesterol                  Cholesten-3-on +H2O2 (Cholesteroloxidase)   
2H2O2 + Phenol + 4-Aminoantipyrin             Chinonimin + 4 H2O (Peroxidase) 
 
The sample cholesterol concentration is assessed by preparation of a standard curve with 
cholesterol. The assay is performed in a 96-well format. Briefly, 4 µl sample are mixed with 
100µl assay reagent and incubated for 15 minutes at room temperature. Standard and a blank 
control (water) are treated equally. The optical density is measured at 492 nm and the sample 
concentration is calculated according to the standard curve. 
5.3.10 ABCD Assay 
5.3.10.1 General principle 
The Avidin-Biotion Conjugation DNA binding assay (ABCD assay) is an in vitro method to 
examine the binding of transcription factors to their respective response elements on the DNA. 
In a broader sense, also transcriptional cofactor binding can be determined, however a 
prerequisite is the stability of the transcription complex under the experimental conditions. 
Either whole cell extracts or nuclear extracts can be investigated depending on the biological 
problem. 
The ABCD-Assay takes advantage of the high affinity binding (KD ~1015 M-1) between 
streptavidin, a protein isolated from Streptomyces avidinii, and biotin. Thus, biotinylated 
oligonucleotides bearing response elements of transcription factors are bound to streptavidin, 
which is covalently linked to agarose. The immobilized oligonucleotides are then exposed to 
protein extracts containing the desired proteins. Unbound proteins are washed away and 
specifically bound proteins are eluted and subsequently examined via western blots.  
5.3.10.2 ABCD Assay for the glucocorticoid receptor 
The cell lysates that are used for this assay are prepared from H4IIE cells. H4IIE cells are 
seeded two days before the assay and at the day of stimulation that should have 80-90% 
confluency. The medium is removed (MEM + 10% FCS + 1% NAA + 1% P/S) and the cell 
layer is washed once with serum-free medium (MEM + 1% NAA + 1% P/S). For the assay cells 
are stimulated with 10 nM Dex or ethanol for 1h in serum-free medium. 
 
For the ABCD assay the following buffers need to be prepared: 
Oligonucleotide annealing buffer 
  10 mM Tris/ HCl 
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  50 mM NaCl 
  pH 8.0 
  
 Oligonucleotide binding buffer 
  5 mM Tris/HCl 
  0,5mM EDTA 
  1M NaCl 
  pH 7.5 
 
 PGC cell lysis buffer for ABCD assay 
  20 mM HEPES 
125 mM NaCl 
0,1% NP40 
1 mM EDTA 
10% (v/v) glycerol 
Prior to use protease inhibitors and phosphatase inhibitors I and II are added. The glycerol 
prevents unspecific binding of proteins to the streptavidin agarose and is therefore 
recommended for use. However, by increasing the viscosity of the buffer it might on the other 
hand also decrease the specific binding of proteins to the investigated DNA elements. 
 
DNA oligonucleotides were synthesized and only the sense oligonucleotide beared a 
biotinylated 5’-end. As a positve control for the assay the consensus glucocorticoid response 
unit (GRU) as described by Granner (48) was chosen. The binding of GR to the cAMP 
responsive element (CRE) and the Notch intracellular domain responsive element (RBP) as they 
occur in the murine Hes-1 promoter sequence were examined. In Table 12 the oligonucleotide 
sequences that have been investigated for glucocorticoid receptor binding are listed. 
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Table 12: Oligonucleotide sequences used in the ABCD assay with the glucocorticoid 
receptor 
name Oligonucleotide sequences of sense and antisense strands 
CRE  
 
5’-[Biotag]ATCCTTTTGATTGACGTTGTAGCCTCCGGTGCCC-3’ 
5’-GGGCACCGGAGGCTACAACGTCAATCAAAAGGAT-3’ 
-440bp/-393bp 
5’-[Biotag]ATCCTCTTTACCTTGTTCCCTCCTTTTTTCAATCACTAAATTTTGTCT-3’ 
5’-AGACAAAATTTAGTGATTGAAAAAAGGAGGGAACAAGGTAAAGAGGAT-3’ 
  
-392bp/-346bp 
5’-Biotag]TGGCCTATATCTGTTCAAAATATTTTTCAAATGAACTTATTATACAAA-3’ 
5’-TTTGTATAATAAGTTCATTTGAAAAATATTTTGAACAGATATAGGCCA-3' 
  
-345bp/-297bp 
5’-[Biotag]GTAGTTATATTGCATGCAGCAAGAACAATAAAAACCAAAGGCCTGGCC-3’ 
5’-GGCCAGGCCTTTGGTTTTTATTGTTCTTGCTGCATGCAATATAACTAC-3’ 
  
-296bp/-261bp 
5’-[Biotag]ACAAAAGAAATAGACTAGACTAAAACTAAGCAAAGC-3’ 
5’-GCTTTGCTTAGTTTTAGTCTAGTCTATTTCTTTTGT-3’ 
  
-260bp/-225bp 
5’-[Biotag]CCAGAGGAAAGAGTTAGCAAAGGGTTAAAATCCTTT-3’ 
5’-AAAGGATTTTAACCCTTTGCTAACTCTTTCCTCTGG-3’ 
  5’-[Bio-Tag]AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-3’ 
random 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3’ 
 
Consensus GRU 
 
5’-[Biotag]TTACGTTGATGGTACAAAATGTTCTAGGGTAC-3’ 
5’-GTACCCTAGAACATTTTGTACCATCAACGTAA-3’ 
 
The oligonucleotides are annealed as such: 
5µl biotinylated sense-oligonucleotide (100µM) 
5µl antisense oligonucleotide (100µM) 
40 µl Annealing buffer  
(48) 
are mixed and incubated for 5 minutes at 95°C for complete denaturation of the oligonucleotides, 
followed by a stepwise controlled cooling of 5°C per 2 min until a final temperature of 25°C is 
reached. Samples are then kept at 4°C. The annealing of the oligonucleotides can be examined 
using a 3% agarose gel. In the meantime, 60 µl of streptavidin agarose (Invitrogen, Cat No: 
SA100-04) are equilibrated with 1 ml oligonucleotide binding buffer in a 1,5 ml Eppendorf tube 
and spinned down for 1 minute at 3000 rpm to remove the binding buffer. The agarose is 
supplemented again with 500 µl oligonucleotide binding buffer and 48 µl annealed 
oligonucleotides are added. The slurry is incubated for 1 hour at room temperature on a rotating 
wheel. The streptavidin agarose is spinned down at 3000 rpm for 3 minutes and the supernatant 
is discarded. The agarose is used without any further washing steps for protein binding.  
During the 1 hour incubation time of biotinylated oligonucleotides to the streptavidin agarose, 
HEK293 cells are harvested by trypsination, followed by wash steps in PBS and centrifugation 
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of the cells. For one experimental  condition in the ABCD assay typically one 15 cm plate of 
HEK 293 cells is used. The cell pellet of one plate is resuspended in 1,5 ml PGC-lysis buffer 
supplemented with protease inhibitors  and phosphatase inhibitors. The suspension is incubated 
on ice for 20 to 30 minutes and vortexed vigorously to facilitate cell lysis. The lysate is 
centrifuged for 15 minutes at 4°C and 13 000 rounds per minute and 1 ml of the lysate is 
transferred to the washed agarose. Furthermore, 50 µl of the cell lysate are diluted with an equal 
volume of 2x SDS buffer and incubated for 5 minutes at 95°C for denaturation. This sample will 
serve as the input control in the western blot analysis. 
The cell lysate is incubated on the agarose for 30 minutes at room temperature. Unbound 
proteins are removed by washing the agarose beads three times with 600 µl PGC cell lysis 
buffer including protease inhibitors. The agarose beads are pelleted by centrifugation for 2 
minutes at 9000 rpm. The washing fraction is removed completely and 60 µl of 2x SDS buffer 
are added to each individual sample. The samples are vortexed once and incubated for 5 minutes 
at 95°C to elute all specifically bound proteins completely. Samples are vortexed again to 
facilitate complete protein recovery and centrifuged for 5 minutes at 13000 rpm at room 
temperature. The supernatant contains the released proteins and is stored at -20°C until 
investigation in western blots. 
5.3.11 Chromatin Immunoprecipitation (ChIP-Assay) 
 
The ChIP assay is a method to test the occupation of a certain protein on a DNA sequence in 
vivo. The assay can be performed starting from cultured cells or with tissue lysates. 
5.3.11.1 ChIP assay from liver lysates 
Approximately 50 mg of snap-frozen liver tissue are homogenized in dry ice powder in a pre-
chilled mortar using a pistil. The frozen tissue powder is transferred into a 50 ml reaction tube 
equipped with 1,5 ml DMA buffer (2,4 mg/ml DMA in triethanolamine pH 8.0) and wrapped 
with aluminium foil. Since the CO2 powder will lead to freezing of the DMA solution the whole 
mixture needs to thaw on ice. After complete thawing the suspension is incubated at room 
temperature for 30 min to crosslink proteins with each other. The suspension is spinned down 
for 3 min at 2000 rpm and the supernatant is discarded. The pellet is re-suspended in 5 ml 1% 
formaldehyde in PBS and incubated for 10 min at room temperature on a rotating wheel to 
facilitate DNA-protein crosslinking. The tissue is pelleted again by centrifugation for 3 min at 
2000 rpm and washed once with 5 ml ice-cold PBS. After removal of PBS the tissue pellet is re-
suspended in 1 ml cell lysis buffer (10 mM Tris pH 8,0, 10mM NaCl, 0,2% NP-40) including 
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protease inhibitors. The mixture is transferred into a pre-chilled Dounce Homogenizer (Size B) 
and homogenisation is done until no tissue clumps are visible anymore. After incubation for 5 
min on ice the solution is transferred to a 2ml reaction tube and spinned down for 5 min at 
13000 rpm. The pellet is re-suspended in SDS lysis buffer (50 mM Tris-HCl pH 8,1, 10 mM 
EDTA, 1% SDS) including protease inhibitors and incubated for 10 min on ice. The samples are 
subsequently sonicated 4 times for 20’’ at Duty cycle 30, Output control 3. After another 
centrifugation step for 10 min at 13000 rpm and 4°C the lysate is transferred to a fresh tube and 
the pellet is discarded.  
The protein concentration of each sample is determined using the 2D Quant Kit (see Section 
5.3.5). Afterwards, all samples are adjusted to the same protein concentration using SDS lysis 
buffer. For the subsequent steps 200µg protein are used and 20µg protein are used for the input 
control samples.  
The solution containing 200µg protein is diluted 10-fold with ChIP dilution buffer (16,7 mM 
Tris-HCl pH 8,1, 167 mM NaCl, 1,2 mM EDTA, 1,1% Triton X-100, 0,01% SDS) to obtain 
final SDS concentration of 0,1%. To each sample the 5µg antibody are added and antigene-
antibody reaction is done overnight at 4°C on a rotating wheel. 
The next day 60µl salmon sperm agarose (Upstate) are added per sample and incubated for 2h at 
4°C on a rotating wheel. The suspension is gently centrifuged for 2min at 1000 rpm and the 
supernatant is discarded. The agarose is washed several times in the following sequence for 5 
min per step and between each step washing solution is removed by centrifugation for 2 min at 
1000 rpm.  
First washing cycle is done once with 1 ml low salt buffer (20 mM Tris-HCl pH 8,1, 150 mM 
NaCl, 2mM EDTA, 1% Triton X-100, 0,1% SDS) per sample followed by washing once with 1 
ml high salt buffer (20 mM Tris-HCl pH 8,1, 500 mM NaCl, 2mM EDTA, 1% Triton X-100, 
0,1% SDS). 1ml immuno-complex buffer (10 mM Tris-HCl pH 8,1, 1% deoxycholic acid, 0,25 
M LiCl, 1% Igepal-CA 630) are then added and finally, to remove LiCl completely agarose is 
rinsed twice with 1ml TE buffer (10mM Tris pH 8,0, 1mM EDTA) per sample. After complete 
removal of TE-buffer, 100µl 10mM DTT per sample are added to the agarose and elution is 
facilitated by incubation for 30 min at 37°C in a Thermomixr (Eppendorf) at 400 rpm. The 
elution is repeated and subsequently the eluates are combined. 
Input samples containing 20µg protein are thawed and diluted with 100µl 10mM DTT. Samples 
are de-crosslinked by addition of 4µl 5M NaCl and 2µl 5M NaCl to the input samples, 
respectively and incubation at 65°C overnight.  
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Next day, samples are briefly spinned down to collect the buffer and then a Proteinase K digest 
of the proteins is performed by addition of 2µl 0,5M EDTA, 4µl 1M Tris-HCl pH 6,5 and 0,4µl 
proteinase K per sample. For the input samples the volumes are bisected. Protein digest is done 
for 1h at 45°C and the DNA is purified using the PCR purification Kit (Qiagen) following the 
manufacturer’s instructions. DNA is eluted with 21µl TE buffer and stored at -20°C until 
evaluation with PCR. 
5.3.11.2 ChIP assay from cultured cells 
For each individual condition one 15cm plate is needed with 80 to 90% confluency. Per 25 ml 
medium 680 µl formalde are used and the cells are incubated for 10 min at 37°C. The medium is 
removed and the cells are washed once with ice-cold PBS. Cells are harvested in 2ml PBS using 
a cell scraper and the suspension is transferred into a fresh tube. The cells are pelleted by 
centrifugation for 5 min at 3000 rpm and the supernatant is discarded. Re-suspension is done in 
400µl SDS lysis buffer containing protease inhibitors. Subsequently, the ChIP protocol is done 
as described in section 2.3.8.1 
 
5.3.11.3 Antibodies used for ChIP Assays 
Table13 lists antibodies used for chromatin immunoprecipitation. 
Table 13: Antibodies used for ChIP assay 
Antibody Source 
CREB 06-863 Upstate 
P-CREB 05-807 Upstate 
p300 N-15 sc-584 Santa Cruz 
acetyl-histone H3 06-599 Upstate 
GR P-20 sc-1002 Santa Cruz 
normal mouse IgG sc-2025 Santa Cruz 
normal rabbit IgG sc-2027 Santa Cruz 
 
5.3.11.4 Evaluation by PCR  
After isolation of DNA protein complexes and subsequent proteinase K digestion DNA with an 
average size of approximately 1000 to 2000 bp is available. To examine the amount of immuno-
precipitated DNA complexes, a PCR reaction is performed. During this work protein complexes 
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on the murine Hes-1 promoter, on the rat Hes1 promoter and on the murine PEPCK promoter 
were used (see Table 14).  
 
Table 14: Specific primers used for the evaluation of ChIP experiments 
Promoter Species Primer Sequence 
Hes-1 Rat Forward 5’-CCCAGAGGAGTTAGCAAA-3’ 
 Rat Reverse 5’-CGAGTGAAACTTCCCAAA-3’ 
Hes-1  Mouse Forward 5’-AGCGGAATCCCCTGTCTACCTCTC-3’ 
 Mouse Reverse 5’-ATATCAGCTGGCATTTTCGTTTTT-3’ 
PEPCK Rat  Forward 5’-GGCCTCCCAACATTCATTAAC-3’ 
 Rat Reverse 5’-GTAGCTAGCCCTCCTCGCTTTAA-3’ 
Per individual PCR reaction 3µl DNA isolated in ChIP experiments, 12,5µl 2x PCR Mix, 7,5µl 
ultra-pure water, 1µl forward primer (1µM) and 1µl reverse primer (1µM) are used to reach a 
final volume of 25µl. 
The PCR follows the this protocol: 
Initial denaturation:   10 min  95°C 
35 cycles   30 sec  95°C 
    30 sec  56°C (Hes-1 primer), 52°C (PEPCK primer) 
    90 sec  72°C 
Final elongation  30 sec  95°C  
    3 min  72°C 
    cool down to 4°C. 
The PCR reaction is interrupted at cycle 28 to 30 and 10µl of the mixture are transferred to a 
fresh tube. The PCR is completed with the remaining reaction mixture, so that finally per 
individual reaction two samples at different times of the PCR reaction are available. The 
samples are diluted with Orange Dye (6-fold, Orange G dye, 50% glycerol, 10 mM EDTA) and 
are run on a 1,5% agarose gel. The signal intensity obtained directly correlates with the amount 
of immuno-precipitated protein complexed with the DNA and therefore is a measure for binding 
affinity under a given experimental condition. 
5.3.12 Radioimmunoassay for corticosterone  
Serum corticosterone levels were measured using the corticosterone RIA Kit from MP 
Biomedicals (MP Biomedicals, Cat No #07120102). Serum samples are slowly thawed on ice 
and briefly spinned to sediment particles for 30’’ at 13 krpm. Dilutions of serum are done in 
Seroid Diluent (included in Kit) depending origin of the sample, e.g. samples from fasted 
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animals and db/db mice are diluted 1:200, serum samples with low corticosterone levels are 
diluted 1:25. The assay is carried out in Fiolax tubes (Roth Cat No: 223.1 8x70 mm) according 
to manufacturer’s instructions. Safety rules valid for work with 125I is applied. A standard curve 
is prepared with stock solutions provided in the Kit. Samples are done in duplicates.  
After addition of all reagents following the kit instructions, samples are incubated for 2h at RT. 
Bound corticosterone is precipitated by centrifugation for 15 min at 2400 rpm at 20°C (Hereaus 
centrifuge). Supernatant is discarded and remaining radioactivity in residue is measured in a 
gamma Counter (Master 1277, LKB Wallac) with 1 min count time per sample.  
Corticosterone levels are calculated based on the standard curve. 
5.4 Animal experiments 
5.4.1 Glucose tolerance test 
Mice are maintained on a 12 h light/dark cycle and fasted for approximately 15 hours starting at 
6 pm. The animals are transferred into fresh cages equipped with fresh water but no food. The 
following morning, the body weight is determined and the initial blood glucose level is 
determined by nicking the tail with a razor blade by a horizontal cut at the very end. A blood 
drop is transferred onto a glucometer stripe and measured. 
The mice are then injected intraperitoneally with 10 µl/g body weight of 20% (w/v) D-glucose. 
The measurement of blood glucose is done by sampling blood from the tail. At 10, 20, 30, 60, 
90 and 120 min after injection the value is determined. Immediately after the end, food is 
provided for the animals. 
5.4.2 Insulin tolerance test 
Mice are maintained on a 12 hour light/dark cycle and the test is performed with animals fed ad 
libitum. For the insulin tolerance test a stock solution of 0,75 U insulin/ ml is prepared 
employing Huminsulin® Normal 40 (Lilly) dissolved in 0,9% sodium chloride. The body  
weight of all animals is determined initially and the blood glucose level is measured by nicking 
the tail with a razor blade. The blood drop is put onto a glucometer strip and measured.  
Per mouse 1,5 U insulin/ kg body weight are injected intraperitoneally. The blood glucose level 
is monitored after 10, 20, 30, 60 and 120 minutes.  
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5.5 Generation and production of Adenoviruses 
5.5.1 Cloning of adenoviruses 
For the generation of adenoviruses, containing shRNA sequences against murine Hes-1 or 
against murine GR, the BLOCK-iT™ Adenoviral RNAi Expression System by Invitrogen was 
used. Suitable oligonucleotide sequences were chosen using Invitrogen’s website tool  BLOCK-
iT™ RNAi Designer (https://rnaidesigner.invitrogen.com/rnaiexpress/setOption.do? 
designOption=stealth). Selected oligonucleotides are targeted against the murine Hes-1 
sequence with the accession number NM_008235 and for GR accession number X04435. 
Oligonucleotides used to specifically target either GR or Hes-1 are listed in Table 15 and 16. 
 
Table 15: shRNA sequences for RNA interference with murine Hes-1. 
Hes 1  Oligonucleotide sequence selection 
shRNA forward CACCGGATGCACTTAAGAAAGATAGCGAACTATCTTTCTTAAGTGCATCC invitrogen 
 reverse AAAAGGATGCACTTAAGAAAGATAGTTCGCTATCTTTCTTAAGTGCATCC 
 
 
shRNA forward CACCGGAAATACCGCGCCGGCTTCACGAATGAAGCCGGCGCGGTATTTCC 
 
invitrogen 
 reverse AAAAGGAAATACCGCGCCGGCTTCATTCGTGAAGCCGGCGCGGTATTTCC  
shRNA forward CACCGCGACACCGGACAAACCAAACGAATTTGGTTTGTCCGGTGTCG 
 
invitrogen 
 reverse AAAACGACACCGGACAAACCAAATTCGTTTGGTTTGTCCGGTGTCGC  
shRNA forward CACCGCACTGCATTTGTATATATTTCAAGAGAATATATACAAATGCAGTGC 
 
promega 
 reverse AAAAGCACTGCATTTGTATATATTCTCTTGAAATATATACAAATGCAGTGC  
shRNA forward CACCGGATTGCGCCTTTGTATTATTCAAGAGATAATACAAAGGCGCAATCC 
 
promega 
 reverse AAAAGGATTGCGCCTTTGTATTATCTCTTGAATAATACAAAGGCGCAATCC  
shRNA forward CACCGCAGACATTCTGGAAATGATTCAAGAGATCATTTCCAGAATGTCTGC 
 
promega 
 reverse AAAAGCAGACATTCTGGAAATGATCTCTTGAATCATTTCCAGAATGTCTGC  
shRNA forward CACCGGCCAATTTGCCTTTCTCATTCAAGAGATGAGAAAGGCAAATTGGCC 
 
promega 
 reverse AAAAGGCCAATTTGCCTTTCTCATCTCTTGAATGAGAAAGGCAAATTGGCC  
Indicated in red are the specific sequences targeting the murine Hes-1 
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Table 16: Oligonucleotides encoding for shRNAs targeting the murine GR 
name  sequence Selection 
shRNA1 forward CACCAGAAATGACTGCCTTACTATTCAAGAGATAGTAAGGCAGTCATTTCT 
 
D. Habermehl 
 reverse AAAAAGAAATGACTGCCTTACTATTCAAGAGATAGTAAGGCAGTCATTTCT 
 
 
shRNA2 forward CACCGGAGATACAATCTTATCAAGCCGAAGCTTGATAAGATTGTATCTCC 
 
invitrogen 
 reverse AAAAGGAGATACAATCTTATCAAGCTTCGGCTTGATAAGATTGTATCTCC 
 
 
shRNA3 forward CACCGGTGTTATATGCAGGATATGACGAATCATATCCTGCATATAACACC 
 
invitrogen 
 reverse AAAAGGTGTTATATGCAGGATATGATTCGTCATATCCTGCATATAACACC  
Indicated in red are the specific sequences targeting the murine GR 
 
The nucleotides were annealed and cloned into the pENTR™/U6 vector plasmid (Invitrogen) 
according to manufacturer’s instructions. Positive clones were identified with as restriction 
enzyme analysis as such: 
Subsequently, pENTR™/U6 constructs containing shRNA sequences were recombined with the 
vector plasmid pAd/BLOCK-iT™ Dest (Invitrogen). This vector contains the viral DNA 
sequence of adenovirus serotyp 5, whereas the genes E1 and E3 , that are important for 
replication of the virus, are deleted. At the 5’-end of the viral genome recombination sequences 
are included and at this site the pENTR™ vector recombines in such a way that the U6 promoter, 
the shRNA sequence and a PolIII termination signal are integrated into the newly formed 
plasmid. During recombination, a chloramphenicol resistance gene is excised and positive 
clones therefore are resistant against kanamycin but chloramphenicol sensitive. 
With colony PCR positive clones are confirmed and subsequently they are propagated for 
preparation of plasmid DNA. 
The viral vector is linearized by restriction with PacI and transfected into 239A cells using 
Lipofectamine according to manufacturer’s instructions. 6 to 8 days after transfection viral 
plaques are visible on the cell monolayer and cells start to detach from the cell culture dish. If 
several plaques are identified, cells are harvested. In the first virus propagation after transfection, 
usually not all cells are transfected or subsequently infected by the virus. It is therefore 
advisable to harvest the virus ten to twelve days after transfection. 
5.5.2 Virus harvest by Freeze-and-Thaw-Method 
293A cells that have been transfected with plasmids containing viral DNA or infected with 
functional viruses are harvested, when cells start to detach from the cell culture dish. For this 
purpose, the cell culture medium, in which the cells were maintained during viral infection is 
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purpose, the cell culture medium, in which the cells were maintained during viral infection is 
used for washing cells from the plate to achieve high viral titers. Cell suspensions from up to 20 
15cm plates are collected and the cells are pelleted for 10 min at 4000 rpm. The supernatant is 
discarded and the cell pellet is resuspended in 2 to 3 ml PBS-TOSH buffer and transferred to a 
15 ml Falcon tube (only use polypropylene tubes!). The tubes are snap-frozen in liquid nitrogen 
for 2 min and then thawing is facilitated in a 37°C water bath. Thawing is accelerated by 
vigorous mixture of the suspension using a vortex. This step is crucial, since the ice crystals 
destroy the cell membranes thereby releasing the viruses.The Freeze-and-Thaw cycle is repeated 
three times. Subsequently, the cell lysate is centrifuged for 15 min at 4000 rpm and 4°C. The 
supernatant contains the virus particles and can be kept until cesium chloride purification at -
80°C. The cell pellet is discarded. 
The storage of virus-containing supernatants after Freeze-and-Thaw cycles at -80°C is not 
critical for the stability of the adenoviruses, probably because proteins in these solution 
contribute to viral stabilisation. 
5.5.3 Virus production  
For the production of adenoviruses for mouse experiments 40 to 80 cell culture dishes with a 
diameter of 15 cm are used. 239A cells are maintained in D-MEM medium containing 10% FCS; 
1% non-essential amino acids and 1 x penicillin/ streptomycin until they reach a confluency of 
70 to 80%.  
After transfection of adenoviruses and the first virus harvest it is advisable to transfect a 
maximum of 10 15 cm plates with 10µl of crude virus lysate (obtained after Freeze-and-Thaw 
cycle). After three to four days cell detachment should be visible, othwerwise, transfection 
should be repeated. 
5.5.4 Cesium chloride gradient 
Crude virus lysates are thawed on ice and the viral solution is diluted with PBS-TOSH buffer to 
a final volume of 18 ml. This solution should contain the virus of 20 plates.  
Before the gradient is poured the pH of all solutions used should be adjusted to pH 7.2. 40 ml 
centrifuge tubes (Beckmann Polyallomer 25mm x 89 mm) are filled with 9 ml 4M cesium 
chloride and carefully covered by a second layer with 2,2M cesium chloride. Finally, the virus-
containing solution should be added slowly to generate a third layer. In the end, three distinct 
layer should be distinguishable. Between each step gradient tubes should be weighed and 
balanced by adding the appropriate solution (different cesium chloride solutions have different 
density and therefore different masses). The virus is purified by ultracentrifugation (Beckmann 
 
5. Methods and Materials 
 
110
ultracentrifuge XL-70) for 2h with a swing bucket rotor (SW28 rotor) at 24000 rpm and 4°C. 
The virusband appears between the 4M and 2,2M cesium chloride layer and is removed by 
carefully plunging the tube with 2ml syringe equipped with a cannula (BD Microlance 3, 18G x 
1 ½’’). The obtained virus band is diluted with the same volume of a saturated cesium chloride 
solution and transferred into a 12 ml centrifuge tube (Beckmann Polyallomer 14mm x 89 mm). 
The maximum volume should not exceed 7 ml. The solution is gently overlayed by 4M cesium 
chloride (2-3 ml). Subsequently, 2 to 3 ml 2,2M cesium chloride are added dropwise to result in 
third distinct layer and the step gradient is centrifuged for 3h at 35000 rpm and 4°C in a swing 
bucket rotor (SW41 Ti rotor). After the second purification step, a bluish-fluorescent band 
should appear between the 4M and 2,2M layers. The virus is isolated again by plunging the tube 
with a 18 gauge needle.  
To remove the high salt concentration the virus is dialyzed three times against 1l PBS 
containing 10% glycerol (v/v) using a dialyis membrane with a 15 kDa cut-off (Spectra/Por® 
Biotech, MWCO 15’000, 10 mm diameter). The first two steps are done 1h each and the third 
dialysis is done overnight. The next day, the virus is transferred into a 2ml cryo-vial and 
aliquots for virus titration etc. are separately frozen to avoid repeated freezing and thawing. 
5.5.5 Virus titration 
Titration of adenoviruses is done using the Tissue Culture Infectious Dose50 (TCID50) Assay. 
For this purpose 293A cells are harvested and a cell suspension with a concentration of 105 
cells/ml is prepared in D-MEM medium containing 2% FCS (v/v) and 1-fold 
penicillin/streptomycin. 
Cells are seeded into a 96-well plate with 100µl/well using a multistep pipet.  
Virus dilutions from 10-2 to 10-12 are prepared in D-MEM medium with 2% FCS and 
penicillin/streptomycin and 100 µl of a certain virus dilution are added per well before the 293A 
cells are attached. Ten wells are used per virus dilution. Usually, the first concentration applied 
to the plate is 10-5. As a negative control 16 wells are treated with 100µl D-MEM medium 
(2%FCS, penicillin/streptomycin) only. Cells are incubated for 10 days at 37°C, 95% humidity 
and 5% CO2. Each virus titration is done twice on 96-well plates. 
Ten days after infection wells are examined for plaque formation microscopically. The virus 
titer is calculated using the formula  
Titer Ta=101+(s-0,5) for 100µl; where s is the sum of all positive wells starting from the dilution   
10-1. Ten positive wells correspond the value of 1 for the individual virus dilution. To obtain the 
vius in ifu/ml Ta has to be multiplied with 10. 
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5.6 Buffers  
 
PBS 10x:   
30 mM KCl; 10 mM KH2PO4; 1,37 M NaCl; 90 mM Na2HPO4; pH-Wert 7,0 
 
SDS-running buffer 10x:  
1,92 M Glycin; 0,45% HCl; 30 mM SDS; 0,25 M Trizma Base 
 
TBE 10x:    
45 mM Borsäure; 10 mM EDTA; 45 mM Trizma Base 
 
TBS 10x:    
1,37 M NaCl; 200 mM Trizma Base 
 
TE 10x:    
1 mM EDTA; 10 mM TrisCl pH 7,5 
 
transfer buffer 10x:    
1,92 M Glycin; 0,25 M Trizma Base 
 
HBSS: 
 
5.3 mM KCl, 0.441 mM KH2PO4, 4.17 mM NaHCO3, 138 mM NaCl, 0.338 mM Na2HPO4 
 
protease inhibitor mix 
0,05% Aprotenin; 1 mM DMSO; 0,05% Leupeptin; 50 mM PMSF; 50 mM NaF; in Ethanol 
 
phosphatase inhibitors (100X) 
200 mM imidazole, 100 mM NaF, 115 mM Na-molybdate, 100 mM Na –ortho-vanadate,  
400 mM Na-tartrate,  
 
6x Orange G Probenpuffer:  
10 mM EDTA; 70% Glycerol; Orange G (1 Spatelspitze) 
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5.7 Plasmids  
 
Table 17: Lists of plasmids used  
Plasmid name origin purpose 
pGVB mHes-1 LUC -467/+46 bp R. Kageyama (135) transfection 
pGL2 mHes-1 LUC -194bp/+160bp D. Ndiaye (209) transfection 
wt PKA McKnight(210) transfection 
mut PKA McKnight(210) transfection 
pCMV bGal A.Vegiopoulos transfection 
GAL4DBD M. Conkright transfection 
GAL4GR M. Conkright transfection 
GAL4CREB R.Screaton transfection 
pCMX VP16 CREB Nicola Rieser (unpublished) transfection 
pCMX VP16 KID R. Screaton transfection 
pCMX VP16 KIX L.Canettieri transfection 
pCMX VP16 bZIP L.Canettieri  transfection 
pCMX VP16 R. Screaton transfection 
pENTR/U6 Invitrogen generation of adenovirus 
pAd BLOCK-iT/DEST Invitrogen generation of adenovirus 
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6 Appendix 
6.1 Abbreviations 
 
11βHSD1 11-β-hydroxysteroid dehydrogenase 
ABCD  avidin-biotin conjugated DNA  
ACC1  acyl-CoA carboxylase 1 
ADP  adenosine-nucleotide diphosphate 
Angptl  angiopoietin-like 
ATF1  activating transcription factor 1 
ATP  adenosine nucleotide triphosphate 
AUC  area under the curve 
BSA  bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
Cav1  caveolin 
CBP  CREB binding protein 
cDNA  complement desoxyribonucleic acid 
ChIP  chromatin immunoprecipitation 
CI  chloroform:isoamylalcohol 
CMV  cytomegalovirus 
CO2  carbon dioxide 
CoA  coenzyme A 
CPT1α carnitine palmitoyl transferase 1α 
CRE  cAMP response element 
CREB  cAMP response element binding protein 
CREM  cyclic AMP responsive element modulator 
CT  computer tomography 
DBD  DNA binding domain 
DMA  dimethyladipimidate 
DMEM Dulbecco’s Modified Eagle Medium 
dNTP  deoxyribonucleotid 
DOI  diet-induced obesity 
DTT  dithiothreitol 
DUSP-1 Dual Specific Phosphatase 
EDTA  ethylenediamine tetraacetic acid 
EGTA  ethyleneglycol tetraacetic acid 
FABP-1 fatty acid binding protein 
FAS  fatty acid binding protein 
FFA  free fatty acids 
FKBP52 FK506 binding protein 52 
FLAG  artificial peptide sequence used as protein tag 
GC  glucocorticoids 
GFP  green fluorescent protein 
GK  glucokinase 
GLUT2 glucose transporter 2 
GLUT4 glucose transporter 4 
Gly-Gly glycylglycin 
GR  glucocorticoid receptor 
GRdim  glucocorticoid receptor bearing a mutation in the DNA binding domain 
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GRE  glucocorticoid response element 
GTT  glucose tolerance test 
HAT  histone acetyltransferase 
HBSS  HEPES buffered saline solution 
HEK  human embryonic kidney 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ) 
Hes-1  Hairy and Enhancer of Split 1 
HFD  high fat diet 
HRP  horse radish peroxidase 
Hsp70  heat shock protein 70 
Hsp90  heat shock protein 90 
ifu  infective units 
IGF-1  insulin-like growth factor 1 
IgG  immunglobulin G 
IRS  insulin receptor substrate 
ITT  insulin tolerance test 
KID  kinase inducible domain 
KOH  potassium hydroxide 
LBD  ligand binding domain 
LB-medium Luria Bertani medium 
L-GRKO liver-specific glucocorticoid receptor knockout 
LPL  lipoprotein lipase 
LUC  luciferase 
MKP-1 mitogen activated protein kinase phosphatase 1 
MOI  multiplicity of infection 
MOPS  3-(N-morpholino)-propansulfonic acid 
MR  magnetic resonance 
MTTP  microsomal triglyceride transfer protein 
NAA  non-essential amino acids 
NADH nicotinamid adenosine dinucleotide, reduced form 
NADPH nicotinamid adenosine dinucleotide phosphate, reduced form 
NAFLD Non-Alcoholic Fattyl Liver Disease 
NASH  Non-Alcoholic Steatohepatitis 
NEFA  non esterified fatty acids 
NIDDM Non-insulin dependent diabetes mellitus 
NZB  New Zealand Black 
NZO  New Zealand Obese 
OD  optical density 
ONPG  ortho-nitrophenyl-β-D-galactopyranosid 
PBS  phosphate buffered saline 
PCI  phenol:chloroform:isoamylalcohol 
PCR  polymerase chain reaction 
PDE  phosphodiesterase 
PEPCK phosphoenol-pyruvate carboxykinase 
PGDH  phosphogluconat dehydrogenase 
PI 3-K  phosphoinositide 3-kinases 
PKA  protein kinase A 
PKC  protein kinase C 
PKI  protein kinase inhibitor 
POD  peroxidase 
PP1  protein phosphatase 1 
 
6. Appendix 
 
115
PP2A  protein phosphatase 2A 
PPAR  peroxisome proliferation-activating receptor 
rpm  rounds per minute 
RT-PCR real time polymerase chain reaction 
SCD1  stearoyl CoA desaturase 1 
SDS  sodium dodecylsulfate 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
shRNA short hairpin RNA 
TBP  TATA box binding protein 
TBS  Tris buffered saline 
TGs  triglycerides 
TRIS  trishydroxymethylaminomethane 
UV  ultraviolett 
VCP  Valosin-containing protein 
VLDL  very-low density lipoprotein 
wt  wildtype 
w/v  weight per volume 
6.2 Figures 
 
Figure 1.1: Glucagon signaling and transcriptional activation of target genes. ........................................ 17 
Figure 1.2: Signal transduction in insulin action....................................................................................... 20 
Figure 3.1: Generation of an adenovirus constitutively expressing an shRNA sequence targeting the 
murine GR. ....................................................................................................................................... 26 
Figure 3.2: Analysis of shRNA-induced GR depletion in the murine liver. ............................................. 28 
Figure 3.3: Target gene analysis in wildtype mice after GR depletion. .................................................... 30 
Figure 3.4: Target gene analysis in db/db mice after GR depletion. ......................................................... 31 
Figure 3.5: Hes-1 expression is up-regulated after GR knockdown.......................................................... 32 
Figure 3.6: Starvation-induced fatty liver and hepatic Hes-1 expression.................................................. 34 
Figure 3.7: Hes-1 expression in db/db mice – a standard model of fatty liver.......................................... 35 
Figure 3.8: Hepatic Hes-1 expression in New Zealand Obese mice. ........................................................ 36 
Figure 3.9: Hepatic Hes-1 levels diet-induced obesity.............................................................................. 36 
Figure 3.10: Serum glucocorticoid levels in different mouse models. ...................................................... 38 
Figure 3.11 Glucocorticoid treatment leads to weight loss. ...................................................................... 39 
Figure 3.12: Chronically elevated glucocorticoid inhibit hepatic Hes-1 expression................................. 42 
Figure 3.13:The Glucocorticoid receptor is necessary for starvation induced Hes-1 down-regulation. ... 43 
Figure 3.14: Adenoviral vector encoding rat Hes-1. ................................................................................. 44 
Figure 3.15: Transient Hes-1 expression in C57Bl/6J mice. ..................................................................... 46 
Figure 3.16: Transient Hes-1 expression in db/db mice improves the metabolic phenotype.................... 49 
Figure 3.17: Evaluation of Hes-1 expression in C57BL/6J mice after three weeks dexamethasone 
treatment. .......................................................................................................................................... 53 
 
6. Appendix 
 
116
Figure 3.18: Rescue of hepatic Hes-1 after glucocorticoid treatment prevents fat accumulation in the 
liver.. ................................................................................................................................................. 53 
Figure 3.19: Transient Hes-1 knock down using adenoviruses................................................................. 54 
Figure 3.20: De-regulation of Hes-1 expression in response to adenoviral injection. .............................. 55 
Figure 3.21: Hes-1 is depleted in primary hepatocytes. ............................................................................ 56 
Figure 3.22: PPARγ and Cav1 are up-regulated after Hes-1 depletion in primary hepatocytes. .............. 56 
Figure 3.23: Glucocorticoids inhibit Hes-1 expression in vitro by dephosphorylation of CREB. ............ 59 
Figure 3.24: Promoter Analysis of proximal Hes-1 promoter region (-440bp to -4bp). ........................... 60 
Figure 3.25: The glucocorticoid associates in vivo with the Hes-1 promoter. .......................................... 62 
Figure 3.26: The GR occupies to binding sites on the Hes-1 promoter. ................................................... 62 
Figure 3.27: MKP-1 mice are protected against GC-induced glucose in tolerance. ................................. 64 
Figure 3.28: In MKP-1 -/- mice improved glucose tolerance does not depend on Hes-1. ........................ 66 
Figure 3.29: Domain structure of CREB and CBP.................................................................................... 67 
Figure 3.30: The VP16 does not interact with either GAL4DBD or GAL4GR. ....................................... 68 
Figure 3.31: GR interacts via the bZIP domain with CREB. .................................................................... 69 
Figure 3.32: Glucocorticoids inhibit CREB activity under basal and activated conditions. ..................... 71 
Figure 3.33: p300 abolishes GC-dependent inhibition of CREB activity. ................................................ 72 
Figure 3.34: Glucocorticoid treatment leads to disruption of P-CREB/p300 transactivation complex on 
the Hes-1 promoter. .......................................................................................................................... 73 
Figure 4.1: Glucocorticoid mediated repression of Hes-1 transcription. .................................................. 82 
 
6.3 Tables 
Table 1: Serum lipid parameters 13 days after Dexamethasone injection................................................. 39 
Table 2: Organ weight parameters and blood glucose in dexamethasone injected C57BL/6J mice ......... 40 
Table 3: Lipid parameters at day of sacrifice. ........................................................................................... 41 
Table 4: Body weight and blood glucose parameters of L-GRKO mice................................................... 43 
Table 5:  Body weight and blood glucose at start and end of experiment................................................. 45 
Table 6: Body weight and blood glucose parameters at day of sacrifice .................................................. 47 
Table 7: Gene expression data from db/db mice treated with Hes-1 virus or control ............................... 50 
Table 8: Weight parameters at day of sacrifice ......................................................................................... 65 
Table 9: Taqman® probes used for qPCR experiments ............................................................................ 89 
Table 10: Composition of polyacrylamide gels with different concentration of acrylamide .................... 95 
Table 11: Primary and secondary antibodies for immunoblot .................................................................. 96 
Table 12: Oligonucleotide sequences used in the ABCD assay with the glucocorticoid receptor.......... 101 
Table 13: Antibodies used for ChIP assay .............................................................................................. 104 
Table 14: Specific primers used for the evaluation of ChIP experiments ............................................... 105 
Table 15: shRNA sequences for RNA interference with murine Hes-1.................................................. 107 
 
6. Appendix 
 
117
Table 16: Oligonucleotides encoding for shRNAs targeting the murine GR.......................................... 108 
Table 17: Lists of plasmids used ............................................................................................................. 112
 
7. Bibliography 
 
118
7 Bibliography 
 
1. Unger, R.H., and Orci, L. 2001. Diseases of liporegulation: new perspective on obesity 
and related disorders. Faseb J 15:312-321. 
2. Mokdad, A.H., Marks, J.S., Stroup, D.F., and Gerberding, J.L. 2004. Actual causes of 
death in the United States, 2000. Jama 291:1238-1245. 
3. Fagot-Campagna, A., Pettitt, D.J., Engelgau, M.M., Burrows, N.R., Geiss, L.S., Valdez, 
R., Beckles, G.L., Saaddine, J., Gregg, E.W., Williamson, D.F., et al. 2000. Type 2 
diabetes among North American children and adolescents: an epidemiologic review and 
a public health perspective. J Pediatr 136:664-672. 
4. Petrie, J.R., Cleland, S.J., and Small, M. 1998. The metabolic syndrome: overeating, 
inactivity, poor compliance or 'dud' advice? Diabet Med 15 Suppl 3:S29-31. 
5. Pinhas-Hamiel, O., Dolan, L.M., Daniels, S.R., Standiford, D., Khoury, P.R., and Zeitler, 
P. 1996. Increased incidence of non-insulin-dependent diabetes mellitus among 
adolescents. J Pediatr 128:608-615. 
6. Canbay, A., Bechmann, L., and Gerken, G. 2007. Lipid metabolism in the liver. Z 
Gastroenterol 45:35-41. 
7. Holloszy, J.O., and Kohrt, W.M. 1996. Regulation of carbohydrate and fat metabolism 
during and after exercise. Annu Rev Nutr 16:121-138. 
8. Weigand, K., and Alpert, E. 1981. Human albumin synthesis via an albumin precursor in 
liver tissue slices. Experientia 37:1145-1147. 
9. Weinhouse, S. 1952. Factors involved in the formation and utilization of ketone bodies. 
Brookhaven Symp Biol 5:201-216; discussion, 216-221. 
10. Booth, R., Gregory, K.W., Malone, E.M., and Robertson, I. 1971. The effect of dietary 
cholesterol on cholesterol biosynthesis and other processes in mammalian liver. Biochem 
J 122:25P-26P. 
11. McCuskey, R.S., McCuskey, P.A., Urbaschek, R., and Urbaschek, B. 1987. Kupffer cell 
function in host defense. Rev Infect Dis 9 Suppl 5:S616-619. 
12. McCuskey, R.S., Urbaschek, R., McCuskey, P.A., Sacco, N., Stauber, W.T., Pinkstaff, 
C.A., and Urbaschek, B. 1984. Deficient Kupffer cell phagocytosis and lysosomal 
enzymes in the endotoxin-low-responsive C3H/HeJ mouse. J Leukoc Biol 36:591-600. 
13. Consoli, A. 1992. Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430-
441. 
14. Shulman, G.I. 2000. Cellular mechanisms of insulin resistance. J Clin Invest 106:171-
176. 
15. Kahn, A. 1997. Transcriptional regulation by glucose in the liver. Biochimie 79:113-118. 
16. Saltiel, A.R., and Kahn, C.R. 2001. Insulin signalling and the regulation of glucose and 
lipid metabolism. Nature 414:799-806. 
17. Miles, J.M., and Jensen, M.D. 1993. Does glucagon regulate adipose tissue lipolysis? J 
Clin Endocrinol Metab 77:5A-5B. 
18. Siddle, K., and Hales, C.N. 1975. Hormonal control of adipose tissue lipolysis. Proc 
Nutr Soc 34:233-239. 
19. Hales, C.N., Luzio, J.P., and Siddle, K. 1978. Hormonal control of adipose-tissue 
lipolysis. Biochem Soc Symp:97-135. 
20. Kawai, A., and Kuzuya, N. 1981. Effects of glucocorticoids on hormone-stimulated 
lipolysis and calcium uptake in the adipose cells. Horm Metab Res 13:224-228. 
21. Divakaran, P., and Friedmann, N. 1976. A fast in vitro effect of glucocorticoids on 
hepatic lipolysis. Endocrinology 98:1550-1553. 
 
7. Bibliography 
 
119
22. Desvergne, B., Michalik, L., and Wahli, W. 2006. Transcriptional regulation of 
metabolism. Physiol Rev 86:465-514. 
23. Kornberg, R.D., and Lorch, Y. 1999. Twenty-five years of the nucleosome, fundamental 
particle of the eukaryote chromosome. Cell 98:285-294. 
24. Hayashi, R., Wada, H., Ito, K., and Adcock, I.M. 2004. Effects of glucocorticoids on 
gene transcription. Eur J Pharmacol 500:51-62. 
25. Urnov, F.D., and Wolffe, A.P. 2001. Chromatin remodeling and transcriptional 
activation: the cast (in order of appearance). Oncogene 20:2991-3006. 
26. Zlatanova, J., Leuba, S.H., Yang, G., Bustamante, C., and van Holde, K. 1994. Linker 
DNA accessibility in chromatin fibers of different conformations: a reevaluation. Proc 
Natl Acad Sci U S A 91:5277-5280. 
27. Janknecht, R., and Hunter, T. 1996. Versatile molecular glue. Transcriptional control. 
Curr Biol 6:951-954. 
28. Collingwood, T.N., Urnov, F.D., and Wolffe, A.P. 1999. Nuclear receptors: coactivators, 
corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 
23:255-275. 
29. de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S., and van Kuilenburg, A.B. 
2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. 
Biochem J 370:737-749. 
30. Foretz, M., Pacot, C., Dugail, I., Lemarchand, P., Guichard, C., Le Liepvre, X., 
Berthelier-Lubrano, C., Spiegelman, B., Kim, J.B., Ferre, P., et al. 1999. ADD1/SREBP-
1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell 
Biol 19:3760-3768. 
31. Foretz, M., Guichard, C., Ferre, P., and Foufelle, F. 1999. Sterol regulatory element 
binding protein-1c is a major mediator of insulin action on the hepatic expression of 
glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A 96:12737-12742. 
32. Shimomura, I., Matsuda, M., Hammer, R.E., Bashmakov, Y., Brown, M.S., and 
Goldstein, J.L. 2000. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin 
resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77-86. 
33. Magana, M.M., Lin, S.S., Dooley, K.A., and Osborne, T.F. 1997. Sterol regulation of 
acetyl coenzyme A carboxylase promoter requires two interdependent binding sites for 
sterol regulatory element binding proteins. J Lipid Res 38:1630-1638. 
34. Kingsley-Kallesen, M., Mukhopadhyay, S.S., Wyszomierski, S.L., Schanler, S., Schutz, 
G., and Rosen, J.M. 2002. The mineralocorticoid receptor may compensate for the loss 
of the glucocorticoid receptor at specific stages of mammary gland development. Mol 
Endocrinol 16:2008-2018. 
35. Aranda, A., and Pascual, A. 2001. Nuclear hormone receptors and gene expression. 
Physiol Rev 81:1269-1304. 
36. Yudt, M.R., and Cidlowski, J.A. 2001. Molecular identification and characterization of a 
and b forms of the glucocorticoid receptor. Mol Endocrinol 15:1093-1103. 
37. Oakley, R.H., Jewell, C.M., Yudt, M.R., Bofetiado, D.M., and Cidlowski, J.A. 1999. 
The dominant negative activity of the human glucocorticoid receptor beta isoform. 
Specificity and mechanisms of action. J Biol Chem 274:27857-27866. 
38. Yudt, M.R., Jewell, C.M., Bienstock, R.J., and Cidlowski, J.A. 2003. Molecular origins 
for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol 
23:4319-4330. 
39. Pratt, W.B., Morishima, Y., Murphy, M., and Harrell, M. 2006. Chaperoning of 
glucocorticoid receptors. Handb Exp Pharmacol:111-138. 
40. Beato, M. 1989. Gene regulation by steroid hormones. Cell 56:335-344. 
41. Beato, M., Chalepakis, G., Schauer, M., and Slater, E.P. 1989. DNA regulatory elements 
for steroid hormones. J Steroid Biochem 32:737-747. 
 
7. Bibliography 
 
120
42. Schaaf, M.J., and Cidlowski, J.A. 2002. Molecular mechanisms of glucocorticoid action 
and resistance. J Steroid Biochem Mol Biol 83:37-48. 
43. Konig, H., Ponta, H., Rahmsdorf, H.J., and Herrlich, P. 1992. Interference between 
pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced 
AP-1 activity without altering AP-1 site occupation in vivo. Embo J 11:2241-2246. 
44. Cole, T.J., Blendy, J.A., Monaghan, A.P., Krieglstein, K., Schmid, W., Aguzzi, A., 
Fantuzzi, G., Hummler, E., Unsicker, K., and Schutz, G. 1995. Targeted disruption of 
the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and 
severely retards lung maturation. Genes Dev 9:1608-1621. 
45. Reichardt, H.M., Kaestner, K.H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., 
Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. 1998. DNA binding of the 
glucocorticoid receptor is not essential for survival. Cell 93:531-541. 
46. Scott, D.K., Stromstedt, P.E., Wang, J.C., and Granner, D.K. 1998. Further 
characterization of the glucocorticoid response unit in the phosphoenolpyruvate 
carboxykinase gene. The role of the glucocorticoid receptor-binding sites. Mol 
Endocrinol 12:482-491. 
47. Wang, J.C., Stromstedt, P.E., Sugiyama, T., and Granner, D.K. 1999. The 
phosphoenolpyruvate carboxykinase gene glucocorticoid response unit: identification of 
the functional domains of accessory factors HNF3 beta (hepatic nuclear factor-3 beta) 
and HNF4 and the necessity of proper alignment of their cognate binding sites. Mol 
Endocrinol 13:604-618. 
48. Stafford, J.M., Waltner-Law, M., and Granner, D.K. 2001. Role of accessory factors and 
steroid receptor coactivator 1 in the regulation of phosphoenolpyruvate carboxykinase 
gene transcription by glucocorticoids. J Biol Chem 276:3811-3819. 
49. Stafford, J.M., Wilkinson, J.C., Beechem, J.M., and Granner, D.K. 2001. Accessory 
factors facilitate the binding of glucocorticoid receptor to the phosphoenolpyruvate 
carboxykinase gene promoter. J Biol Chem 276:39885-39891. 
50. Schoneveld, O.J., Gaemers, I.C., and Lamers, W.H. 2004. Mechanisms of glucocorticoid 
signalling. Biochim Biophys Acta 1680:114-128. 
51. Schoneveld, O.J., Hoogenkamp, M., Stallen, J.M., Gaemers, I.C., and Lamers, W.H. 
2007. cyclicAMP and glucocorticoid responsiveness of the rat carbamoylphosphate 
synthetase gene requires the interplay of upstream regulatory units. Biochimie 89:574-
580. 
52. Patti, M.E., and Kahn, C.R. 1998. The insulin receptor--a critical link in glucose 
homeostasis and insulin action. J Basic Clin Physiol Pharmacol 9:89-109. 
53. Araki, E., Lipes, M.A., Patti, M.E., Bruning, J.C., Haag, B., 3rd, Johnson, R.S., and 
Kahn, C.R. 1994. Alternative pathway of insulin signalling in mice with targeted 
disruption of the IRS-1 gene. Nature 372:186-190. 
54. White, M.F. 1998. The IRS-signalling system: a network of docking proteins that 
mediate insulin action. Mol Cell Biochem 182:3-11. 
55. White, M.F. 1996. The IRS-signalling system in insulin and cytokine action. Philos 
Trans R Soc Lond B Biol Sci 351:181-189. 
56. Pessin, J.E., and Saltiel, A.R. 2000. Signaling pathways in insulin action: molecular 
targets of insulin resistance. J Clin Invest 106:165-169. 
57. Shepherd, P.R., Nave, B.T., and Siddle, K. 1995. Insulin activates glycogen synthase by 
a novel PI 3-kinase/p70s6k dependent pathway in 3T3-L1 adipocytes. Biochem Soc 
Trans 23:202S. 
58. Shepherd, P.R., Nave, B.T., and Siddle, K. 1995. Involvement of PI 3-kinase in 
stimulation of glucose transport and recruitment of transferrin receptors in 3T3-L1 
adipocytes. Biochem Soc Trans 23:201S. 
 
7. Bibliography 
 
121
59. Haigh, R.J., Shepherd, P.R., Nave, B.T., and Siddle, K. 1995. The role of 
phosphatidylinositol 3-kinase activity in insulin-stimulated mitogenesis in 3T3-L1 
adipocytes. Biochem Soc Trans 23:179S. 
60. Alessi, D.R., Deak, M., Casamayor, A., Caudwell, F.B., Morrice, N., Norman, D.G., 
Gaffney, P., Reese, C.B., MacDougall, C.N., Harbison, D., et al. 1997. 3-
Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional 
homology with the Drosophila DSTPK61 kinase. Curr Biol 7:776-789. 
61. O'Brien, R.M., and Granner, D.K. 1996. Regulation of gene expression by insulin. 
Physiol Rev 76:1109-1161. 
62. O'Brien, R.M., Streeper, R.S., Ayala, J.E., Stadelmaier, B.T., and Hornbuckle, L.A. 2001. 
Insulin-regulated gene expression. Biochem Soc Trans 29:552-558. 
63. Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K., and Fukamizu, A. 2003. Insulin-
induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc 
Natl Acad Sci U S A 100:11285-11290. 
64. Tran, H., Brunet, A., Griffith, E.C., and Greenberg, M.E. 2003. The many forks in 
FOXO's road. Sci STKE 2003:RE5. 
65. Nakae, J., Kitamura, T., Ogawa, W., Kasuga, M., and Accili, D. 2001. Insulin regulation 
of gene expression through the forkhead transcription factor Foxo1 (Fkhr) requires 
kinases distinct from Akt. Biochemistry 40:11768-11776. 
66. Nakae, J., Park, B.C., and Accili, D. 1999. Insulin stimulates phosphorylation of the 
forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive 
pathway. J Biol Chem 274:15982-15985. 
67. Shimabukuro, M., Zhou, Y.T., Levi, M., and Unger, R.H. 1998. Fatty acid-induced beta 
cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95:2498-
2502. 
68. Shimabukuro, M., Ohneda, M., Lee, Y., and Unger, R.H. 1997. Role of nitric oxide in 
obesity-induced beta cell disease. J Clin Invest 100:290-295. 
69. Lipton, S.A., Choi, Y.B., Pan, Z.H., Lei, S.Z., Chen, H.S., Sucher, N.J., Loscalzo, J., 
Singel, D.J., and Stamler, J.S. 1993. A redox-based mechanism for the neuroprotective 
and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 
364:626-632. 
70. Chiu, H.C., Kovacs, A., Ford, D.A., Hsu, F.F., Garcia, R., Herrero, P., Saffitz, J.E., and 
Schaffer, J.E. 2001. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 
107:813-822. 
71. Zhou, Y.T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., 
and Unger, R.H. 2000. Lipotoxic heart disease in obese rats: implications for human 
obesity. Proc Natl Acad Sci U S A 97:1784-1789. 
72. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. 1993. Adipose expression of 
tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 
259:87-91. 
73. Shoelson, S.E., Lee, J., and Goldfine, A.B. 2006. Inflammation and insulin resistance. J 
Clin Invest 116:1793-1801. 
74. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.W., Karin, M., and Shoelson, 
S.E. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or 
targeted disruption of Ikkbeta. Science 293:1673-1677. 
75. Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M., and Hotamisligil, G.S. 
2006. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and 
insulin resistance. Proc Natl Acad Sci U S A 103:10741-10746. 
76. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M., 
and Hotamisligil, G.S. 2002. A central role for JNK in obesity and insulin resistance. 
Nature 420:333-336. 
 
7. Bibliography 
 
122
77. Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. 2006. TLR4 
links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-
3025. 
78. Angulo, P. 2007. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol 
Ther 25:883-889. 
79. Powell, E.E., Jonsson, J.R., and Clouston, A.D. 2005. Steatosis: co-factor in other liver 
diseases. Hepatology 42:5-13. 
80. Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., and 
Angulo, P. 2005. The natural history of nonalcoholic fatty liver disease: a population-
based cohort study. Gastroenterology 129:113-121. 
81. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., 
McCullough, A.J., Natale, S., Forlani, G., and Melchionda, N. 2001. Nonalcoholic fatty 
liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850. 
82. Jacobson, P.B., von Geldern, T.W., Ohman, L., Osterland, M., Wang, J., Zinker, B., 
Wilcox, D., Nguyen, P.T., Mika, A., Fung, S., et al. 2005. Hepatic glucocorticoid 
receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve 
glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 314:191-200. 
83. Liang, Y., Osborne, M.C., Monia, B.P., Bhanot, S., Watts, L.M., She, P., DeCarlo, S.O., 
Chen, X., and Demarest, K. 2005. Antisense oligonucleotides targeted against 
glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia 
in diabetic mice. Metabolism 54:848-855. 
84. Liu, Y., Nakagawa, Y., Wang, Y., Sakurai, R., Tripathi, P.V., Lutfy, K., and Friedman, 
T.C. 2005. Increased glucocorticoid receptor and 11{beta}-hydroxysteroid 
dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 
2 diabetes in db/db mice. Diabetes 54:32-40. 
85. Jenson, M., Kilroy, G., York, D.A., and Braymer, D. 1996. Abnormal regulation of 
hepatic glucocorticoid receptor mRNA and receptor protein distribution in the obese 
Zucker rat. Obes Res 4:133-143. 
86. Cole, T.G., Wilcox, H.G., and Heimberg, M. 1982. Effects of adrenalectomy and 
dexamethasone on hepatic lipid metabolism. J Lipid Res 23:81-91. 
87. Tomlinson, J.W., Walker, E.A., Bujalska, I.J., Draper, N., Lavery, G.G., Cooper, M.S., 
Hewison, M., and Stewart, P.M. 2004. 11beta-hydroxysteroid dehydrogenase type 1: a 
tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866. 
88. Holmes, M.C., Kotelevtsev, Y., Mullins, J.J., and Seckl, J.R. 2001. Phenotypic analysis 
of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 
genes. Mol Cell Endocrinol 171:15-20. 
89. Paterson, J.M., Morton, N.M., Fievet, C., Kenyon, C.J., Holmes, M.C., Staels, B., Seckl, 
J.R., and Mullins, J.J. 2004. Metabolic syndrome without obesity: Hepatic 
overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc 
Natl Acad Sci U S A 101:7088-7093. 
90. Letteron, P., Brahimi-Bourouina, N., Robin, M.A., Moreau, A., Feldmann, G., and 
Pessayre, D. 1997. Glucocorticoids inhibit mitochondrial matrix acyl-CoA 
dehydrogenases and fatty acid beta-oxidation. Am J Physiol 272:G1141-1150. 
91. Nagao, M., Parimoo, B., and Tanaka, K. 1993. Developmental, nutritional, and 
hormonal regulation of tissue-specific expression of the genes encoding various acyl-
CoA dehydrogenases and alpha-subunit of electron transfer flavoprotein in rat. J Biol 
Chem 268:24114-24124. 
92. Bjorntorp, P. 1991. Adipose tissue distribution and function. Int J Obes 15 Suppl 2:67-
81. 
 
7. Bibliography 
 
123
93. Rebrin, K., Steil, G.M., Mittelman, S.D., and Bergman, R.N. 1996. Causal linkage 
between insulin suppression of lipolysis and suppression of liver glucose output in dogs. 
J Clin Invest 98:741-749. 
94. Mittelman, S.D., and Bergman, R.N. 2000. Inhibition of lipolysis causes suppression of 
endogenous glucose production independent of changes in insulin. Am J Physiol 
Endocrinol Metab 279:E630-637. 
95. Bostrom, K., Boren, J., Wettesten, M., Sjoberg, A., Bondjers, G., Wiklund, O., Carlsson, 
P., and Olofsson, S.O. 1988. Studies on the assembly of apo B-100-containing 
lipoproteins in HepG2 cells. J Biol Chem 263:4434-4442. 
96. Vegiopoulos, A., and Herzig, S. 2007. Glucocorticoids, metabolism and metabolic 
diseases. Mol Cell Endocrinol 275:43-61. 
97. Tronche, F., Opherk, C., Moriggl, R., Kellendonk, C., Reimann, A., Schwake, L., 
Reichardt, H.M., Stangl, K., Gau, D., Hoeflich, A., et al. 2004. Glucocorticoid receptor 
function in hepatocytes is essential to promote postnatal body growth. Genes Dev 
18:492-497. 
98. Opherk, C., Tronche, F., Kellendonk, C., Kohlmuller, D., Schulze, A., Schmid, W., and 
Schutz, G. 2004. Inactivation of the glucocorticoid receptor in hepatocytes leads to 
fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes 
mellitus. Mol Endocrinol 18:1346-1353. 
99. Danielsen, M., Northrop, J.P., and Ringold, G.M. 1986. The mouse glucocorticoid 
receptor: mapping of functional domains by cloning, sequencing and expression of wild-
type and mutant receptor proteins. Embo J 5:2513-2522. 
100. Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J. 2000. An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 
404:293-296. 
101. Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. 2003. 
Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208. 
102. Finn, P.F., and Dice, J.F. 2006. Proteolytic and lipolytic responses to starvation. 
Nutrition 22:830-844. 
103. Birnbaum, M.J. 2003. Lipolysis: more than just a lipase. J Cell Biol 161:1011-1012. 
104. Yasuhara, M., Ohama, T., Matsuki, N., Saito, H., Shiga, J., Inoue, K., Kurokawa, K., and 
Teramoto, T. 1991. Induction of fatty liver by fasting in suncus. J Lipid Res 32:887-891. 
105. Ohama, T., Matsuki, N., Saito, H., Tsukamoto, K., Kinoshita, M., Katsuragawa, K., 
Okazaki, S., Yamanaka, M., and Teramoto, T. 1994. Effect of starving and refeeding on 
lipid metabolism in suncus. J Biochem (Tokyo) 115:190-193. 
106. Angulo, P. 2007. Obesity and nonalcoholic fatty liver disease. Nutr Rev 65:S57-63. 
107. Fei, H., Okano, H.J., Li, C., Lee, G.H., Zhao, C., Darnell, R., and Friedman, J.M. 1997. 
Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain 
and other tissues. Proc Natl Acad Sci U S A 94:7001-7005. 
108. Friedman, J.M. 1997. The alphabet of weight control. Nature 385:119-120. 
109. Anstee, Q.M., and Goldin, R.D. 2006. Mouse models in non-alcoholic fatty liver disease 
and steatohepatitis research. Int J Exp Pathol 87:1-16. 
110. Dallman, M.F., Strack, A.M., Akana, S.F., Bradbury, M.J., Hanson, E.S., Scribner, K.A., 
and Smith, M. 1993. Feast and famine: critical role of glucocorticoids with insulin in 
daily energy flow. Front Neuroendocrinol 14:303-347. 
111. Fujimoto, K., Koishi, R., Shimizugawa, T., and Ando, Y. 2006. Angptl3-null mice show 
low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim 
55:27-34. 
112. Herzig, S., Hedrick, S., Morantte, I., Koo, S.H., Galimi, F., and Montminy, M. 2003. 
CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-
gamma. Nature 426:190-193. 
 
7. Bibliography 
 
124
113. Leiter, E.H., Reifsnyder, P.C., Flurkey, K., Partke, H.J., Junger, E., and Herberg, L. 1998. 
NIDDM genes in mice: deleterious synergism by both parental genomes contributes to 
diabetogenic thresholds. Diabetes 47:1287-1295. 
114. Leiter, E.H., and Reifsnyder, P.C. 2004. Differential levels of diabetogenic stress in two 
new mouse models of obesity and type 2 diabetes. Diabetes 53 Suppl 1:S4-11. 
115. Reifsnyder, P.C., Churchill, G., and Leiter, E.H. 2000. Maternal environment and 
genotype interact to establish diabesity in mice. Genome Res 10:1568-1578. 
116. Subrahmanyam, K. 1960. Metabolism in the New Zealand strain of obese mice. Biochem 
J 76:548-556. 
117. Coenen, K.R., and Hasty, A.H. 2007. Obesity Potentiates Development of Fatty Liver 
and Insulin Resistance, but Not Atherosclerosis in High Fat Diet-Fed Agouti LDLR 
Deficient Mice. Am J Physiol Endocrinol Metab. 
118. Alberts, P., Ronquist-Nii, Y., Larsson, C., Klingstrom, G., Engblom, L., Edling, N., 
Lidell, V., Berg, I., Edlund, P.O., Ashkzari, M., et al. 2005. Effect of high-fat diet on 
KKAy and ob/ob mouse liver and adipose tissue corticosterone and 11-
dehydrocorticosterone concentrations. Horm Metab Res 37:402-407. 
119. Legendre, A., and Harris, R.B. 2006. Exaggerated response to mild stress in rats fed 
high-fat diet. Am J Physiol Regul Integr Comp Physiol 291:R1288-1294. 
120. Bernal-Mizrachi, C., Weng, S., Feng, C., Finck, B.N., Knutsen, R.H., Leone, T.C., 
Coleman, T., Mecham, R.P., Kelly, D.P., and Semenkovich, C.F. 2003. Dexamethasone 
induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null 
mice. Nat Med 9:1069-1075. 
121. Andrews, R.C., and Walker, B.R. 1999. Glucocorticoids and insulin resistance: old 
hormones, new targets. Clin Sci (Lond) 96:513-523. 
122. Askari, H., Liu, J., and Dagogo-Jack, S. 2005. Energy adaptation to glucocorticoid-
induced hyperleptinemia in human beings. Metabolism 54:876-880. 
123. Tung, Y.L., Hewson, A.K., and Dickson, S.L. 2004. Glucocorticoid-dependent 
stimulation of adiposity and appetite by a ghrelin mimetic in the rat. Eur J Endocrinol 
150:905-911. 
124. Gura, T. 2001. Obesity research. Pot-bellied mice point to obesity enzyme. Science 
294:2071-2072. 
125. Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R., and 
Flier, J.S. 2001. A transgenic model of visceral obesity and the metabolic syndrome. 
Science 294:2166-2170. 
126. Kageyama, R., Ohtsuka, T., and Kobayashi, T. 2007. The Hes gene family: repressors 
and oscillators that orchestrate embryogenesis. Development 134:1243-1251. 
127. Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R.M., and Whitington, 
P.F. 2004. Obese and diabetic db/db mice develop marked liver fibrosis in a model of 
nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J 
Physiol Gastrointest Liver Physiol 287:G1035-1043. 
128. Olsson, B., Bohlooly, Y.M., Fitzgerald, S.M., Frick, F., Ljungberg, A., Ahren, B., 
Tornell, J., Bergstrom, G., and Oscarsson, J. 2005. Bovine growth hormone transgenic 
mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and 
diabetes on a high-fat diet. Endocrinology 146:920-930. 
129. Ntambi, J.M., Miyazaki, M., and Dobrzyn, A. 2004. Regulation of stearoyl-CoA 
desaturase expression. Lipids 39:1061-1065. 
130. Ntambi, J.M. 1999. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty 
acids and cholesterol. J Lipid Res 40:1549-1558. 
131. Walker, J.E., and Gordon, E.R. 1970. Biochemical aspects associated with an ethanol-
induced fatty liver. Biochem J 119:511-516. 
 
7. Bibliography 
 
125
132. Kusunoki, M., Tsutsumi, K., Hara, T., Ogawa, H., Nakamura, T., Miyata, T., Sakakibara, 
F., Fukuzawa, Y., Suga, T., Kakumu, S., et al. 2002. Correlation between lipid and 
glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the 
lipoprotein lipase activator NO-1886. Metabolism 51:792-795. 
133. Iso, T., Kedes, L., and Hamamori, Y. 2003. HES and HERP families: multiple effectors 
of the Notch signaling pathway. J Cell Physiol 194:237-255. 
134. Insel, P.A., and Ostrom, R.S. 2003. Forskolin as a tool for examining adenylyl cyclase 
expression, regulation, and G protein signaling. Cell Mol Neurobiol 23:305-314. 
135. Takebayashi, K., Sasai, Y., Sakai, Y., Watanabe, T., Nakanishi, S., and Kageyama, R. 
1994. Structure, chromosomal locus, and promoter analysis of the gene encoding the 
mouse helix-loop-helix factor HES-1. Negative autoregulation through the multiple N 
box elements. J Biol Chem 269:5150-5156. 
136. Issack, P.S., and Ziff, E.B. 1998. Genetic elements regulating HES-1 induction in Wnt-
1-transformed PC12 cells. Cell Growth Differ 9:827-836. 
137. Truss, M., and Beato, M. 1993. Steroid hormone receptors: interaction with 
deoxyribonucleic acid and transcription factors. Endocr Rev 14:459-479. 
138. Scheidereit, C., Geisse, S., Westphal, H.M., and Beato, M. 1983. The glucocorticoid 
receptor binds to defined nucleotide sequences near the promoter of mouse mammary 
tumour virus. Nature 304:749-752. 
139. Payvar, F., DeFranco, D., Firestone, G.L., Edgar, B., Wrange, O., Okret, S., Gustafsson, 
J.A., and Yamamoto, K.R. 1983. Sequence-specific binding of glucocorticoid receptor to 
MTV DNA at sites within and upstream of the transcribed region. Cell 35:381-392. 
140. Chan, G.C., Hess, P., Meenakshi, T., Carlstedt-Duke, J., Gustafsson, J.A., and Payvar, F. 
1991. Delayed secondary glucocorticoid response elements. Unusual nucleotide motifs 
specify glucocorticoid receptor binding to transcribed regions of alpha 2u-globulin DNA. 
J Biol Chem 266:22634-22644. 
141. Morin, B., Zhu, C., Woodcock, G.R., Li, M., Woodward, R.N., Nichols, L.A., and 
Holland, L.J. 2000. The binding site for Xenopus glucocorticoid receptor accessory 
factor and a single adjacent half-GRE form an independent glucocorticoid response unit. 
Biochemistry 39:12234-12242. 
142. Canettieri, G., Morantte, I., Guzman, E., Asahara, H., Herzig, S., Anderson, S.D., Yates, 
J.R., 3rd, and Montminy, M. 2003. Attenuation of a phosphorylation-dependent activator 
by an HDAC-PP1 complex. Nat Struct Biol 10:175-181. 
143. Wadzinski, B.E., Wheat, W.H., Jaspers, S., Peruski, L.F., Jr., Lickteig, R.L., Johnson, 
G.L., and Klemm, D.J. 1993. Nuclear protein phosphatase 2A dephosphorylates protein 
kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol 
Cell Biol 13:2822-2834. 
144. Wu, J.J., and Bennett, A.M. 2005. Essential role for mitogen-activated protein (MAP) 
kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol 
Chem 280:16461-16466. 
145. Bazuine, M., Carlotti, F., Tafrechi, R.S., Hoeben, R.C., and Maassen, J.A. 2004. 
Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK 
during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 
18:1697-1707. 
146. Wu, J.J., Roth, R.J., Anderson, E.J., Hong, E.G., Lee, M.K., Choi, C.S., Neufer, P.D., 
Shulman, G.I., Kim, J.K., and Bennett, A.M. 2006. Mice lacking MAP kinase 
phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. 
Cell Metab 4:61-73. 
147. Parker, D., Ferreri, K., Nakajima, T., LaMorte, V.J., Evans, R., Koerber, S.C., Hoeger, 
C., and Montminy, M.R. 1996. Phosphorylation of CREB at Ser-133 induces complex 
formation with CREB-binding protein via a direct mechanism. Mol Cell Biol 16:694-703. 
 
7. Bibliography 
 
126
148. Radhakrishnan, I., Perez-Alvarado, G.C., Parker, D., Dyson, H.J., Montminy, M.R., and 
Wright, P.E. 1997. Solution structure of the KIX domain of CBP bound to the 
transactivation domain of CREB: a model for activator:coactivator interactions. Cell 
91:741-752. 
149. Radhakrishnan, I., Perez-Alvarado, G.C., Parker, D., Dyson, H.J., Montminy, M.R., and 
Wright, P.E. 1999. Structural analyses of CREB-CBP transcriptional activator-
coactivator complexes by NMR spectroscopy: implications for mapping the boundaries 
of structural domains. J Mol Biol 287:859-865. 
150. Lee, J.S., Zhang, X., and Shi, Y. 1996. Differential interactions of the CREB/ATF 
family of transcription factors with p300 and adenovirus E1A. J Biol Chem 271:17666-
17674. 
151. Imai, E., Miner, J.N., Mitchell, J.A., Yamamoto, K.R., and Granner, D.K. 1993. 
Glucocorticoid receptor-cAMP response element-binding protein interaction and the 
response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J Biol 
Chem 268:5353-5356. 
152. Sheppard, K.A., Phelps, K.M., Williams, A.J., Thanos, D., Glass, C.K., Rosenfeld, M.G., 
Gerritsen, M.E., and Collins, T. 1998. Nuclear integration of glucocorticoid receptor and 
nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor 
coactivator-1. J Biol Chem 273:29291-29294. 
153. Angulo, P. 2006. NAFLD, obesity, and bariatric surgery. Gastroenterology 130:1848-
1852. 
154. Tsukamoto, H. 2005. Fat paradox in liver disease. Keio J Med 54:190-192. 
155. Westerbacka, J., Kolak, M., Kiviluoto, T., Arkkila, P., Siren, J., Hamsten, A., Fisher, 
R.M., and Yki-Jarvinen, H. 2007. Genes involved in fatty acid partitioning and binding, 
lipolysis, monocyte/macrophage recruitment and inflammation are overexpressed in the 
human fatty liver of insulin resistant subjects. Diabetes. 
156. Matsusue, K., Haluzik, M., Lambert, G., Yim, S.H., Gavrilova, O., Ward, J.M., Brewer, 
B., Jr., Reitman, M.L., and Gonzalez, F.J. 2003. Liver-specific disruption of 
PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic 
phenotypes. J Clin Invest 111:737-747. 
157. Yu, S., Matsusue, K., Kashireddy, P., Cao, W.Q., Yeldandi, V., Yeldandi, A.V., Rao, 
M.S., Gonzalez, F.J., and Reddy, J.K. 2003. Adipocyte-specific gene expression and 
adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor 
gamma1 (PPARgamma1) overexpression. J Biol Chem 278:498-505. 
158. Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R., Nicol, 
C.J., Vinson, C., Gonzalez, F.J., and Reitman, M.L. 2003. Liver peroxisome proliferator-
activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and 
regulation of body fat mass. J Biol Chem 278:34268-34276. 
159. Schadinger, S.E., Bucher, N.L., Schreiber, B.M., and Farmer, S.R. 2005. PPARgamma2 
regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol 
Endocrinol Metab 288:E1195-1205. 
160. Bugianesi, E., McCullough, A.J., and Marchesini, G. 2005. Insulin resistance: a 
metabolic pathway to chronic liver disease. Hepatology 42:987-1000. 
161. Lewis, G.F., Carpentier, A., Adeli, K., and Giacca, A. 2002. Disordered fat storage and 
mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 
23:201-229. 
162. Usami, A., Ueki, S., Ito, W., Kobayashi, Y., Chiba, T., Mahemuti, G., Oyamada, H., 
Kamada, Y., Fujita, M., Kato, H., et al. 2006. Theophylline and dexamethasone induce 
peroxisome proliferator-activated receptor-gamma expression in human eosinophils. 
Pharmacology 77:33-37. 
 
7. Bibliography 
 
127
163. Hausman, G.J. 2003. Dexamethasone induced preadipocyte recruitment and expression 
of CCAAT/enhancing binding protein alpha and peroxisome proliferator activated 
receptor-gamma proteins in porcine stromal-vascular (S-V) cell cultures obtained before 
and after the onset of fetal adipogenesis. Gen Comp Endocrinol 133:61-70. 
164. She, Q.M., Zhao, J., Wang, X.L., Zhou, C.M., and Shi, X.Z. 2007. Effect of 
dexamethasone on peroxisome proliferator activated receptor-gamma mRNA expression 
in 3T3-L1 adipocytes with the human recombinant adiponectin. Chin Med J (Engl) 
120:155-158. 
165. Vidal-Puig, A.J., Considine, R.V., Jimenez-Linan, M., Werman, A., Pories, W.J., Caro, 
J.F., and Flier, J.S. 1997. Peroxisome proliferator-activated receptor gene expression in 
human tissues. Effects of obesity, weight loss, and regulation by insulin and 
glucocorticoids. J Clin Invest 99:2416-2422. 
166. Razani, B., Combs, T.P., Wang, X.B., Frank, P.G., Park, D.S., Russell, R.G., Li, M., 
Tang, B., Jelicks, L.A., Scherer, P.E., et al. 2002. Caveolin-1-deficient mice are lean, 
resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte 
abnormalities. J Biol Chem 277:8635-8647. 
167. Cohen, A.W., Razani, B., Wang, X.B., Combs, T.P., Williams, T.M., Scherer, P.E., and 
Lisanti, M.P. 2003. Caveolin-1-deficient mice show insulin resistance and defective 
insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 
285:C222-235. 
168. Van Nieuwenhoven, F.A., Verstijnen, C.P., Abumrad, N.A., Willemsen, P.H., Van Eys, 
G.J., Van der Vusse, G.J., and Glatz, J.F. 1995. Putative membrane fatty acid translocase 
and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal 
muscles. Biochem Biophys Res Commun 207:747-752. 
169. Poirier, H., Degrace, P., Niot, I., Bernard, A., and Besnard, P. 1996. Localization and 
regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. 
Comparison with fatty acid-binding proteins (FABP). Eur J Biochem 238:368-373. 
170. Abumrad, N.A., el-Maghrabi, M.R., Amri, E.Z., Lopez, E., and Grimaldi, P.A. 1993. 
Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-
chain fatty acids that is induced during preadipocyte differentiation. Homology with 
human CD36. J Biol Chem 268:17665-17668. 
171. Coburn, C.T., Hajri, T., Ibrahimi, A., and Abumrad, N.A. 2001. Role of CD36 in 
membrane transport and utilization of long-chain fatty acids by different tissues. J Mol 
Neurosci 16:117-121; discussion 151-117. 
172. Febbraio, M., Abumrad, N.A., Hajjar, D.P., Sharma, K., Cheng, W., Pearce, S.F., and 
Silverstein, R.L. 1999. A null mutation in murine CD36 reveals an important role in 
fatty acid and lipoprotein metabolism. J Biol Chem 274:19055-19062. 
173. Llaverias, G., Vazquez-Carrera, M., Sanchez, R.M., Noe, V., Ciudad, C.J., Laguna, J.C., 
and Alegret, M. 2004. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells 
through a PPAR-dependent mechanism. J Lipid Res 45:2015-2024. 
174. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans, R.M. 2001. PPAR-
gamma dependent and independent effects on macrophage-gene expression in lipid 
metabolism and inflammation. Nat Med 7:48-52. 
175. Moore, K.J., Rosen, E.D., Fitzgerald, M.L., Randow, F., Andersson, L.P., Altshuler, D., 
Milstone, D.S., Mortensen, R.M., Spiegelman, B.M., and Freeman, M.W. 2001. The role 
of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47. 
176. Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., Suzuki, 
Y., Saito, H., Kohgo, Y., and Okumura, T. 2005. Increased expression of PPARgamma 
in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336:215-
222. 
 
7. Bibliography 
 
128
177. Kretz, O., Reichardt, H.M., Schutz, G., and Bock, R. 1999. Corticotropin-releasing 
hormone expression is the major target for glucocorticoid feedback-control at the 
hypothalamic level. Brain Res 818:488-491. 
178. Friedman, J.E., Sun, Y., Ishizuka, T., Farrell, C.J., McCormack, S.E., Herron, L.M., 
Hakimi, P., Lechner, P., and Yun, J.S. 1997. Phosphoenolpyruvate carboxykinase (GTP) 
gene transcription and hyperglycemia are regulated by glucocorticoids in genetically 
obese db/db transgenic mice. J Biol Chem 272:31475-31481. 
179. Blokzijl, A., Dahlqvist, C., Reissmann, E., Falk, A., Moliner, A., Lendahl, U., and 
Ibanez, C.F. 2003. Cross-talk between the Notch and TGF-beta signaling pathways 
mediated by interaction of the Notch intracellular domain with Smad3. J Cell Biol 
163:723-728. 
180. Aguilera, C., Hoya-Arias, R., Haegeman, G., Espinosa, L., and Bigas, A. 2004. 
Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional 
repression. Proc Natl Acad Sci U S A 101:16537-16542. 
181. Shinozuka, Y., Okada, M., Oki, T., Sagane, K., Mizui, Y., Tanaka, I., Katayama, K., and 
Murakami-Murofushi, K. 2001. Altered expression of HES-1, BETA2/NeuroD, and 
PDX-1 is involved in impaired insulin synthesis induced by glucocorticoids in HIT-T15 
cells. Biochem Biophys Res Commun 287:229-235. 
182. Cantarini, M.C., de la Monte, S.M., Pang, M., Tong, M., D'Errico, A., Trevisani, F., and 
Wands, J.R. 2006. Aspartyl-asparagyl beta hydroxylase over-expression in human 
hepatoma is linked to activation of insulin-like growth factor and notch signaling 
mechanisms. Hepatology 44:446-457. 
183. Stockhausen, M.T., Sjolund, J., and Axelson, H. 2005. Regulation of the Notch target 
gene Hes-1 by TGFalpha induced Ras/MAPK signaling in human neuroblastoma cells. 
Exp Cell Res 310:218-228. 
184. Fu, J., Tay, S.S., Ling, E.A., and Dheen, S.T. 2006. High glucose alters the expression of 
genes involved in proliferation and cell-fate specification of embryonic neural stem cells. 
Diabetologia 49:1027-1038. 
185. Sasai, Y., Kageyama, R., Tagawa, Y., Shigemoto, R., and Nakanishi, S. 1992. Two 
mammalian helix-loop-helix factors structurally related to Drosophila hairy and 
Enhancer of split. Genes Dev 6:2620-2634. 
186. Ishibashi, M., Ang, S.L., Shiota, K., Nakanishi, S., Kageyama, R., and Guillemot, F. 
1995. Targeted disruption of mammalian hairy and Enhancer of split homolog-1 (HES-1) 
leads to up-regulation of neural helix-loop-helix factors, premature neurogenesis, and 
severe neural tube defects. Genes Dev 9:3136-3148. 
187. Ohtsuka, T., Ishibashi, M., Gradwohl, G., Nakanishi, S., Guillemot, F., and Kageyama, 
R. 1999. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. Embo 
J 18:2196-2207. 
188. Kunisato, A., Chiba, S., Nakagami-Yamaguchi, E., Kumano, K., Saito, T., Masuda, S., 
Yamaguchi, T., Osawa, M., Kageyama, R., Nakauchi, H., et al. 2003. HES-1 preserves 
purified hematopoietic stem cells ex vivo and accumulates side population cells in vivo. 
Blood 101:1777-1783. 
189. Kumano, K., Chiba, S., Shimizu, K., Yamagata, T., Hosoya, N., Saito, T., Takahashi, T., 
Hamada, Y., and Hirai, H. 2001. Notch1 inhibits differentiation of hematopoietic cells 
by sustaining GATA-2 expression. Blood 98:3283-3289. 
190. Shojaei, F., Trowbridge, J., Gallacher, L., Yuefei, L., Goodale, D., Karanu, F., Levac, K., 
and Bhatia, M. 2005. Hierarchical and ontogenic positions serve to define the molecular 
basis of human hematopoietic stem cell behavior. Dev Cell 8:651-663. 
191. Matsue, M., Kageyama, R., Denhardt, D.T., and Noda, M. 1997. Helix-loop-helix-type 
transcription factor (HES-1) is expressed in osteoblastic cells, suppressed by 1,25(OH)2 
 
7. Bibliography 
 
129
vitamin D3, and modulates 1,25(OH)2 vitamin D3 enhancement of osteopontin gene 
expression. Bone 20:329-334. 
192. Deregowski, V., Gazzerro, E., Priest, L., Rydziel, S., and Canalis, E. 2006. Notch 1 
overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone 
morphogenetic protein signaling. J Biol Chem 281:6203-6210. 
193. Ross, D.A., Rao, P.K., and Kadesch, T. 2004. Dual roles for the Notch target gene Hes-1 
in the differentiation of 3T3-L1 preadipocytes. Mol Cell Biol 24:3505-3513. 
194. Soukas, A., Socci, N.D., Saatkamp, B.D., Novelli, S., and Friedman, J.M. 2001. Distinct 
transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 276:34167-
34174. 
195. Ross, D.A., Hannenhalli, S., Tobias, J.W., Cooch, N., Shiekhattar, R., and Kadesch, T. 
2006. Functional analysis of Hes-1 in preadipocytes. Mol Endocrinol 20:698-705. 
196. Kamakura, S., Oishi, K., Yoshimatsu, T., Nakafuku, M., Masuyama, N., and Gotoh, Y. 
2004. Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT 
signalling. Nat Cell Biol 6:547-554. 
197. Inoue, H., Ogawa, W., Ozaki, M., Haga, S., Matsumoto, M., Furukawa, K., Hashimoto, 
N., Kido, Y., Mori, T., Sakaue, H., et al. 2004. Role of STAT-3 in regulation of hepatic 
gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10:168-174. 
198. Inoue, H., Ogawa, W., Asakawa, A., Okamoto, Y., Nishizawa, A., Matsumoto, M., 
Teshigawara, K., Matsuki, Y., Watanabe, E., Hiramatsu, R., et al. 2006. Role of hepatic 
STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267-275. 
199. Fisher, A.L., Ohsako, S., and Caudy, M. 1996. The WRPW motif of the hairy-related 
basic helix-loop-helix repressor proteins acts as a 4-amino-acid transcription repression 
and protein-protein interaction domain. Mol Cell Biol 16:2670-2677. 
200. Fisher, A.L., and Caudy, M. 1998. Groucho proteins: transcriptional corepressors for 
specific subsets of DNA-binding transcription factors in vertebrates and invertebrates. 
Genes Dev 12:1931-1940. 
201. Nuthall, H.N., Husain, J., McLarren, K.W., and Stifani, S. 2002. Role for Hes1-induced 
phosphorylation in Groucho-mediated transcriptional repression. Mol Cell Biol 22:389-
399. 
202. Guardiola-Diaz, H.M., Kolinske, J.S., Gates, L.H., and Seasholtz, A.F. 1996. Negative 
glucorticoid regulation of cyclic adenosine 3', 5'-monophosphate-stimulated 
corticotropin-releasing hormone-reporter expression in AtT-20 cells. Mol Endocrinol 
10:317-329. 
203. Alcorn, J.L., Islam, K.N., Young, P.P., and Mendelson, C.R. 2004. Glucocorticoid 
inhibition of SP-A gene expression in lung type II cells is mediated via the TTF-1-
binding element. Am J Physiol Lung Cell Mol Physiol 286:L767-776. 
204. Focking, M., Holker, I., and Trapp, T. 2003. Chronic glucocorticoid receptor activation 
impairs CREB transcriptional activity in clonal neurons. Biochem Biophys Res Commun 
304:720-723. 
205. Rosen, L.B., Majzoub, J.A., and Adler, G.K. 1992. Effects of glucocorticoid on 
corticotropin-releasing hormone gene regulation by second messenger pathways in 
NPLC and AtT-20 cells. Endocrinology 130:2237-2244. 
206. Del Monaco, M., Covello, S.P., Kennedy, S.H., Gilinger, G., Litwack, G., and Uitto, J. 
1997. Identification of novel glucocorticoid-response elements in human elastin 
promoter and demonstration of nucleotide sequence specificity of the receptor binding. J 
Invest Dermatol 108:938-942. 
207. Chandrasekhar, S., Souba, W.W., and Abcouwer, S.F. 1999. Identification of 
glucocorticoid-responsive elements that control transcription of rat glutamine synthetase. 
Am J Physiol 276:L319-331. 
 
7. Bibliography 
 
130
208. Forman, B.M., and Samuels, H.H. 1990. Interactions among a subfamily of nuclear 
hormone receptors: the regulatory zipper model. Mol Endocrinol 4:1293-1301. 
209. Jarriault, S., Le Bail, O., Hirsinger, E., Pourquie, O., Logeat, F., Strong, C.F., Brou, C., 
Seidah, N.G., and Isra l, A. 1998. Delta-1 activation of notch-1 signaling results in HES-
1 transactivation. Mol Cell Biol 18:7423-7431. 
210. Orellana, S.A., and McKnight, G.S. 1992. Mutations in the catalytic subunit of cAMP-
dependent protein kinase result in unregulated biological activity. Proc Natl Acad Sci U 
S A 89:4726-4730. 
 
 
